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Abstract 
 
Tuberculosis is one of the leading causes of death by infectious disease in the world 
today.  However, the majority of individuals infected with Mycobacterium tuberculosis 
are able to contain bacterial growth and establish a latent infection.  The aim of this 
thesis is to develop mathematical models to study the progression of disease in 
individuals infected with Mycobacterium tuberculosis.  This work focuses on 
understanding bacterial and host defence mechanisms that govern the outcome of 
infection, and on identifying factors that affect the outcome of anti-tuberculosis 
chemotherapy. 
 
A detailed model of human tuberculosis infection in the lung and peripheral draining 
lymph node is developed that builds on models published in the literature.  Analysis of 
this model suggests a differential role for innate and adaptive immune responses in 
determining the outcome of infection, and a possible role for an intracellular bacterial 
population in establishing a persistent infection.  For certain parameter values this 
system has multiple steady states so the outcome of infection may also depend on initial 
conditions.  This model is then modified to incorporate the effect of treatment with the 
antimycobacterial agent rifampicin.  The model is used to investigate different treatment 
regimens and simulation results suggest that the length of tuberculosis therapy can be 
reduced by further optimizing the standard rifampicin dosing regimen. 
 
Simple predator-prey type models of infection are constructed to gain further insight 
into the mechanisms that control the establishment and maintenance of latency.  These 
models support observations made from the full disease model regarding the roles of 
innate and adaptive immunity in fighting infection and the influence of an intracellular 
bacterial population that is protected from the innate immune system.  The addition of a 
population of non-replicating or slow growing bacteria contributes to the establishment 
of latent infection and generally makes latency a more robust and stable state. 
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Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, a 
slow-growing acid-fast bacterium.  Mycobacterium tuberculosis (M. tuberculosis or 
Mtb) was first identified as the causative agent of tuberculosis by Robert Koch in 1882 
(Koch, 1882).  M. tuberculosis belongs to the genus Mycobacterium, which also 
includes the species Mycobacterium bovis (M. bovis), the causative agent of bovine TB, 
and Mycobacterium leprae, the causative agent of leprosy (Good, 1985). 
 
Tuberculosis most commonly affects the lungs, but it can also cause disease in other 
organs (Flynn and Chan, 2001a).  The symptoms of pulmonary TB include coughing, 
often with sputum or blood, chest pain, fatigue, weight loss, fever and night sweats 
(World Health Organization, 2010b). 
 
Tuberculosis is a major cause of illness and death worldwide, particularly in Asia and 
Africa.  The World Health Organization (WHO) estimates that one third of the world’s 
population is infected with the bacillus (World Health Organization, 2012b).  In 2011 
there were approximately 8.7 million incident cases of tuberculosis.  An estimated 1.4 
million people died from the disease.  TB is the second leading cause of death from an 
infectious disease worldwide, after human immunodeficiency virus (HIV) (World 
Health Organization, 2012a). 
 
The tubercle bacillus enters the body when respiratory droplets (aerosols) containing M. 
tuberculosis are inhaled.  Once an individual has been exposed to M. tuberculosis, there 
are four possible outcomes (!"#$%&'()(): 
 
• The initial immune response can be completely effective and kill all bacilli such 
that the host has no chance of developing tuberculosis.  It is thought that only 30% 
of individuals exposed to M. tuberculosis become infected (purified protein 
derivative (PPD)-positive by skin test) (Manabe and Bishai, 2000; Wigginton and 
Kirschner, 2001).  However, there is evidence that some tuberculin skin test (TST)-
negative individuals mount transient M. tuberculosis-specific effector T cell 
 15 
responses.  Longitudinal contact studies have shown interferon-!  release assay 
(IGRA) reversion following a positive IGRA result, suggesting that an acute 
resolving infection may occur in some individuals (Ewer et al., 2006; Hill et al., 
2007; Pai et al., 2006). 
• The host may be unable to control the growth of the organisms immediately after 
infection leading to clinical disease known as primary tuberculosis.  5-10% of 
infected individuals progress to primary disease within one to five years (Sud et al., 
2006; Tufariello et al., 2003). 
• The host immune response may be able to contain, but not clear, infection such that 
the patient has latent tuberculosis, manifest only by a positive tuberculin test 
(Schluger and Rom, 1998).  90-95% of all infections remain latent (Tufariello et al., 
2003; Wigginton and Kirschner, 2001).  Individuals with latent infection have no 
clinical symptoms and are not contagious to others (Flynn and Chan, 2001b). 
• Perturbations in the immune response following the establishment of latent 
infection may result in clinical disease, known as reactivation tuberculosis (Flynn 
and Chan, 2001a).  In otherwise healthy hosts with latent infection there is a 5-10% 
chance of developing active disease over a lifetime (Schluger and Rom, 1998).  In 
immunocompromised hosts the potential for reactivation of latent tuberculosis is 
greater.  The immune system may be compromised due to HIV infection, the use of 
corticosteroids or other immunosuppressive agents, aging, malnutrition, 
chemotherapy and alcohol or drug abuse (Flynn and Chan, 2001a; Frieden et al., 
2003; Tufariello et al., 2003).  In patients with HIV infection, the risk may be as 
high as 8-10% each year (Flynn and Chan, 2001a). 
 
Pathogens that persist in their host for a prolonged time present a major challenge for 
disease control.  Tuberculosis is an example of an infectious disease where the pathogen 
may persist for the lifetime of the host.  The immune response to M. tuberculosis is 
complex and the mechanisms that determine infection outcome are not well understood.  
It is still not known why some individuals develop active disease while others are able 
to control infection.  A more complete understanding of host-pathogen interactions is 
required for the development of improved prevention and treatment strategies. 
 
Mathematical models can be used as a tool to investigate the behaviour of complex 
biological systems.  Modelling may provide us with a better understanding of the 
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underlying principles that govern these systems, offering explanations and insights.  
Models allow us to predict biological phenomena and suggest new experiments to test 
hypotheses. 
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Figure 1.1 Outcomes of exposure to Mycobacterium tuberculosis. 
 
This project uses mathematical techniques to study the within-host dynamics of M. 
tuberculosis infection and anti-tuberculosis chemotherapy.  The aim of this work is to 
gain a better understanding of the host-pathogen interactions that govern the outcome of 
infection and to identify factors that affect the outcome of drug treatment. 
 
The first model presented builds on some of the models of tuberculosis infection 
published in the literature.  This model incorporates two compartments: the lung and the 
peripheral draining lymph node, and describes the temporal dynamics of bacteria and 
various components of the immune system.  This work captures a number of key 
processes involved in the initiation of a specific immune response, (including the 
trafficking of cells between the site of infection and secondary lymphoid tissue, antigen 
presentation by dendritic cells, T cell differentiation and cytokine production).  The 
model is used to explore the role played by innate and adaptive immune responses in 
 17 
determining the outcome of infection, and the dependence of the system on initial 
conditions.  This model is presented in Chapter 4. 
 
In Chapter 5 the disease model is modified to incorporate the effect of drug treatment.  
Pharmacokinetic and pharmacodynamic (PK/PD) equations are added to the model to 
describe the concentration of the drug in the body and the antibacterial effect of the 
drug.  The model is used to investigate the effect of variability in pharmacokinetic and 
pharmacodynamic parameters and to predict the outcome of different treatment 
regimens.  This allows us to determine factors that may improve the outcome of drug 
treatment and make suggestions on how to improve the success of the treatment. 
 
In the final part of the thesis a series of simple predator-prey type models of infection 
are developed.  These models consist of one or two bacterial populations and a single 
variable representing the adaptive immune response.  The details of the immune system 
are ignored and a more heuristic approach is taken to gain a better insight into the 
underlying mechanisms that control the establishment and maintenance of latency.  A 
non-replicating or slow growing population is then added to the model to investigate 
how bacterial dynamics contribute to the establishment of a latent state.  This work is 
presented in Chapter 6. 
 
The thesis has the following structure: in Chapter 2 the biological background of 
Mycobacterium tuberculosis infection is reviewed.  This includes a summary of the role 
played by major components of the immune system in fighting infection, as well as the 
possible mechanisms employed by M. tuberculosis to avoid elimination and persist in 
its host.  In Chapter 3 some of the existing models of host-pathogen interactions are 
introduced and published models of tuberculosis infection are described.  
Pharmacokinetic and pharmacodynamic modelling principles are also reviewed.  The 
two-compartment model of tuberculosis infection is presented in Chapter 4, and in 
Chapter 5 this model is extended to include drug treatment.  Predator-prey type models 
of infection are presented in Chapter 6.  Chapter 7 summarizes the results of the thesis 
and provides suggestions for further work. 
 18 
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2.1 Introduction 
 
Mycobacterium tuberculosis is a facultative intracellular pathogen that targets 
macrophages as its preferred habitat.  The organism has a unique wax-rich cell wall 
composed of long-chain fatty acids, glycolipids and other components, which 
contributes to the capacity of M. tuberculosis to survive in its host.  M. tuberculosis is a 
slow-growing organism with a replication time of approximately twenty hours in vitro.  
This slow growth contributes to the long incubation time and chronic nature of disease, 
and necessitates long-term drug treatment (Kaufmann, 1993; Kaufmann, 2001). 
 
The host immune response to tuberculosis involves components of innate and adaptive 
immunity that act complimentarily and synergistically to fight infection (van Crevel et 
al., 2002).  In this chapter host defence mechanisms against M. tuberculosis are 
reviewed.  We describe the role played by macrophages, dendritic cells, lymphocytes, 
cytokines and chemokines in mounting a protective immune response and summarize 
methods employed by M. tuberculosis to evade detection and elimination by its host.  
We also look at the current treatment and vaccination strategies. 
 
2.2 Granuloma Formation 
 
The immune response to M. tuberculosis infection involves the formation of 
multicellular lesions, called granulomas, in the lungs of infected individuals (Gammack 
et al., 2004).  Granulomas are dynamic structures that form in response to persistent 
antigenic stimulation.  The granuloma creates a microenvironment that can facilitate 
interactions between immune cells such as macrophages and T lymphocytes, leading to 
inhibition of growth or death of M. tuberculosis.  The granuloma also attempts to 
physically contain the bacilli by ‘walling-off’ the organisms in order to prevent bacterial 
spread in cases where bacteria cannot be cleared (Algood et al., 2003; Gammack et al., 
2005). 
 19 
 
The granuloma consists of many different cells, including macrophages, epithelioid 
macrophages, foamy macrophages, multinucleated Langhans giant cells, T 
lymphocytes, B lymphocytes and fibroblasts (Flynn and Chan, 2001a; Reece and 
Kaufmann, 2012; Russell et al., 2009).  Necrosis can occur in granulomas, beginning in 
the centre of the structure (Algood et al., 2003).  Necrotic tissue provides the nutritional 
source for persistent mycobacteria (Ulrichs and Kaufmann, 2006).  The necrotic centre 
may progress to caseous necrosis in human tissue.  The caseous material is usually 
solid, but can liquefy if the infection is not controlled and support extracellular 
replication of M. tuberculosis.  Caseous granulomas can progress to cavities in the lung 
(Algood et al., 2003).  Different types of granulomas are shown in !"#$%&'*)(. 
 
The formation and maintenance of these granulomatous lesions may play a key role in 
the pathogenesis of disease.  It is thought that small, solid granulomas form in patients 
whose immune system is controlling the infection, whereas large, caseous granulomas 
are associated with bacterial dissemination and greater pathology (Segovia-Juarez et al., 
2004).  A study by Emile et al. (1997) found that there is a strong correlation between 
granuloma size and structure and clinical outcome.  The breakdown of granulomas in 
the lung promotes the replication of M. tuberculosis, release of bacteria into the airways 
and effective aerosol transmission (Young et al., 2008). 
 
During active TB different stages of granulomas coexist in the lung, providing a range 
of diverse microenvironments to which the pathogen has to adapt.  Tubercle bacilli are 
found in different areas of the granulomas; intracellularly within host cells such as 
monocytes and macrophages, as well as extracellularly in the caseous centre 
(Gengenbacher and Kaufmann, 2012).  Histological examination of different lesions 
obtained from resected lungs of patients with incurable TB shows that bacilli are most 
numerous at the surface of cavities, with bacilli growing inside macrophages at this site 
(Kaplan et al., 2003). 
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Figure 2.1 Types of granulomas observed during tuberculosis infection.  Granulomas are composed of 
many different types of cells including macrophages, T lymphocytes, B lymphocytes and fibroblasts.  
Macrophages can differentiate into foam cells or epithelioid cells and fuse together to form 
multinucleated Langhans giant cells (Lay et al., 2007; Russell et al., 2009).  Solid granulomas are defined 
by a lack of central necrosis.  Necrosis may occur in granulomas leading to a central region of demarcated 
cell death where bacteria can be detected.  The necrotic region may progress to caseous necrosis and 
subsequently liquefaction resulting in bacterial dissemination  (Algood et al., 2003; Reece and 
Kaufmann, 2012). 
 
2.3 Innate Immune Response 
 
The initial site of M. tuberculosis infection is the alveoli of the lung, where bacteria 
come into contact with alveolar macrophages, dendritic cells and monocytes recruited 
from the bloodstream (Bhatt and Salgame, 2007).  These monocytes differentiate into 
macrophages in the lung (van Crevel et al., 2002). 
 
Innate immunity provides the first line of host defence against infection.  The main cells 
of the innate immune system are macrophages and monocytes, granulocytes 
(neutrophils, eosinophils, basophils), mast cells, natural killer (NK) cells and dendritic 
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cells (DCs).  Innate immune responses occur rapidly following exposure to infectious 
agents, but they do not generate long-term protective immunity to reinfection with the 
same pathogen.  The cells of innate immunity rely on a limited and invariant repertoire 
of receptors to recognize features that are common to many microorganisms (Murphy et 
al., 2008). 
 
2.3.1 Macrophages 
 
Macrophages play a dual role during M. tuberculosis infection: they are the primary 
mechanism for containing infection and the preferred location for bacterial growth (Ray 
et al., 2009).  Macrophages are relatively long-lived cells that perform several different 
functions during the course of an infection.  They are capable of inhibiting bacterial 
growth through phagocytosis and of participating in the broader immune response 
through the processes of antigen (Ag) presentation, cytokine secretion and effector cell 
recruitment (Schluger and Rom, 1998).  Macrophages are directed to the site of 
infection by chemokines released by bacteria (and other cells) (Gammack et al., 2004). 
 
The process of phagocytosis involves the engulfment and killing of bacteria (and other 
foreign particles).  The macrophage first uses its receptors to bind to the bacteria.  The 
bound pathogen is surrounded by a membrane and internalized in a membrane-enclosed 
vesicle called a phagosome (or endocytic vacuole).  The phagosome then becomes 
acidic, killing many pathogens.  Once bacteria have been engulfed into phagosomes 
they can be killed by a variety of different mechanisms, including phagosome-lysosome 
fusion.  Lysosomes are membrane-enclosed granules within the macrophage that 
contain enzymes, proteins and peptides that can attack bacteria.  The phagosome can 
fuse with one or more lysosomes to generate a phagolysosome in which the lysosomal 
contents are released to destroy the pathogen (!"#$%&'*)*).  Macrophages also produce a 
variety of other products that are directly toxic to engulfed bacteria.  These include 
reactive oxygen intermediates (ROI) such as hydrogen peroxide (H2O2) generated via 
the respiratory burst, reactive nitrogen intermediates (RNI) such as nitric oxide (NO) 
generated by the action of inducible nitric oxide synthase (iNOS), and antimicrobial 
peptides (Flynn and Chan, 2001a; Murphy et al., 2008). 
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Figure 2.2 Phagocytosis of M. tuberculosis.  M. tuberculosis enters macrophages via specific binding 
to receptor molecules including complement receptors, mannose receptors, CD14, scavenger receptors, 
Fc! receptors and Toll-like receptors (Ernst, 1998; van Crevel et al., 2002).  Bacteria are taken up into 
intracellular vesicles, or phagosomes, which can fuse with lysosomes to form a phagolysosome where the 
pathogen is destroyed.  This figure is adapted from Murphy et al. (2008). 
 
Macrophages need to be activated in order to destroy their pathogen load more 
efficiently.  Macrophage activation is induced by the cytokine interferon-!  (IFN-! ).  
Tumor necrosis factor-!  (TNF-! ) synergizes with IFN-!  to inhibit mycobacterial 
growth by inducing iNOS expression and the production of NO and RNI (Flynn and 
Chan, 2001a).  Resting macrophages are able to kill their intracellular bacteria, but their 
killing capacity is much lower than that of activated macrophages.  Chronically infected 
macrophages have diminished phagocytic potential, a decreased level of major 
histocompatibility complex (MHC) class II presentation (which is important for 
macrophage activation) and produce fewer chemokines than activated macrophages 
(Gammack et al., 2004).  Mycobacteria in resting macrophages interfere with the 
normal progression of the phagosome and prevent it from fusing with a lysosomal 
compartment.  The capacity of M. tuberculosis to block phagosome maturation is 
diminished in macrophages activated by IFN-!  prior to infection (Rohde et al., 2007).  
Macrophages produce a range of cytokines following the internalization of bacteria 
including interleukin-1!  (IL-1! ), IL-6, IL-12, IL-18, IFN-! , TNF-!  and IL-10 (Dao 
et al., 2004; Fenton et al., 1997; Giacomini et al., 2001; Ladel et al., 1997b; Murphy et 
al., 2008). 
 
The production of NO and related RNIs by activated macrophages plays an essential 
role in the killing and growth inhibition of M. tuberculosis in the murine model of TB 
infection (Chan et al., 1995; Chan et al., 1992).  iNOS-deficient mice are highly 
susceptible to M. tuberculosis infection (MacMicking et al., 1997; Scanga et al., 2001).  
Herbst et al. (2011) showed that NO induces apoptosis in IFN- ! -activated 
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macrophages, resulting in the killing of intracellular mycobacteria. 
 
In contrast, the significance of RNIs such as NO in human host defence against M. 
tuberculosis is less clear (Gupta et al., 2012; Lin and Flynn, 2010).  There is evidence 
that early inhibition of mycobacterial growth by alveolar macrophages in vitro is not 
mediated by NO (Aston et al., 1998).  However, it has been shown that alveolar 
macrophages taken from healthy control subjects and infected with M. tuberculosis are 
able to produce NO, and that NO production is correlated with intracellular growth 
inhibition (Rich et al., 1997).  Kuo et al. (2000) observed that NO production is 
enhanced in alveolar macrophages obtained by bronchoalveolar lavage (BAL) from TB 
patients.  iNOS has also been detected in macrophages of patients with pulmonary 
tuberculosis (Nicholson et al., 1996; Wang et al., 1998). Wang et al. (1998) reported an 
increase in exhaled NO due to the up-regulation of iNOS expression.  
Immunohistochemical analysis of lung specimens resected from TB patients revealed 
increased expression of iNOS in epithelioid macrophages, multinuceleated giant cells 
and alveolar macrophages (Choi et al., 2002).  This suggests that iNOS may be 
functionally important in human TB (Nathan, 2002).  Recent studies have shown that 
the gene encoding iNOS (NOS2A) influences the susceptibility for developing TB and 
that variations in the NOS2A gene may contribute to increased susceptibility to TB 
(Gomez et al., 2007; Velez et al., 2009). 
 
Macrophages within granulomas can differentiate into epithelioid cells and/or fuse 
together to form multinucleated giant cells.  Multinucleated giant cells appear to have a 
reduced capacity to mediate mycobacterial uptake, but have conserved antigen 
presentation ability (Lay et al., 2007).  Macrophages can also differentiate into foam 
cells packed with lipid bodies (Russell et al., 2009). 
 
The activation of macrophages must be tightly regulated to avoid tissue damage.  
Macrophage activation is associated with localized tissue destruction that results from 
the release of oxygen radicals, NO and proteases, which are toxic to host cells (Murphy 
et al., 2008). 
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2.3.2 Dendritic Cells 
 
Dendritic cells and monocytes are also able to internalize bacteria, secrete cytokines and 
present antigen to T cells.  Dendritic cells (DCs) are professional antigen presenting 
cells (APCs) specialized for antigen uptake and processing.  They play a key role in 
establishing an effective adaptive immune response to M. tuberculosis by forming a link 
between innate and adaptive immunity (Marino et al., 2004). 
 
Immature dendritic cells are present in large numbers in the lung.  Following 
internalization of bacteria immature DCs differentiate into the mature phenotype and 
migrate to secondary lymphoid tissues (lymph nodes).  Mature DCs have reduced 
phagocytic and endocytic capability and express molecules for antigen presentation and 
adhesion molecules for migration.  Migration of DCs from nonlymphoid tissues into the 
draining lymph node (DLN) is promoted by cytokines produced during the 
inflammatory response and by other agents that are generated during local infection or 
trauma (Marino et al., 2004). 
 
When infection occurs dendritic cells migrate through lymphatic vessels and enter the 
DLN where they activate antigen-specific naïve T cells (!"#$%&' *)+).  Mature DCs 
present antigen to naïve T cells, which undergo a period of proliferation and 
differentiation into effector cells.  The activated lymphocytes then leave the DLN 
through lymphatic vessels and return to the bloodstream, eventually entering the site of 
infection (Murphy et al., 2008). 
 
Dendritic cells produce a variety of cytokines, including IL-1! , IL-6, IL-12, IL-18, 
IFN-! , IFN-!  and TNF-!  (Fricke et al., 2006; Giacomini et al., 2001; Murphy et al., 
2008).  M. tuberculosis infected DCs also produce IL-10.  The production of IL-12 by 
M. tuberculosis infected dendritic cells is critical for the polarization of CD4+ T cells 
towards a T helper type 1 (Th1) response (Demangel et al., 2002). 
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Figure 2.3 Antigen presentation by dendritic cells.  Antigen is recognized by the T cell receptor in the 
form of a peptide bound to a major histocompatibility complex (MHC) molecule on the dendritic cell.  
The T cell will only be activated if the dendritic cell expresses the co-stimulatory molecule B7.  This 
figure is adapted from Murphy et al. (2008). 
 
A number of cell surface receptor molecules play a role in the detection of M. 
tuberculosis by phagocytic cells.  M. tuberculosis enters macrophages via specific 
binding to several distinct receptor molecules including complement receptors (CRs), 
mannose receptors (MRs), surfactant protein-A (Sp-A) receptor, CD14, the class A 
scavenger receptor and mannose-binding lectin (MBL) and Fc!  receptors (Ernst, 1998; 
van Crevel et al., 2002).  Monoclonal antibodies against CR1, CR3 and CR4 
significantly inhibit phagocytosis of M. tuberculosis by monocyte-derived macrophages 
(Schlesinger, 1993; Schlesinger et al., 1990).  The precise route of entry may determine 
the fate of the organism within the macrophage.  Fc receptor-mediated uptake results in 
the production of ROI (Fenton and Vermeulen, 1996).  The primary receptor for M. 
tuberculosis on dendritic cells is dendritic cell-specific intracellular adhesion molecule-
3 (ICAM-3)-grabbing non-integrin (DC-SIGN) (CD209) (Berrington and Hawn, 2007). 
 
Macrophages and dendritic cells also express Toll-like receptors (TLRs) that recognize 
conserved molecular patterns found on pathogens and their products.  TLRs form a 
crucial link between innate and adaptive immunity (Bhatt and Salgame, 2007).  Ligation 
of TLRs results in the activation of the transcription factor nuclear factor (NF)-!B that 
induces the production of a variety of cytokines including TNF-!  and IL-12 (Aderem 
and Ulevitch, 2000).  Different members of the TLR family are involved in the 
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recognition of mycobacterial components including TLR2, TLR4, TLR9 and the 
heterodimerization of TLR2 with TLR6 or TLR1 (van Crevel et al., 2002). 
 
Other components of innate immunity such as neutrophils and natural killer (NK) cells 
are also involved in controlling the growth of mycobacteria.  Neutrophils are phagocytic 
cells and are among the first immune cells to migrate to the site of infection.  NK cells 
are granular lymphocytes capable of directly killing infected cells via cytotoxic effector 
functions.  NK cells also produce the cytokine IFN-!  (Korbel et al., 2008). 
 
2.4 Adaptive Immune Response 
 
If a pathogen is able to evade or overwhelm the innate immune system an adaptive 
immune response ensues.  This involves the generation of antigen-specific effector cells 
which have the ability to target a specific pathogen and focus the immune response on 
eliminating that pathogen.  These cells can recognize and respond to individual antigens 
by means of highly specialized antigen receptors on their surface (Murphy et al., 2008). 
 
An adaptive immune response also results in the formation of immunological memory.  
This means that any subsequent exposure to a previously encountered pathogen results 
in a stronger and faster immune response. 
 
There are two types of lymphocytes: B lymphocytes (B cells), which are responsible for 
humoral immunity or antibody (Ab) responses, and T lymphocytes (T cells), which are 
responsible for cell-mediated immunity.  These cells possess a vast repertoire of antigen 
receptors and are able to recognize and respond to virtually any antigen a person is 
likely to be exposed to (Murphy et al., 2008). 
 
The main types of T cells include CD4+, CD8+ and natural killer T cells, which express 
the !"  T cell receptor, and !"  T cells, which express the !"  T cell receptor.  CD4+ T 
cells recognize antigens that have been processed in endocytic vesicles and presented as 
small peptide fragments bound to major histocompatibility complex (MHC) class II 
molecules on the surface of antigen presenting cells such as monocytes, macrophages, 
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dendritic cells or B cells.  CD8+ T cells recognize antigens that have been processed in 
the cytosol and that are presented by MHC class I molecules on the cell surface. 
 
The B cell receptor (surface immunoglobulin) can bind a variety of chemical structures 
including natural proteins, glycoproteins, polysaccharides, virus particles and bacterial 
cells.  The activation of naïve B cells usually requires helper T cells.  Some microbial 
antigens can activate B cells in the absence of T cell help (Murphy et al., 2008). 
 
2.4.1 Cell-Mediated Immunity 
 
Tuberculosis is an example of a disease for which a cell-mediated immune response is 
required to fight infection.  M. tuberculosis is an intracellular pathogen so T cell 
effector mechanisms are needed to control or eliminate bacteria (Flynn and Chan, 
2001a). 
 
Many different types of T cells play a role in the host immune response to M. 
tuberculosis, including CD4+ and CD8+ T cells, and !"  T cells.  M. tuberculosis 
resides primarily in a vacuole within the macrophage, so MHC class II presentation of 
mycobacterial antigens to CD4+ T cells is an outcome of infection.  These cells, 
therefore, appear to be the most important components of cell-mediated immunity in 
tuberculosis (Flynn and Chan, 2001a). 
 
CD4+ T cells amplify the host immune response by activating effector cells and by 
recruiting additional immune cells to sites of infection.  CD8+ T cells are more likely to 
be directly cytotoxic to target cells, killing cells that are infected with intracellular 
pathogens (Schluger and Rom, 1998). 
 
Naïve CD4+ T cells can differentiate into a number of different classes of effector T 
cells following stimulation by antigen presenting cells.  The main functional subsets of 
effector T cells are T helper (Th) 1, Th2, Th17 and regulatory T cells (Tregs) (Murphy 
et al., 2008).  Th1 and Th2 cells derive from Th0 or null cells, and their differentiation 
from these precursor cells depends on the signals received (Schluger and Rom, 1998). 
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T helper cell subsets are defined on the basis of the cytokines they secrete.  Th1 cells 
are characterized by their production of IFN-" and IL-2.  They also produce TNF-!  
and IL-10.  The main function of Th1 cells is the activation of infected macrophages, 
which makes these cells more efficient at killing engulfed bacteria.  Th2 cells produce 
the cytokines IL-4, IL-5, IL-10 and IL-13 and are mainly involved in stimulating B cells 
to produce antibody.  Th17 cells are characterized by their ability to produce IL-17.  
They also produce IL-21, IL-22 (Korn et al., 2009), IL-6 and TNF-! .  These cells help 
recruit neutrophils to sites of infection early in the immune response.  Tregs produce 
transforming growth factor- !  (TGF- ! ) and IL-10 and limit immunopathology 
(Murphy et al., 2008).  Th0 cells produce both Th1- (IFN-!  and IL-2) and Th2-type 
(IL-4) cytokines (O'Garra, 1998). 
 
Murine studies have shown that CD4+ T cells are essential for control of M. 
tuberculosis infection (Flynn and Chan, 2001a).  CD4+ T cell-depleted mice show 
impaired resistance to infection with M. tuberculosis compared with wild-type mice 
(Muller et al., 1987), and transgenic mice deficient in either MHC class II or CD4 
molecules are more susceptible to M. tuberculosis (Caruso et al., 1999).  Antibody-
mediated depletion of CD4+ T cells six months after infection results in a rapid 
reactivation of a chronic persistent infection with high bacterial numbers in the organs, 
increased pathology in the lungs and decreased survival (Scanga et al., 2000).  In 
humans, the reduction in the number and immune activation state of CD4+ T cells 
during HIV infection greatly increases susceptibility to both acute and reactivation TB 
(Barnes et al., 1991; Flynn and Chan, 2001a; Schluger and Rom, 1998; Selwyn et al., 
1989). 
 
In addition to activation of macrophages by secreted cytokines, lymphocytes can kill 
infected macrophages that are unable to destroy their bacterial load through cytotoxic T 
lymphocyte (CTL) activity.  These lymphocytes have the ability to lyse alveolar 
macrophages and peripheral monocytes infected with mycobacteria (Schluger and Rom, 
1998). 
 
Cytotoxic T cells induce apoptosis, or programmed cell death, in their target cells.  The 
main mechanisms of CTL activity are apoptosis via the Fas-Fas ligand (FasL) apoptotic 
pathway and via the cytotoxic effector proteins perforin, granzymes and granulysin.  
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Granulysin, (which is expressed in humans but not in mice), has direct antimicrobial 
activity as well as the ability to induce apoptosis in target cells (Murphy et al., 2008). 
 
Both CD4+ and CD8+ T cells have cytotoxic capabilities and lyse M. tuberculosis-
infected macrophages (Canaday et al., 2001; Tan et al., 1997).  The majority of 
cytotoxic T cells are CD8+ T cells and these cells play a significant role in protection 
against TB (Woodworth and Behar, 2006).  CD8+ T cells are also capable of secreting 
cytokines such as IFN-!  and TNF-!  (Murphy et al., 2008) and secrete these cytokines 
upon recognition of mycobacterial antigens (Caccamo et al., 2006).  Many CD8+ T cell 
effector responses are dependent on help from CD4+ T cells (Murphy et al., 2008).  
CD8+ T cell-depleted mice (Muller et al., 1987) and mice lacking MHC class I 
molecules that fail to develop functional CD8+ T cells (Flynn et al., 1992) are more 
susceptible to infection with M. tuberculosis than wild-type mice.  Depletion of CD8+ T 
cells in Mycobacterium bovis bacillus Calmette-Guérin (BCG)-vaccinated rhesus 
macaques leads to a significant decrease in vaccine-induced immunity against TB.  
Additionally, depletion of CD8+ T cells in animals that had previously been infected 
with M. tuberculosis and cured by antibiotic therapy resulted in a loss of immunity upon 
reinfection (Chen et al., 2009). 
 
There is a substantial amount of data suggesting that !"  T cells play a role in the host 
immune response to tuberculosis.  !"  T cells are large granular lymphocytes that can 
develop a dendritic morphology in lymphoid tissues (Schluger and Rom, 1998).  They 
typically comprise less than 10% of T cells in peripheral blood and lymphoid tissues 
(Kaufmann, 1996). 
 
!"  T cell receptors are specialized to bind certain kinds of ligands, including heat-shock 
proteins and nonpeptide ligands such as phosphorylated ligands or mycobacterial lipid 
antigens.  They are not restricted by MHC class I and class II molecules and may bind 
free antigen or antigens presented by non-classical MHC-like molecules (Murphy et al., 
2008). 
 
!"  T cells can lyse M. tuberculosis infected macrophages and monocytes (Tsukaguchi 
et al., 1995) and produce the cytokines IFN- !  and TNF- !  in response to M. 
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tuberculosis (Barnes et al., 1993a).  They are also an important source of IL-17 during 
M. tuberculosis infection (Torrado and Cooper, 2010).  A study by Peng et al. (2008) 
found that a large proportion (59.2%) of IL-17-producing cells in the peripheral blood 
of TB patients were !"  T cells. 
 
Barnes et al. (1992) demonstrated that the percentages of !"  T cells in peripheral blood 
from patients with ‘protective and resistant immunity’ (tuberculin-skin-positive patients 
and patients with tuberculous pleuritis), 25-30% of total T lymphocytes, were 
significantly greater than in those with ineffective immunity (advanced pulmonary 
tuberculosis or miliary tuberculosis), 2-9% of total T lymphocytes.  Studies have also 
found that tuberculin-positive individuals in frequent contact with patients with active 
TB had a greater percentage of !"  T cells in their peripheral blood than those without 
constant contact (Ueta et al., 1994).  Patients with active tuberculosis showed no 
increase in the percentage of !"  T cells.  Tazi et al. (1992) also found no increase in 
circulating !"  cells among patients with active TB as compared with normal tuberculin-
negative control subjects. 
 
Mycobacterial cell wall products, especially the cell wall component 
lipoarabinomannan (LAM), release chemokines that promote the migration of T cells to 
the site of infection (Schluger and Rom, 1998; Wigginton and Kirschner, 2001). 
 
2.4.2 Humoral Immunity 
 
Activated B cells differentiate into antibody-secreting plasma cells.  Antibodies 
contribute to host immunity in three main ways: neutralization, opsonization and 
complement activation.  Antibodies can bind to pathogens and their products and 
prevent them from entering cells that they might infect or destroy.  This process is 
known as neutralization.  Neutralization by antibodies is important for protection 
against viruses and bacterial toxins.  Antibodies protect against bacteria that multiply 
outside cells by facilitating the uptake of the pathogen by phagocytic cells such as 
macrophages or neutrophils.  The coating of pathogens and foreign particles to enhance 
phagocytosis is known as opsonization.  Antibodies bound to pathogens can activate 
proteins of the complement system.  The main function of complement proteins is 
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opsonization.  Complement components can also recruit phagocytic cells to the site of 
infection and destroy certain microorganisms directly.  Terminal complement 
components (C5b-C9) interact to form a membrane-attack complex, which creates a 
pore in the cell membrane of pathogens, leading to their death (Murphy et al., 2008). 
 
B cells are professional antigen presenting cells capable of enhancing cell-mediated 
immunity through antigen presentation to T cells.  They bind specific soluble molecules 
via cell-surface receptors and internalize the bound molecules by receptor-mediated 
endocytosis.  B cells can then process the internalized protein and display the peptide 
fragments as peptide:MHC class II complexes for presentation to antigen-specific CD4+ 
T cells (Murphy et al., 2008). 
 
The role of B cells in M. tuberculosis infection has been largely overlooked as antibody 
responses are not thought to offer significant protection against intracellular microbes.  
However, recent studies have shown that B cells do participate in the immune response 
to a variety of intracellular pathogens, including M. tuberculosis.  Ectopic follicle-like B 
cell aggregates have been found in the lungs of TB patients (Maglione and Chan, 2009).  
B lymphocytes are present in large numbers in human and murine granulomas (Algood 
et al., 2003). 
 
M. tuberculosis is a facultative intracellular pathogen that has both intracellular and 
extracellular phases in its infectious cycle (Abebe and Bjune, 2009).  Antibody can bind 
extracellular bacteria and may have an opsonizing role in TB infection, facilitating 
bacterial uptake by phagocytic cells. 
 
de Valliere et al. (2005) investigated the ability of antibodies induced by BCG 
vaccination to protect against mycobacterial infections.  Mycobacterium-specific 
antibodies were detected in serum samples from volunteers who had received two 
intradermal BCG vaccinations six months apart.  Vaccination led to a significant 
increase in lipoarabinomannan (LAM)-specific immunoglobulin G (IgG).  
Antimycobacterial antibodies were found to enhance both innate and cell-mediated 
immune responses.  Internalization and killing of BCG by neutrophils, monocytes and 
macrophages were significantly enhanced in post-vaccination serum samples.  
Mycobacteria coated with antibodies were also processed and presented more 
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effectively by dendritic cells.  In the presence of dendritic cells BCG-induced antibodies 
led to enhanced proliferation of both IFN-! -producing Mycobacterium-specific CD4+ 
and CD8+ T cells, and degranulating CD8+ T cells. 
 
2.4.3 Immunological Memory 
 
Immunological memory enables the immune system to respond to previously 
encountered pathogens more rapidly and effectively.  Memory responses are called 
secondary immune responses, tertiary immune responses etc., depending on the number 
of exposures to the antigen.  Immunological memory consists of a population of long-
lived antigen-specific lymphocytes formed during the adaptive immune response that 
can persist once the antigen has been eliminated (Murphy et al., 2008). 
 
CD4+ and CD8+ T cells can differentiate into two types of memory cells: effector 
memory cells (TEM) and central memory cells (TCM).  These cells have different 
phenotypic and functional properties.  Linear T cell differentiation (as described by 
Lanzavecchia and Sallusto (2000)) is shown in !"#$%&' *),.  Effector memory cells 
readily migrate to inflamed tissues and display rapid effector function.  CD8 TEM carry 
large amounts of perforin and CD4 and CD8 TEM produce large amounts of cytokines.  
The TEM pool contains Th1 cells, Th2 cells and cytotoxic T cells.  Central memory cells 
home to T cell areas of peripheral lymphoid tissue.  These cells have little or no effector 
function but readily proliferate and differentiate into effector cells (TEM) following 
antigen stimulation (Sallusto et al., 2004).  TEM migrate through non-lymphoid tissues, 
whereas TCM reside mainly in secondary lymphoid tissue.  Memory T cells have a lower 
activation threshold than naïve cells and do not require costimulation (Sallusto et al., 
1999). 
 
The development of memory T cells during chronic infections such as tuberculosis is 
not well understood.  Antigen persistence may result in continual activation signals to T 
cells and prevent effector cells from developing into memory cells (Goldsack and 
Kirman, 2007).  Chronic viral infections inhibit the development of memory T cells 
(Wherry and Ahmed, 2004). 
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Figure 2.4 Linear T cell differentiation.  The expression of many proteins changes when T cells 
differentiate.  Markers which allow us to distinguish between different cell types include CCR7, a 
chemokine receptor which affects migration to the lymph node, CD62L, a receptor for homing to the 
lymph node, CD69, an early activation marker, CD25, part of the receptor for IL-2 and CD127, part of 
the receptor for IL-7 (De Rosa et al., 2001; Iezzi et al., 2001; Kaech et al., 2002; Lanzavecchia and 
Sallusto, 2000; Lozza et al., 2008; McKinstry et al., 2008; Murphy et al., 2008; Sallusto et al., 1999).  
This figure is adapted from Lanzavecchia and Sallusto (2000). 
 
Serbina and Flynn (2001) investigated the T cell memory and recall response to M. 
tuberculosis.  Mice were infected with M. tuberculosis and treated with anti-
mycobacterial drugs to allow the development of memory cells.  The lungs of the mice 
contained CD4+ and CD8+ T cells with the cell surface phenotype characteristic of 
memory cells.  Upon secondary challenge, there was a rapid response of both subsets in 
the lungs resulting in enhanced control of infection.  At one week post-challenge more 
than 30% of CD4+ and CD8+ T cells in the lungs of immune mice expressed the 
activation marker CD69 and could be re-stimulated to produce IFN-! .  Less than 6% of 
T cells in the lungs of naïve challenged mice were CD69+ and IFN-!  production was 
not observed.  CD8+ T cells from both naïve and memory mice were cytotoxic towards 
M. tuberculosis-infected macrophages.  A study by Kamath et al. (2006) found that 
antigen-specific CD8+ T cells with properties of central memory cells develop in 
lymphoid organs of mice during chronic infection and persist after clearance of 
infection. 
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!"  T cells from the peripheral blood of BCG-vaccinated adults display enhanced 
responsiveness to mycobacterial antigens compared to non-sensitized controls.  This 
suggests that !"  T cells may develop a memory-like phenotype (Hoft et al., 1998). 
 
2.5 Cytokines and Chemokines 
 
Cytokines and chemokines initiate the inflammatory response to a pathogen.  
Inflammation recruits cells and molecules of the innate immune system out of the blood 
and into the site of infection where they are needed to destroy the pathogen directly.  It 
also increases the flow of lymph carrying microbes and antigen-bearing cells to nearby 
lymphoid tissues, where they activate lymphocytes and initiate the adaptive immune 
response.  Once the adaptive immune response has been initiated, inflammation recruits 
the effector cells and molecules (antibody molecules and effector T cells) of the 
adaptive immune system to the site of infection (Murphy et al., 2008).  The local 
inflammatory response is crucial to the control of an infection, but it may also 
contribute to the chronic infection and associated pathology (Flynn and Chan, 2001a). 
 
2.5.1 Cytokines 
 
Cytokines are small proteins secreted by cells that affect the behaviour of nearby cells 
via specific cytokine receptors (Murphy et al., 2008).  Cytokines play a key role in the 
protective response to TB infection.  Cytokines regulate the cells of the immune system 
and are responsible for cellular activation, deactivation and differentiation (Flynn and 
Chan, 2001a; Wigginton and Kirschner, 2001). 
 
Interleukin-12 (IL-12) is a key cytokine in the control of M. tuberculosis infection.  It is 
a pro-inflammatory cytokine produced by macrophages and dendritic cells following 
phagocytosis of M. tuberculosis bacilli (Henderson et al., 1997; Ladel et al., 1997b).  
IL-12 promotes the development of a Th1 response by inducing the differentiation of 
Th0 cells to Th1 cells (O'Garra, 1998).  IL-12 also enhances the production of IFN-!  
(Flynn and Chan, 2001a).  IL-12p40 (a subunit of IL-12 and IL-23 (Cooper and Khader, 
2007))-deficient mice are highly susceptible to M. tuberculosis infection and are unable 
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to control bacterial growth.  These mice suffer from substantially reduced IFN-!  and 
TNF-!  production (resulting in reduced macrophage activation) and delayed activation 
of antigen-specific T cells (Cooper et al., 1997).  Individuals with mutations in 
IL-12p40 or IL-12 receptor genes are prone to mycobacterial infections (BCG or 
Mycobacterium avium infection) (Ottenhoff et al., 1998). 
 
Interferon-!  (IFN-! ) plays a major role in the host response to M. tuberculosis.  It is 
produced by macrophages, natural killer cells, CD4+ T cells (Th0 and Th1 cells), CD8+ 
T cells and !"  T cells (Barnes et al., 1993a; Fenton et al., 1997; Korbel et al., 2008).  
IFN-!  induces macrophage activation and promotes the differentiation of Th0 cells to 
Th1 cells (O'Garra, 1998).  IFN-!  also increases the expression of MHC class I and 
class II molecules, leading to increased antigen presentation (Murphy et al., 2008), and 
stimulates the production of IL-15 and IL-18 by monocytes (Vankayalapati et al., 
2004).  Mice in which the IFN-!  gene has been disrupted are unable to contain M. 
tuberculosis infection and suffer from widespread tissue damage and necrosis 
associated with a very high bacterial load (Cooper et al., 1993; Flynn et al., 1993).  
Macrophage activation and antigen presentation are also defective in mice deficient in 
IFN-! .  Such mice have impaired production of macrophage antimicrobial products 
(RNI and ROI) and reduced expression of macrophage MHC class II molecules (Dalton 
et al., 1993).  Individuals with mutations in IFN-!  receptor genes are susceptible to 
infection from poorly pathogenic mycobacteria (Ottenhoff et al., 1998). 
 
Tumour necrosis factor-!  (TNF-! ) is produced by macrophages, dendritic cells, 
CD4+ T cells (Th1 cells), CD8+ T cells and !"  T cells in response to M. tuberculosis 
infection (Barnes et al., 1993a; Henderson et al., 1997; Ladel et al., 1997b; Serbina and 
Flynn, 1999).  This cytokine plays multiple roles in the host response to tuberculosis.  
TNF-!  activates macrophages and is involved in granuloma formation, maintenance 
and function.  TNF-!  affects cell localization within the lung tissue as well as the 
migration of cells to the lung by influencing the expression of adhesion molecules, 
chemokines and chemokine receptors (Flynn and Chan, 2001a).  TNF-!  also induces 
the apoptosis of infected macrophages (Keane et al., 1997).  The use of monoclonal 
anti-TNF-!  antibody for the treatment of rheumatoid arthritis and Crohn’s disease is 
associated with reactivation of tuberculosis (van Crevel et al., 2002).  Mice deficient in 
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TNF-!  or the TNF-!  receptor succumb rapidly to M. tuberculosis infection with a 
high bacterial burden.  Granuloma formation is defective in such mice and a delay in 
macrophage RNI production is observed (Flynn et al., 1995).  TNF-!  has also been 
implicated in the pathology of TB and is a major factor in host-mediated lung tissue 
damage (Flynn and Chan, 2001a). 
 
IL-1!  is another pro-inflammatory cytokine that has a protective role in tuberculosis 
infection.  It is produced by monocytes, macrophages and dendritic cells (van Crevel et 
al., 2002).  IL-1 ! / "  double knockout (KO) mice develop significantly larger 
granulomatous lesions in their lungs than wild-type mice and produce less NO (Yamada 
et al., 2000).  There are two receptors that bind IL-1, IL-1 receptor type 1 and IL-1 
receptor type 2 (Murphy et al., 2008).  IL-1 binding to IL-1 receptor type 1 results in 
signal transduction, while the IL-1 type 2 receptor acts as a decoy receptor.  IL-1 type I 
receptor-deficient mice are more susceptible to pulmonary TB and suffer increased 
mycobacterial outgrowth and defective granuloma formation (Juffermans et al., 2000). 
 
IL-2 plays a critical role in initiating adaptive immune responses by driving the 
proliferation and differentiation of activated T cells (Murphy et al., 2008).  Naïve CD4+ 
T cells produce IL-2 in response to antigenic stimulation.  IL-2 is also produced by Th0 
and Th1 cells (O'Garra, 1998). 
 
IL-15 mediates protection against M. tuberculosis.  It is produced primarily by 
monocytes and macrophages (Doherty et al., 1996).  IL-15 stimulates the proliferation 
and activation of T cells and NK cells (van Crevel et al., 2002), enhances the long-term 
survival and proliferation of CD8+ memory T cells (Murphy et al., 2008) and promotes 
the survival of naïve CD8+ T cells (Berard et al., 2003).  IL-15 is also a potent 
chemoattractant (Wilkinson and Liew, 1995).  Defective CD8+ T cell responses have 
been observed in IL-15-deficient mice following aerosol infection with M. tuberculosis.  
CD8+ T cells failed to accumulate efficiently in the draining lymph node and at the site 
of infection, and IFN-!  production and cytotoxicity were impaired in CD8+ T cells 
(Rausch et al., 2006). 
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IL-7 is required for the survival of CD4+ and CD8+ memory T cells (Murphy et al., 
2008).  IL-7 supports the growth of !"  and !"  T cells and the proliferation of mature 
T cells, increases CTL activity and enhances the antimicrobial activity of monocytes 
(Sieling et al., 1995).  Infection of macrophages with M. tuberculosis induces the 
production of IL-7 and IL-15.  Both these cytokines are able to enhance the survival of 
M. tuberculosis infected mice when given as a therapy (three weeks post-infection) 
(Maeurer et al., 2000). 
 
IL-17 is a pro-inflammatory cytokine that induces chemokine expression and recruits 
neutrophils to the site of infection.  It is produced by Th17 cells and !"  T cells (Khader 
and Cooper, 2008).  IL-17 has been found to play a role in the induction of IFN-!  
producing T cells and granuloma formation following pulmonary infection of mice by 
BCG.  IL-17-deficient mice produce less IFN-!  than wild-type mice following BCG 
infection and display impaired granuloma formation.  The bronchoalveolar lavage 
(BAL) cells of IL-17 KO mice also contain significantly lower numbers of neutrophils.  
However, bacterial numbers in the organs of KO mice are similar to those in wild-type 
mice (Umemura et al., 2007). 
 
IL-23 is produced by dendritic cells in response to M. tuberculosis infection.  IL-23 
promotes the expansion of Th17 cells and induces the expression of IL-17 by !"  T cells 
(Khader and Cooper, 2008).  IL-23 can also compensate for the absence of IL-12 during 
infection by inducing antigen-specific IFN-! -producing CD4+ T cells (Khader et al., 
2005).  Neither IL-17 nor IL-23 plays a significant role in the protective response to M. 
tuberculosis infection in mice (Chackerian et al., 2006; Umemura et al., 2007), but 
there is evidence that both these cytokines are required for an accelerated IFN-!  
response by memory CD4+ T cells following a secondary M. tuberculosis infection 
(Khader et al., 2007).  Vaccination induces the generation of IL-23-dependent, IL-17-
producing memory T cells that populate the lung and trigger the expression of 
chemokines that recruit IFN-! -producing CD4+ T cells.  The absence of IL-17 or 
IL-23 results in reduced chemokine expression and a lower IFN-!  recall response. 
 
IL-18 plays a role in the generation of protective immunity against TB.  IL-18 is 
produced by macrophages.  It induces the production of IFN-!  by T cells and NK cells 
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and promotes Th1 differentiation (Murphy et al., 2008).  IL-18 KO mice infected with 
M. tuberculosis have a higher bacterial load and display decreased IFN-!  production 
compared to wild-type mice (Sugawara et al., 1999). 
 
IL-6 plays a role in early immune responses to tuberculosis.  It has both pro- and anti-
inflammatory effects (van Crevel et al., 2002) and is produced by dendritic cells 
(Murphy et al., 2008).  IL-6 initiates early inflammatory responses and is involved in 
hematopoiesis and differentiation of lymphocytes (Flynn and Chan, 2001a; Ladel et al., 
1997a), inducing the differentiation of Th17 cells in the presence of TGF-!  (Korn et 
al., 2009).  However, there is evidence that this cytokine suppresses the production of 
TNF-!  and IL-1!  induced by lipopolysaccharide (LPS) (Schindler et al., 1990).  Early 
increases in bacterial load and delayed IFN-!  production were observed in IL-6 KO 
mice following a low-dose aerosol challenge, but these mice were able to contain 
bacterial growth and develop a protective memory response to secondary infection 
(Saunders et al., 2000). 
 
IL-4 is a key Th2-type cytokine.  It is an anti-inflammatory cytokine produced by CD4+ 
T cells (Th0 and Th2 cells).  IL-4 promotes the development of a Th2 response, 
inducing the differentiation of Th0 cells to Th2 cells, and down-regulating Th0/Th1 
differentiation (O'Garra, 1998).  The role of IL-4 in tuberculosis is the subject of some 
controversy.  Detection of IL-4 in tuberculosis patients is variable (Flynn and Chan, 
2001a).  Several studies have detected increased IL-4 production in TB patients, 
especially those with cavitary disease, (Casarini et al., 1999; Sanchez et al., 1994; Seah 
et al., 2000; Surcel et al., 1994; van Crevel et al., 2000), while others have indicated 
that a prominent Th2 response is not associated with TB (Barnes et al., 1993b; Condos 
et al., 1998; Lin et al., 1996; Zhang et al., 1995a).  In one study analyzing cytokine 
gene expression in the granulomas of five patients with advanced TB, no correlation 
was found between the presence of IL-4 and the prognosis of the patient.  IL-4 was 
detected in the granulomas of three patients, but all five patients were successfully 
treated and remained disease free for at least two years after surgery (Fenhalls et al., 
2000).  IL-4 deficient mice are no more capable at resisting mycobacterial infection 
than wild-type mice (Erb et al., 1998; North, 1998).  These data suggest that the 
 39 
presence of IL-4 does not prevent the control of infection, but may be a consequence of 
disease (van Crevel et al., 2002). 
 
IL-10 is primarily an anti-inflammatory cytokine.  It is produced by macrophages, 
dendritic cells and T cells during M. tuberculosis infection (Barnes et al., 1993a; 
Demangel et al., 2002; Giacomini et al., 2001).  IL-10 deactivates macrophages and 
down-regulates the production of IL-12, IFN-!  and TNF-!  (van Crevel et al., 2002).  
This cytokine also induces the differentiation of Tregs (Murphy et al., 2008), inhibits T 
cell responses and affects the antigen-presenting ability of infected cells (Flynn and 
Chan, 2001a), down-regulating MHC class II expression (Koppelman et al., 1997).  
Transgenic mice that produce excess IL-10 are more susceptible to M. tuberculosis 
infection and develop high bacterial burdens (Murray et al., 1997).  The excess IL-10 
did not have a significant effect on T cell function or development, suggesting that the 
inability to control infection is due to the reduced antimicrobial activity of 
macrophages.  In contrast, IL-10 deficient mice have lower bacterial burdens than wild-
type mice early in the infection (Murray and Young, 1999).  However, other studies 
have shown that IL-10 has little to no effect on bacterial burden (Erb et al., 1998; North, 
1998). 
 
Transforming growth factor- !  (TGF- ! ) is an anti-inflammatory cytokine.  M. 
tuberculosis induces the production of TGF-!  by monocytes and dendritic cells (van 
Crevel et al., 2002).  TGF-!  induces the differentiation of Th17 cells and Tregs (Korn 
et al., 2009).  It is involved in the deactivation of macrophages, inhibiting the 
production of RNI and ROI.  TGF-!  also inhibits T cell proliferation, interferes with 
NK and CTL activity and down-regulates the production of IFN-! , TNF-!  and IL-1 
(Schluger and Rom, 1998).  TGF-!  inhibits proliferation and IFN-!  production by M. 
tuberculosis-reactive CD4+ T cells and !"  T cells (Rojas et al., 1999). 
 
Anti-inflammatory cytokines help regulate immune responses during infection, 
preventing excessive tissue damage (van Crevel et al., 2002).  The destruction of lung 
tissue, which is mediated by the vigorous immune response that is crucial for protection 
during the initial stages of infection, benefits the pathogen by enhancing the 
transmission of disease (Young et al., 2008). 
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2.5.2 Chemokines 
 
Chemokines are small proteins that have chemoattractant properties.  They stimulate 
cell migration and localization and play a key role in granuloma formation and 
maintenance.  Chemokines attract effector cells such as neutrophils, basophils, 
monocytes/macrophages, lymphocytes, dendritic cells and natural killer cells bearing 
appropriate chemokine receptors to sites of infection (Flynn and Chan, 2001a; Murphy 
et al., 2008). 
 
A number of chemokines are produced in response to M. tuberculosis infection.  Human 
alveolar macrophages produce CCL2 (monocyte chemoattractant protein-1 (MCP-1)), 
CCL3 (macrophage inflammatory protein 1-!  (MIP1-! )), CCL4 (MIP1-! ), CCL5 
(regulated upon activation normal T cell expressed and secreted (RANTES)) and 
CXCL8 (IL-8) in response to M. tuberculosis infection (Sadek et al., 1998; Saukkonen 
et al., 2002; Zhang et al., 1995b).  Granulocytes stimulated with M. tuberculosis or 
LAM in vitro secrete CXCL8 and CXCL1 (growth regulated oncogene-!  (GRO-! )) 
(Riedel and Kaufmann, 1997).  Bronchial epithelial cells produce CXCL9 (monokine 
induced by interferon-!  (Mig)), CXCL10 (interferon-inducible protein (IP-10)) and 
CXCL11 (interferon-inducible T cell !  chemoattractant (I-TAC)) (Algood et al., 
2003).  Elevated levels of CCL2, CCL5, CCL7, CCL12, CXCL8 and CXCL10 have 
been found in BAL fluid from TB patients compared to uninfected controls (Kurashima 
et al., 1997; Miotto et al., 2001; Sadek et al., 1998; Sauty et al., 1999).  
 
2.6 Latent Tuberculosis 
 
The ability of M. tuberculosis to persist in the host and establish a latent infection is one 
of the features that make it such a successful pathogen.  Latently infected individuals 
are a reservoir for future disease and pose a significant obstacle to the eradication of 
TB. 
 
Latent TB can be viewed as an equilibrium between bacteria and host.  Most individuals 
infected with M. tuberculosis generate a strong immune response and are able to 
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contain, but not eliminate, infection.  M. tuberculosis has developed mechanisms to 
evade elimination by the immune system.  However, the detailed mechanisms involved 
in achieving and maintaining latency are poorly understood. 
 
The physiological state of tubercle bacilli during latent infection is unknown.  The 
organism may be in a dormant non-replicating state, actively replicating but killed off 
by the immune system at the same rate, or metabolically altered with limited or 
infrequent replicative cycles (Flynn and Chan, 2001a; Flynn and Chan, 2001b; 
Tufariello et al., 2003). 
 
Infection with M. tuberculosis is usually viewed in terms of a binary outcome – active 
disease or latent infection.  This is thought to be an oversimplification that has given 
rise to other terminologies in the literature to qualify infection.  A continuous spectrum 
of responses to TB infection has been proposed that better represents the biology of 
infection: innate immune response, acquired immune response, quiescent infection, 
active infection and disease (!"#$%&'*)-).  Innate immune response represents infection 
that is eliminated by innate immunity, without the need for an adaptive immune 
response.  Acquired immune response is proposed for infection that is cleared following 
the initiation of an adaptive immune response.  Quiescent infection represents an 
infection that is controlled by the immune response, but in which bacteria persist in a 
non-replicating form.  Active infection represents an infection in which bacterial 
replication is controlled by the immune system at a subclinical level.  Clinical disease 
denotes the development of symptoms caused by bacteria that replicate despite the 
ongoing immune response (Young et al., 2009). 
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Figure 2.5 Spectrum of tuberculosis infection.  This figure is adapted from Young et al. (2009). 
 
2.6.1 Immune evasion by Mycobacterium tuberculosis 
 
Mycobacterium tuberculosis has evolved a variety of mechanisms to subvert the 
protective mechanisms of the immune response and avoid recognition by its host.  M. 
tuberculosis is able to persist in macrophages within a granuloma for many years and is 
equipped with a variety of immune evasion strategies that allows its survival inside 
macrophages.  M. tuberculosis prevents T cell recognition of infected macrophages by 
inhibiting a number of intracellular processes associated with antigen presentation 
including antigen processing, MHC class II expression, trafficking of MHC class II 
molecules and peptide-MHC class II binding (Chang et al., 2005).  M. tuberculosis is 
also able to limit activation of macrophages by IFN-!  (Flynn and Chan, 2001a) and 
evade macrophage killing processes by interfering with phagolysosome fusion and 
evading RNI toxicity (Flynn and Chan, 2003).  M. tuberculosis inhibits macrophage 
responses to IFN-!  by disrupting IFN-!  signalling and the transcription of IFN-! -
responsive genes (Fortune et al., 2004; Kincaid and Ernst, 2003; Ting et al., 1999).  
Several M. tuberculosis products appear to be responsible for modulating phagosome 
maturation, including cell wall components such as LAM (Gupta et al., 2012; Rohde et 
al., 2007; Russell, 2011).  M. tuberculosis can interfere with the recruitment and 
function of molecules involved in the vesicle tethering and fusion machinery (Flynn and 
Chan, 2003; Vergne et al., 2003).  LAM binding to DC-SIGN inhibits dendritic cell 
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maturation, decreases IL-12 production and induces the production of IL-10 by DCs.  
This inhibits antigen presentation, expression of MHC molecules and expression of co-
stimulatory receptors (Dietrich and Doherty, 2009). 
 
2.7 Treatment 
 
The aims of treatment of tuberculosis are to cure infected individuals without 
subsequent relapse, to prevent death from active tuberculosis, to reduce transmission to 
others, and to prevent the emergence and transmission of drug resistance (Frieden et al., 
2003). 
 
Anti-tuberculosis chemotherapy requires long-term treatment with a combination of 
drugs.  A TB treatment regimen usually consists of two phases: an initial intensive 
phase designed to kill actively growing and semi-dormant bacilli, and a continuation 
phase designed to eliminate remaining bacteria and prevent failure and relapse (Frieden 
et al., 2003).  Drug-susceptible TB can be treated with first-line anti-TB drugs, isoniazid 
(INH), rifampicin (RIF), pyrazinamide (PZA), ethambutol (EMB) and streptomycin 
(SM).  For new patients with drug-susceptible TB the World Health Organization 
recommends an initial phase of two months followed by a continuation phase of four 
months.  The initial phase of treatment reduces the duration of infectiousness and results 
in high sputum smear conversion rates.  During the initial phase treatment consists of 
isoniazid, rifampicin, pyrazinamide and ethambutol in fixed-dose combination.  The 
continuation phase consists of isoniazid and rifampicin in fixed-dose combination.  The 
optimal dosing frequency for new patients with pulmonary TB is daily throughout the 
course of treatment.  An acceptable alternative is a daily intensive phase followed by a 
three times weekly continuation phase (or three times weekly throughout therapy for 
patients not living with HIV or in an HIV-prevalent setting), provided that the patient is 
receiving directly observed therapy.  For TB patients living with HIV or living in HIV-
prevalent settings, daily dosing throughout the course of therapy is preferred (World 
Health Organization, 2010b). 
 
Isoniazid and rifampicin are the most powerful bactericidal drugs.  Isoniazid is highly 
bactericidal against actively replicating bacilli (bacilli in the exponential phase of 
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growth).  Rifampicin is bactericidal against all populations of tubercle bacilli, including 
non-replicating bacilli.  Pyrazinamide is bactericidal against the slower-growing 
population of TB bacilli in acidic environments (Gumbo et al., 2007c), and shows 
bacteriostatic activity for growing bacilli with active metabolism (Zhang, 2005).  
Ethambutol is bacteriostatic (Frieden et al., 2003) and is used alongside more powerful 
drugs to prevent or delay the emergence of drug-resistant strains (World Health 
Organization, 2003; World Health Organization, 2010b).  The effect of a drug on 
bacteria in the exponential phase of growth is typically measured using the index of 
early bactericidal activity (EBA) (Gumbo et al., 2007b).  EBA is measured as the fall in 
counts of colony forming units (CFU)/mL sputum/day during the first two days of 
treatment (Donald and Diacon, 2008).  Isoniazid is responsible for an initial kill of up to 
95% of bacilli during the first two days of treatment.  Its bactericidal role in the initial 
phase of treatment is then replaced by rifampicin (which kills non-replicating bacilli) 
and pyrazinamide (which kills slower-growing bacilli) (Mitchison, 2000). 
 
Non-adherence to tuberculosis treatment has been common so national TB programmes 
are advised to provide supervision and support for all TB patients to ensure completion 
of the full course of therapy.  Globally, the cure rate for new cases of drug-susceptible 
TB in HIV negative patients is around 90% (World Health Organization, 2012a), but 
treatment may be successful in 95% of cases or more under ideal conditions by directly 
observed treatment, short-course (DOTS) strategy (Nuermberger et al., 2010). 
 
The recommended treatment regimen for individuals with latent tuberculosis infection 
(LTBI) is isoniazid given daily for nine months (Cohn et al., 2000).  Alternative 
regimens include rifampicin given for four months and isoniazid and rifampicin given 
daily for three months (Nuermberger et al., 2010). 
 
2.7.1 Drug Resistance 
 
Strains of M. tuberculosis resistant to all major anti-TB drugs have emerged.  Drug 
resistance is caused by mismanagement of tuberculosis treatment, including inadequate 
treatment, non-adherence and unreliable drug supplies.  Drug-resistant TB is transmitted 
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from person to person in the same way as drug susceptible TB (World Health 
Organization, 2011c; World Health Organization, 2012b). 
 
Multidrug-resistant TB (MDR-TB) is disease caused by TB bacilli resistant to at least 
isoniazid and rifampicin (standard first-line drugs).  The World Health Organization 
estimates that there were 630,000 prevalent cases of MDR-TB in 2011.  MDR-TB cases 
accounted for approximately 3.7% of all new TB cases, and 20% of retreatment cases 
(World Health Organization, 2012a).  It was estimated that there were 440,000 incident 
cases in 2008.  The proportion of MDR-TB among previously treated TB cases reported 
globally ranges from 0-61.6%, compared to 0-28.3% among new cases.   In 2008, an 
estimated 150,000 deaths were caused by MDR-TB (World Health Organization, 
2010a). 
 
MDR-TB is generally treatable, but it requires longer treatment with more expensive 
second-line anti-TB drugs (which also produce more severe side effects) (World Health 
Organization, 2012b).  Second-line anti-TB drugs include the injectable agents 
amikacin, kanamycin and capreomycin, the fluoroquinolones levofloxacin, 
moxifloxacin and ofloxacin, and the oral bacteriostatic agents para-aminosalicylic acid, 
cycloserine, terizidone, ethionamide and protionamide (World Health Organization, 
2010b).  WHO guidelines recommend a total treatment duration of twenty months for 
most patients diagnosed with MDR-TB (World Health Organization, 2011b).  MDR-TB 
is usually treated for a minimum of eighteen months and for at least twelve months after 
culture conversion (Orenstein et al., 2009). 
 
Extensively drug-resistant TB (XDR-TB) occurs when resistance to any 
fluoroquinolone and at least one of the second-line injectable anti-TB drugs (amikacin, 
kanamycin or capreomycin) emerges alongside MDR-TB.  XDR-TB has been identified 
in eighty-four countries, and the World Health Organization estimates that the 
proportion of XDR-TB among MDR-TB cases is 9% (World Health Organization, 
2012a).  There are no official estimates on the number of XDR-TB cases, but it is 
thought that 25,000 cases emerge every year (World Health Organization, 2011c).  
Patients with XDR-TB have limited treatment options and a poor prognosis (World 
Health Organization, 2007). 
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2.7.2 Antimycobacterial Agents 
 
Isoniazid is a prodrug that is inactive until it is processed by M. tuberculosis catalase-
peroxidase (KatG) into its active form to generate ROI and RNI, which attack multiple 
targets in the tubercle bacilli.  INH inhibits cell wall mycolic acid synthesis.  The target 
of INH was identified to be enoyl acyl carrier protein reductase (InhA).  The reactive 
species produced during INH activation also affect deoxyribonucleic acid (DNA), lipids 
and carbohydrates and inhibit nicotinamide adenine dinucleotide (NAD) metabolism.  
Rifampicin inhibits ribonucleic acid (RNA) synthesis by binding to the bacterial DNA-
dependent RNA polymerase ! -subunit.  Pyrazinamide is a prodrug that is converted to 
its active form, pyrazinoic acid (POA), by the pyrazinamidase/nicotinamidase enzyme 
of M. tuberculosis.  PZA disrupts membrane transport and depletes membrane energy 
(Zhang, 2005).  However, its molecular target remains unknown (Shi et al., 2011).  PZA 
has high in vivo sterilizing activity and shortens the duration of TB chemotherapy from 
the nine to twelve months required before its introduction to the current standard of six 
months.  PZA is more active against old cultures than young cultures and more active at 
low oxygen or anaerobic conditions.  Ethambutol interferes with the biosynthesis of cell 
wall arabinogalactan.  The target of EMB is arabinosyl transferase.  Streptomycin 
inhibits protein synthesis by inhibiting initiation of messenger RNA (mRNA) 
translation, inducing misreading of the genetic code and damaging the cell membrane.  
The site of action is at ribosomal protein S12 and 16S ribosomal RNA (rRNA) in the 
30S subunit of the ribosome (Zhang, 2005). 
 
The fluoroquinolones are bactericidal against M. tuberculosis.  They inhibit DNA 
synthesis by targeting the DNA gyrase A and B subunits (Zhang, 2005).  They have 
effective tissue penetration and distribution into lungs and alveolar macrophages 
(Ginsburg et al., 2003).  Fluoroquinolones such as moxifloxacin are active against non-
growing tubercle bacilli (Sala et al., 2010) and are able to kill a subpopulation of 
bacteria not killed by RIF in vitro (RIF-tolerant persister cells) (Hu et al., 2003). 
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2.8 Immunization 
 
Vaccination has made a significant contribution to public health, dramatically reducing 
death from infectious disease.  Vaccination involves the injection of a dead or 
attenuated (nonpathogenic) form of an organism to induce an antigen-specific adaptive 
immune response to the pathogen.  This results in the generation of immunological 
memory, which provides long-lasting protective immunity to reinfection with the same 
pathogen (Murphy et al., 2008). 
 
2.8.1 Bacillus Calmette-Guérin 
 
The current vaccine against tuberculosis is Mycobacterium bovis bacillus Calmette-
Guérin (BCG), an attenuated strain of M. bovis.  The BCG vaccine is cheap and safe 
and has been the most widely used vaccine in the world over the past fifty years 
(Andersen and Doherty, 2005). 
 
However, the efficacy of BCG in the prevention of TB is variable.  BCG protects 
children against tuberculosis, including the most severe childhood manifestations of the 
disease such as TB meningitis, but is unreliable against adult pulmonary TB, 
particularly in regions where TB is endemic.  BCG only provides protection against 
disease for a limited period of time, inducing protective memory that lasts for ten to 
twenty years (Aagaard et al., 2009; Colditz et al., 1995; Doherty and Andersen, 2005; 
Sterne et al., 1998).  Estimates of protection from vaccine field trials range from 0-80% 
(Colditz et al., 1994; Fine, 1995).  The observed variation in BCG efficacy may be due 
to differences in the strain of BCG, the age at vaccination or geographic location 
(Brandt et al., 2002). 
 
Studies indicate that prior sensitization to mycobacterial antigens, e.g. from exposure to 
environmental mycobacteria, M. tuberculosis infection or BCG vaccination, can affect 
the development of BCG-induced protective immunity against TB (Aagaard et al., 
2009).  Exposure to non-tuberculous mycobacteria can result in antimycobacterial 
immunity that is recalled rapidly after BCG vaccination, inhibiting multiplication of the 
vaccine and preventing the induction of an efficient BCG-mediated immune response.   
Protection provided by environmental mycobacteria can also mask the effect of 
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subsequent immunization (Brandt et al., 2002).  The failure of BCG to replicate in 
sensitized individuals suggests that BCG may be ineffective when used as a booster 
vaccine to counteract the waning effect of BCG-induced protection (Aagaard et al., 
2009; Karonga Prevention Trial Group, 1996; Leung et al., 2001; Sepulveda et al., 
1992; Tala-Heikkila et al., 1998). 
 
There is still a lack of understanding regarding the immunological action of BCG, 
including the stability and longevity of induced memory T cell subsets.  BCG appears to 
generate large numbers of effector memory T cells in the lungs, but only relatively low 
numbers of central memory cells (McShane et al., 2012).  The failure of the memory T 
cell response may result from immune evasion by M. tuberculosis or an impaired 
memory T cell response (Kamath et al., 2006). 
 
Vaccination is the most effective means of controlling M. tuberculosis infection.  There 
is a pressing need for new and improved vaccines to fight TB (Young and Dye, 2006).  
However, a lack of complete knowledge of the mechanisms of host immunity against 
M. tuberculosis and how M. tuberculosis is able to counteract the immune response is a 
significant barrier to the rational design of a novel vaccine. 
 
2.9 Persistence of Mycobacterium tuberculosis 
 
Mycobacterium tuberculosis has the ability to survive in its host for decades without 
causing active disease.  Tubercle bacilli can persist in human tissue to establish a latent 
infection, but with the potential to cause primary TB in the future (reactivation TB). 
 
This phenomenon depends on both host and bacterial factors.  The majority of 
individuals infected with M. tuberculosis mount an effective immune response and are 
able to control bacterial growth, while the bacilli themselves have developed 
mechanisms that allow them to survive in adverse environmental conditions.  Among 
these is the ability of M. tuberculosis to enter a quiescent state, or a state of ‘non-
replicating persistence’ (NRP), but maintain the ability to reactivate or resume growth 
when conditions become more favourable (e.g. when the host immune response is 
compromised).  Factors that may induce NRP of tubercle bacilli include nutrient 
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limitation, oxygen depletion, shifts in pH and the production of growth-limiting 
products (Wayne and Sohaskey, 2001). 
 
Bacteria that are growing exponentially are more sensitive to antibiotics and stress 
(Zhang, 2004).  Bacterial growth involves various processes that can be corrupted or 
deregulated by different lethal agents, so one way in which bacterial cells can respond 
to stress is through the reduction or arrest of growth (Balaban, 2011).  Slow-growing or 
non-replicating bacteria and bacteria in the stationary phase of the growth cycle are 
tolerant to stress (Booth, 2002; Jayaraman, 2008). 
 
2.9.1 Persistence, Dormancy and Latency 
 
The terms persistence, dormancy and latency are frequently used when describing M. 
tuberculosis and disease pathogenesis.  However, they have not always been used 
consistently in the literature and this has created some confusion in the field (Gomez 
and McKinney, 2004; Zhang, 2004). 
 
The term ‘persistence’ is used to describe the capacity of bacterial cells to survive 
exposure to stress, such as immune pressure from the host or antibiotic treatment 
(Balaban et al., 2004; Zhang et al., 2012).  Bacteria have evolved numerous 
mechanisms that allow them to adapt to hostile conditions, including stress responses 
and antibiotic resistance (Keren et al., 2011). 
 
Dormancy is a stable, reversible, non-replicating state of a bacterial cell characterized 
by a global slowdown of metabolic processes.  Dormant bacteria (i.e. bacteria in a state 
of dormancy) have low/negligible metabolic activity and do not divide, but they are 
ultimately culturable.  They do not form colonies immediately on media that normally 
support their growth but can be resuscitated to yield colonies under appropriate 
conditions.  Dormant bacteria show enhanced tolerance to stress and antimicrobial 
agents (Chao and Rubin, 2010; Kell et al., 1998; Lewis, 2007; Zhang, 2004). 
 
The term latency, or latent tuberculosis, refers to the situation where an individual has 
been exposed to M. tuberculosis and subsequently develops a subclinical or 
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asymptomatic infection (Cosma et al., 2003).  However, it does not tell us anything 
about the physiological state of the bacilli themselves (Zhang, 2004). 
 
Understanding the mechanisms behind mycobacterial persistence is important not only 
from a scientific perspective, but also for medical and public health reasons (Cosma et 
al., 2003).  Slow-growing and non-replicating bacilli may be responsible for latent 
infection, which presents a major challenge for effective TB control.  They are also 
more difficult to eliminate with current antimycobacterial drugs, leading to lengthy 
chemotherapy.  The prolonged nature of TB treatment regimens may contribute to the 
emergence of drug resistance due to patient non-adherence (Russell et al., 2010; Zhang, 
2004).  The physiological state of persistent bacilli (replicative and metabolic status) has 
important implications for antimycobacterial chemotherapy and the development of 
new, faster-acting drugs that can shorten the duration of treatment (Munoz-Elias et al., 
2005).  Non-growing microorganisms can exist in different physiological states (Kell et 
al., 1998). 
 
The location and phenotypic status of the bacterial population during latent infection is 
not well established and remains the subject of some controversy (Cosma et al., 2003; 
Gomez and McKinney, 2004).  Infected tissue may consist of a physiologically 
heterogeneous population of tubercle bacilli in different metabolic stages (Wayne and 
Hayes, 1996). 
 
It has been widely hypothesized that the bacterial population during latency consists of 
bacilli in a state of very slow replication or non-replicating persistence that are 
insensitive to killing by the host or antibiotics (Wayne and Sohaskey, 2001).  This 
hypothesis is consistent with observations from the murine model of TB.  For example, 
Munoz-Elias et al. (2005) reported that the stability of bacterial numbers in chronically 
infected mice is the result of slow or absent bacterial multiplication, and not bacterial 
replication balanced by killing by the host immune response.  However, there is 
evidence of ongoing bacterial replication during chronic infection in mice (Gill et al., 
2009).  A recent study in non-human primates showed that M. tuberculosis continues to 
acquire mutations during latency (Ford et al., 2011).  These mutations may be due to 
mycobacterial replication, or the result of oxidative damage.  In addition, the use of 
isoniazid in the prophylactic treatment of LTBI indicates that there must be at least 
 51 
some replicative activity during latency since isoniazid reduces the reactivation rate of 
PPD-positive individuals (Comstock et al., 1979). 
 
2.9.2 Evidence for Persistent Infection in Humans 
 
There is convincing evidence that M. tuberculosis can persist in its host from years to 
decades before giving rise to reactivation disease.  A molecular epidemiology study in 
Denmark provided evidence of the reactivation of M. tuberculosis in an individual 
thirty-three years after the initial infection (Lillebaek et al., 2002).  The extent to which 
reactivation disease contributes to the incidence of TB is unclear.  In low-prevalence 
settings where the risk of reinfection is low, an interval between a positive tuberculin 
skin test and clinical disease shows that an initial infection can leave a population of 
bacteria capable of causing disease in the future.  In high-prevalence settings it is more 
difficult to distinguish between reactivation disease and reinfection (Gomez and 
McKinney, 2004; Stewart et al., 2003). 
 
The hypothesis that M. tuberculosis can enter a quiescent state in humans is supported 
by clinical evidence from autopsy studies and studies of surgically resected lung tissue.  
Surgery has been used as a last resort to remove regions of affected tissue from patients 
who have failed drug treatment.  Examination of infected lung tissue revealed the 
heterogeneity of tuberculous lesions in individual patients, including open cavities, 
closed cavities and end-stage cavities.  The inner surface of open cavities contained 
high numbers of bacilli, indicating abundant bacterial growth at this site.  Homogenates 
from these lesions yielded colonies of tubercle bacilli in the normal timeframe (three to 
eight weeks).  In contrast, few bacteria were found in closed lesions, and these bacteria 
appeared to be in an altered state.  Closed lesions only yielded colonies of tubercle 
bacilli after prolonged incubation (three to ten months) (Boshoff and Barry, 2005; 
Kaplan et al., 2003; Loring and Vandiviere, 1956; McKinney, 2000; Ulrichs et al., 
2005; Vandiviere et al., 1956; Via et al., 2008). 
 
Varying rates of positive cultures have been reported in autopsy studies on 
asymptomatic individuals living in endemic areas but dying from causes other than TB, 
with different lesion types exhibiting different rates of positive cultures (Feldman and 
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Baggenstoss, 1938; Feldman and Baggenstoss, 1939; Griffith, 1929; Opie and Aronson, 
1927; Robertson, 1933; Young et al., 2009).  M. tuberculosis could be cultured from 
lesions of the apex of the lung, but recovery of readily culturable bacteria declined with 
increasing fibrosis and calcification.  Homogenates of lesions of the apical region of the 
lung typically caused TB when injected into guinea pigs, whereas homogenates of 
closed, calcified lesions rarely did.  Bacteria could also be cultured from lesion-free 
samples of lungs and lymph nodes, and samples from superficially normal lung tissue 
were found to cause infection in guinea pigs (Gomez and McKinney, 2004; Parrish et 
al., 1998; Stewart et al., 2003).  M. tuberculosis DNA has been detected in 
histologically normal lung tissue from fifteen of forty-seven individuals in Ethiopia and 
Mexico (Hernandez-Pando et al., 2000).  However, the presence of DNA does not allow 
the distinction between live and dead bacilli (Cosma et al., 2003). 
 
Pathological observations are confirmed by computed tomography (CT) scans of 
patients with active TB and patients with latent TB.  Integrating CT and positron 
emission tomography (PET) images provides a structural and functional map of the 
disease process.  18F-fluorodeoxyglucose (FDG)-PET can be used to reflect glucose 
uptake and metabolically active cells.  A range of findings are seen in CT scans of 
individuals with latent TB, some of which correspond to what is seen in patients with 
active disease.  FDG uptake varies greatly among lesions.  The range of results reported 
from autopsy studies and CT scans suggests that latent TB can be viewed as a spectrum 
of conditions that include diversity in bacterial load and overlap with those seen in 
active disease.  This could represent a slowly progressing form of disease, a chronic 
non-progressing percolating infection or the remnants of a waning infection (Barry et 
al., 2009). 
 
2.9.3 Models of Persistence 
 
Various animal and in vitro models have been developed to aid our understanding of 
mycobacterial persistence and provide insight into the mechanisms behind the 
production of persistent or dormant bacilli. 
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2.9.3.1 Animal Models 
 
Several animal models have been used to explore different aspects of human 
tuberculosis.  Although there is no natural animal reservoir for M. tuberculosis, many 
different animal species are susceptible to infection with this pathogen.  The most 
commonly used experimental animals are the mouse, rabbit and guinea pig.  Nonhuman 
primates, cattle and zebrafish and frogs infected with Mycobacterium marinum (Flynn, 
2006) have also been used in TB research (Dharmadhikari and Nardell, 2008).  A 
number of considerations need to made when choosing an animal model, including the 
research question being addressed, as well as more practical issues such as cost, 
laboratory space requirements and availability of immunologic reagents (Flynn, 2006). 
 
No animal model, with the possible exception of the nonhuman primate, is able to 
reproduce the complex spectrum of disease seen in humans (Hett and Rubin, 2008).  
There are substantial differences in TB susceptibility and disease manifestations among 
the species.  Nevertheless, animal models have contributed significantly to our 
understanding of the pathogenesis, pathology and immunology of TB and the efficacy 
of antimycobacterial therapy and vaccination (Dharmadhikari and Nardell, 2008; Flynn, 
2006).  Small animal models remain a useful tool for understanding TB pathogenesis 
because they allow the analysis of bacterial burden, histopathology and host survival 
(Stallings and Glickman, 2010). 
 
Mouse 
 
The murine model is the most extensively used because of its low cost, the availability 
of genetically defined strains, the availability of immunologic reagents and extensive 
literature regarding the immunology and chemotherapy of infectious diseases in the 
mouse (Boshoff and Barry, 2005; Gomez and McKinney, 2004).  Most of our 
knowledge regarding the immune response to TB comes from studies in mice (e.g. 
using transgenic and gene KO mice which have gain or loss of cell type or function, and 
antibody depletion studies to remove cell types or neutralize cytokines) (Kirschner et 
al., 2010). 
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Mice are relatively resistant to M. tuberculosis infection and are able to sustain a high 
bacterial load for months without any overt signs of disease (McMurray, 2001).  
Chemotherapy is usually required to reduce bacterial numbers (Flynn, 2006). 
 
There are significant differences between the granulomas that form in mice and those 
that form in humans.  In contrast to human granulomas, the granulomas that develop in 
mice are not well-formed structures, but a collection of macrophages and lymphocytes.  
One of the hallmarks of tuberculosis infection in humans is the formation of necrotic, 
caseating granulomas.  In active disease the human lung may contain a diverse spectrum 
of granuloma types – solid, necrotic, caseous and cavitary – with varying numbers of 
bacteria (Flynn, 2006).  The oxygen tension in human granulomas is also assumed to be 
low (Gill et al., 2009).  In contrast, tuberculosis granulomas in conventional mice 
strains rarely progress to necrosis, caseation and liquefaction (McMurray, 2001), and 
they lack hypoxia (Aly et al., 2006; Tsai et al., 2006; Via et al., 2008).  However, it has 
been reported that granulomas in a highly susceptible mouse strain display central 
caseous necrosis (Pan et al., 2005), and these necrotic lesions were recently found to be 
hypoxic (Harper et al., 2012). 
 
The mouse is considered to be a poor model for latent TB in humans because the 
bacterial load in chronically infected mice is high, tissue damage is progressive and the 
animals invariably succumb to disease.  In humans latency is associated with a low 
bacterial load and limited tissue destruction (Gomez and McKinney, 2004).  There is no 
‘true,’ paucibacillary latent phase in mice, although a latent-like state can be induced 
with drug intervention (Chao and Rubin, 2010; Rustad et al., 2009). 
 
In mice infected with M. tuberculosis bacteria replicate exponentially during the acute 
phase of infection.  This is followed by the chronic phase of infection at the onset of an 
adaptive immune response, which is characterized by relatively stable numbers of 
bacteria.  This characteristic plateau in the bacterial growth curve could be the result of 
a ‘static’ equilibrium in which bacterial growth is slow or absent, or a ‘dynamic’ 
equilibrium, in which continuous replication is balanced by bacterial killing by the host 
immune system (Munoz-Elias et al., 2005). 
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Rees and Hart (1961) attempted to distinguish between these two models of host-
pathogen equilibrium.  They argued that in the static equilibrium model there should be 
close correspondence between the ‘total counts’ (acid-fact bacilli, live plus dead bacilli) 
and ‘viable counts’ (colony forming units (CFU), live bacilli), while in the dynamic 
model total counts and viable counts would diverge over time due to the accumulation 
of dead bacteria which would contribute to the total counts but not the viable counts.  
They found that the total counts from the lungs of M. tuberculosis-infected mice were 
similar to the viable counts and that the two counts remained relatively constant 
throughout the observation period.  They concluded that the majority of the bacilli in the 
chronic phase were ‘viable and not multiplying’ and were in a ‘static or resting phase.’  
The authors noted that this conclusion was subject to the proviso that dead bacilli were 
neither being removed from the lungs nor losing their acid-fastness.  In mice treated 
with INH and PZA sixty days after infection viable counts fell throughout the treatment 
period while total counts remained high before falling slowly after three weeks of 
treatment.  They argued that this result indicates that most of the dead bacilli were not 
removed from the lungs and did not lose their acid-fastness. 
 
Wallace (1961) supported the hypothesis that bacteria in the chronic phase of infection 
are in a resting state.  He observed that the heat resistance of tubercle bacilli in the lungs 
of chronically infected mice resembled that of stationary phase cultures, and that these 
bacilli were more resistant to heat than those in the acute phase of infection.  Cultures of 
bacilli in the stationary phase were found to be less susceptible to heat than cultures in 
the exponential phase in vitro.  This difference was also observed when the cultures 
were added to lung homogenates, so the author concluded that the heat resistance of the 
bacilli is determined by the physiological state of the bacteria and not the presence or 
nature of lung tissue. 
 
The loss of acid-fast staining could result in an underestimate of the total number of 
bacilli.  INH is known to interfere with acid-fast staining, and this may explain the fall 
in total counts seen by Rees and Hart (1961) in treated mice (Munoz-Elias et al., 2005).  
It has also been suggested that M. tuberculosis bacilli lose their acid-fast staining during 
persistent infection following distinct cell-wall alterations (Seiler et al., 2003). 
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Munoz-Elias et al. (2005) revisited the work of Rees and Hart (1961) using bacterial 
chromosome equivalents for the ‘total count’ and obtained similar results.  An M. 
tuberculosis transcription pattern characteristic of non-replicating persistence has also 
been observed during chronic infection in mice (Shi et al., 2003). 
 
However, there is evidence that M. tuberculosis continues to replicate during the course 
of chronic infection (Cosma et al., 2003; Ehlers, 2009; Zhang, 2004).  Gill et al. (2009) 
found that active replication of M. tuberculosis occurs not only during the acute phase, 
but throughout chronic infection. They show that chronic infection in M. tuberculosis 
infected mice represents a state of ‘dynamic equilibrium’ in which bacterial replication 
is contained by the host immune response.  They found ‘substantial ongoing bacterial 
replication’ but were unable to distinguish whether there is slowed but continuous 
replication of all bacteria or rapid growth amongst a dormant subset. 
 
Other studies have found that events in the lung during chronic infection are dynamic 
rather than static, with mice exhibiting deteriorating histopathology despite the 
relatively stable numbers of bacteria (Rhoades et al., 1997).  The tissue damage and 
progressive inflammation that is observed in histological examination is more likely to 
occur if bacteria are still replicating.  It is also suggested that the rapid increase in 
bacterial numbers after immunosuppression is consistent with diminished stress on a 
dividing population, rather than a revival of non-replicating organisms (Gill et al., 
2009).  Lazarevic et al. (2005) also found that M. tuberculosis-infected mice exhibit 
dynamic immune responses throughout chronic infection. 
 
Variations on two murine models of ‘latent’ TB infection have been described in the 
literature: a low-dose or chronic model and the Cornell or drug-induced model (Cosma 
et al., 2003; Scanga et al., 1999).  In the low-dose model Orme (1988) attempted to 
construct an animal model of the re-emergence, or recrudescence, of tuberculosis.  In 
this study three-month-old mice were exposed to a low dose aerosol of M. tuberculosis 
(five to ten bacilli) and observed throughout the course of infection.  Following the 
initial period of replication in the lungs, the number of bacteria remained stable until the 
mice reached eighteen months of age, when the bacillary counts increased until the 
animals succumbed to disease.  Infected mice died at a median age of twenty-four 
months; uninfected mice lived at least three to six months longer.  The increase in lung 
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bacterial numbers in old mice reflects a decline in their ability to recall adequate levels 
of acquired immunity. 
 
The chronic model is attractive because it mimics the natural course of latency by 
reproducing an infection that is contained, but not eliminated, by the host immune 
response (Stewart et al., 2003).  However, this model may result in a high bacillary 
burden that is typically not found in latent TB infection in humans (Cosma et al., 2003; 
Scanga et al., 1999).  Histological examination of lung lesions in chronically infected 
mice shows the steady accumulation of tissue damage throughout the chronic phase 
(Rhoades et al., 1997). 
 
The ability of the mice to control infection depends on the dose and route of inoculation 
(Gomez and McKinney, 2004), as well as the immune status of the animal and the 
virulence of the mycobacterial strain used to induce infection.  It may be possible to 
achieve a lower bacterial burden with different mouse strains (Cosma et al., 2003). 
 
The Cornell model is a murine model of microbial persistence developed by Robert 
McCune and colleagues at Cornell University in the 1950s (McCune et al., 1956; 
McCune and Tompsett, 1956).  In this model mice were infected with a virulent strain 
of M. tuberculosis and treated with the antimycobacterial drugs isoniazid (INH) and 
pyrazinamide (PZA) for twelve weeks following an infection period of less than twenty 
minutes.  Upon completion of the treatment the infection had apparently been sterilized; 
tubercle bacilli were not detectable in the lungs or spleen of the animals and bacilli were 
not recoverable by culture or guinea pig inoculation (McCune and Tompsett, 1956).  
However, ninety days after cessation of chemotherapy, tubercle bacilli could be cultured 
from the tissues of approximately one third of the mice.  The majority of bacilli were 
susceptible to the drugs when tested in vitro, indicating that their survival represented 
microbial persistence rather than drug resistance (McCune et al., 1956).  When the post-
treatment observation period was increased to nine months, culturable bacilli appeared 
in approximately two thirds of mice.  This suggests that the ‘non-culturable’ state can 
exist for months.  The time required for the revival of tubercle bacilli could be 
accelerated by the administration of cortisone (an immunosuppressant) after 
chemotherapy, and was most effective when given three to four months after treatment 
(McCune et al., 1966). 
 58 
 
This drug-induced model resembles the latent state in humans in the sense that it is able 
to achieve very low or undetectable levels of bacilli, and maintain those levels for many 
weeks.  However, this state is artificially induced because drug intervention is required 
to establish latency.  There is also no standardized protocol for inducing latency with 
the Cornell model and the results (including the rate of spontaneous reactivation 
following treatment) depend on the route and size of the inoculum, the duration of 
antibiotic therapy, the drug dosages, and the interval between cessation of 
chemotherapy and immunologic intervention (Cosma et al., 2003; Scanga et al., 1999).  
Different immunosuppressive agents have been used to reactivate infection. 
 
The Cornell model focuses on the ability of M. tuberculosis to persist following 
antibiotic treatment, rather than on the role of host immunity in maintaining latency.  
The initiation of treatment within twenty minutes of infection interferes with the 
induction of a natural immune response (Scanga et al., 1999).  Using a variation of the 
original Cornell model de Wit et al. (1995) reported the existence of significant 
quantities of bacterial DNA in the organs of mice in the ‘sterile’ state, but were unable 
to determine whether this represents dead bacilli, free DNA or dormant or variant 
forms.  The authors suggested that testing the tissue extracts for M. tuberculosis RNA 
would enable the distinction between dead bacilli and living organisms.  Subsequent 
studies have shown that mRNA can be detected in ‘non-culturable’ persistent bacilli in a 
drug-induced model, indicating that they are transcriptionally (metabolically) active.  
Bacterial mRNA generally has a short half-life and is very unstable, so it rapidly 
disappears from dead cells.  The detection of mRNA is a good indicator for live 
organisms and its presence is usually indicative of recent transcriptional activity (Hu et 
al., 2000; Pai et al., 2000).  Hu et al. (2000) found that these bacilli also contain rRNA. 
 
Guinea Pig 
 
The guinea pig and rabbit models mimic the pathology of human disease more closely.  
Guinea pigs are extremely susceptible to TB, and invariably progress to fatal disease 
following infection with even a few mycobacteria as they are unable to contain bacterial 
growth.  Their granulomas are well organized, show caseous necrosis (Flynn, 2006) and 
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are hypoxic (Via et al., 2008).  However, due to their high susceptibility to M. 
tuberculosis latency is not seen in guinea pigs (Chao and Rubin, 2010).  The guinea pig 
has been a useful model for vaccine testing, since an effective vaccine should be able to 
protect the most susceptible host (Flynn, 2006).  BCG-vaccinated guinea pigs are more 
resistant to infection (Boshoff and Barry, 2005).  Guinea pigs are relatively inexpensive 
and easy to house, but the use of the guinea pig is hampered by a lack of immunologic 
reagents (Dharmadhikari and Nardell, 2008; Flynn, 2006). 
 
Rabbit 
 
Rabbits are more resistant to M. tuberculosis, but are susceptible to M. bovis.  Most 
studies in these animals have been carried out with M. bovis.  The granulomatous 
lesions in rabbits are remarkably similar to those found in humans.  They form 
organized granulomas with caseous, necrotic centres (Flynn, 2006).  Rabbit granulomas 
often progress to liquefaction, and the rabbit is the only small animal model in which 
cavitation is seen (McMurray, 2001).  Rabbit granulomas are also hypoxic (Via et al., 
2008).  Due to their resistance to M. tuberculosis, rabbits can be used to model a 
paucibacillary state (Dharmadhikari and Nardell, 2008).  A recent study has shown that 
rabbits infected with M. tuberculosis can develop a true latent infection, defined by a 
low bacillary burden and lack of clinical symptoms.  The infection is controlled by the 
host immune response.  Culturable bacilli were present throughout the infection, 
contained within caseous granulomas.  Reactivation of disease could be induced by 
immune suppression, but spontaneous reactivation did not occur (Manabe et al., 2008).  
Compared to mice and guinea pigs, rabbits are expensive to maintain and have larger 
laboratory requirements.  Immunologic reagents are also more limited than for mice 
(Dharmadhikari and Nardell, 2008; Flynn, 2006). 
 
Nonhuman Primate 
 
Nonhuman primates are likely to be the most suitable animal model for studying 
tuberculosis in humans.  Infection of cynomolgus macaques leads to a spectrum of 
outcomes, including primary TB (rapidly progressive and active-chronic), latent 
infection and resolving infection.  Approximately 60% of animals infected with a low 
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dose of M. tuberculosis developed primary TB.  The rest of the animals showed no 
signs of disease throughout the study, but had clinical characteristics of latent TB in 
humans.  The pathology of disease in the nonhuman primate is very similar to that seen 
in human TB, with evidence of solid, necrotic, caseous or cavitary granulomas.  
Granulomas in monkeys with latent infection have lower bacterial burdens than those in 
active disease (Capuano et al., 2003; Lin et al., 2009).  Their granulomas also show 
hypoxia (Via et al., 2008).  Reactivation in nonhuman primates can occur spontaneously 
or following immune suppression.  This model mimics human infection more closely 
than any other animal model.  Another advantage of this model is that it provides the 
opportunity to study the interaction of an HIV-type virus, simian immunodeficiency 
virus (SIV), and M. tuberculosis as a model for M. tuberculosis and HIV co-infection in 
humans.  Vaccines and drugs tested in the nonhuman primate model may also be useful 
before doing clinical trials in humans.  A variety of immunologic reagents are available 
for this model.  However, high costs and space requirements limit its widespread use 
(Flynn, 2006). 
 
2.9.3.2 In Vitro Models 
 
In vitro models aim to reproduce the environmental conditions that may be encountered 
by M. tuberculosis in its host.  They provide a simple, inexpensive and easily 
manipulated system in which to study the long-term persistence of M. tuberculosis.  
While in vitro models are important for the study of latent TB and mycobacterial 
persistence, it is unlikely that they are able to reproduce conditions in vivo, since the 
host immune system is believed to play a key role in latent infections (Gomez and 
McKinney, 2004; Shleeva et al., 2010).  However, these models may allow the 
identification of M. tuberculosis genes or proteins that are involved in the development 
and maintenance of persistence, and the exit of bacilli from this state (Cosma et al., 
2003). 
 
It has been proposed that hostile conditions inside tuberculous lesions, such as nutrient 
limitation, low oxygen tension, low pH and NO, trigger the metabolic slowdown of 
subpopulations of M. tuberculosis (Gengenbacher and Kaufmann, 2012; Keren et al., 
2011).  Researchers have attempted to produce slow-growing or non-replicating bacilli 
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through exposure to various stresses that may be experienced inside macrophages and 
granulomas (Cosma et al., 2003). 
 
In vitro models have been used to study the response of M. tuberculosis to a variety of 
environmental conditions.  These include reduced oxygen tension (Rustad et al., 2008; 
Voskuil et al., 2004; Wayne and Hayes, 1996; Wayne and Sohaskey, 2001), exposure to 
nitric oxide (Ohno et al., 2003; Voskuil et al., 2003), acidic conditions (Fisher et al., 
2002), the absence of iron, phosphate or other nutrients (Betts et al., 2002; Rifat et al., 
2009) and stationary phase survival (Hampshire et al., 2004; Voskuil et al., 2004).  
Other studies have attempted to mimic conditions in the phagosome by combining 
different stresses (Bryk et al., 2008; Deb et al., 2009). 
 
The effect of oxygen shortage on M. tuberculosis has been given the most attention.  It 
has been proposed that oxygen limitation, or hypoxia, is one of the major factors in 
inducing the NRP of tubercle bacilli, and that the persistence of M. tuberculosis is 
dependent on its survival in poorly oxygenated lesions (Stewart et al., 2003; Wayne and 
Sohaskey, 2001).  While information on the oxygen tension in human disease is limited 
(Boshoff and Barry, 2005; Cosma et al., 2003; Gill et al., 2009), measurement of the 
gaseous content inside cavities has shown that tuberculous lesions are partially depleted 
for oxygen (Deb et al., 2009; Gomez and McKinney, 2004; Haapanen et al., 1959; 
Sohaskey, 2008). 
 
TB infections are preferentially associated with the most oxygen-rich sites in the body 
(Cosma et al., 2003).  Histological examination of different lung lesions from patients 
who underwent surgery for incurable TB reveals heterogeneous morphology and 
distribution of tubercle bacilli.  High numbers of bacilli were found at the surface of 
cavities in granulomas with direct connection to the airways.  Bacillary numbers were 
substantially lower in the necrotic and deeper fibrotic regions of the granulomas that 
have little to no access to air.  Macrophages and T cells were found to be co-localized in 
this area, suggesting that this site represents a microenvironment within the lung where 
an efficient immune response is generated that is capable of inhibiting bacterial 
replication (Kaplan et al., 2003).  Open cavities are insulated from the immune system 
(Boshoff and Barry, 2005).  Reactivation TB in humans occurs most frequently in the 
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upper lobes of the lung, which is thought to be the most oxygenated region in the body 
(Cosma et al., 2003). 
 
The replication of M. tuberculosis requires the presence of oxygen.  Oxygen deprivation 
is lethal to M. tuberculosis, but tubercle bacilli are capable of surviving anaerobic 
conditions in vitro if they have the time to adapt to the gradual depletion of available 
oxygen (Wayne and Sohaskey, 2001). 
 
Lawrence Wayne developed an in vitro model of M. tuberculosis growth under low 
oxygen tension.  This model relies on the gradual depletion of oxygen in sealed M. 
tuberculosis cultures (Wayne and Sohaskey, 2001).  Tubercle bacilli were able to shift 
down into at least two different stages of non-replicating persistence, allowing the 
bacilli to survive under microaerophilic and anaerobic conditions (Wayne and Hayes, 
1996).  The shift to the first stage, NRP stage 1, occurred when the declining oxygen 
level approached 1% saturation (the microaerophilic stage).  In NRP stage 1 bacilli stop 
replicating while thickening their cells walls.  The bacilli shifted to the second stage, 
NRP stage 2, when the oxygen level dropped below 0.06% saturation (the anaerobic 
stage).  Cell enlargement ceases in NRP stage 2. 
 
It was observed that bacilli in a state of NRP restrict biosynthetic activity in order to 
conserve energy, shift to alternative energy pathways and stabilize essential cell 
components minimizing the need for repair or replacement (Wayne and Sohaskey, 
2001).  The Wayne model has also led to the identification of specific enzymes that may 
be involved in the persistence of M. tuberculosis in mice (McKinney et al., 2000; 
Zhang, 2004). 
 
Bacilli in either NRP stage 1 or NRP stage 2 exhibited increased tolerance to the 
antimycobacterial agents isoniazid, rifampicin and ciprofloxacin.  Bacilli in NRP stage 
2 were susceptible to metronidazole, which is bactericidal to M. tuberculosis under 
anaerobic conditions (Wayne and Sramek, 1994).  However, this drug has only a small 
effect on bacterial numbers during the chronic phase of infection in mice (Brooks et al., 
1999), and during the drug-induced ‘sterile’ state in the Cornell model (Dhillon et al., 
1998).  This suggests that the oxygen tension in the murine model is unlikely to be 
sufficiently low to allow metronidazole to act. 
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Bacilli in the Wayne model have been described as dormant, despite the maintenance of 
high culturability (Shleeva et al., 2002); bacilli in NRP stage 2 exhibited synchronous 
replication upon resumption of aeration (Wayne and Hayes, 1996).  This model appears 
to reflect bacterial adaptation to low oxygen levels rather than the transition to a 
dormant state (Shleeva et al., 2010; Zhang, 2004).  However, the Wayne model may 
represent a stage on the way to dormancy, since this state can be triggered by low 
oxygen upon extended incubation (Shleeva et al., 2002). 
 
Transcriptional profiling of M. tuberculosis has been carried out in various in vitro 
models in an attempt to identify genes that may be important for the formation and 
maintenance of persistent cells.  Microarray analysis has shown down-regulation of 
genes involved in biosynthesis, cell division and energy metabolism, while genes that 
are up-regulated may facilitate the survival of M. tuberculosis in these conditions.  
Further investigation is required to determine the relevance of these genes to 
mycobacterial persistence.  There is evidence that genes involved in the induction of 
NRP may be different from those that maintain it over time (Betts et al., 2002; Fisher et 
al., 2002; Rifat et al., 2009; Rustad et al., 2008; Voskuil et al., 2003; Voskuil et al., 
2004). 
 
2.9.4 Phenotypic Heterogeneity 
 
Bacterial populations may be exposed to a variety of stresses in their lifetime.  Living 
organisms must be able to adapt their behaviour in order to survive in fluctuating 
environments.  This diversity ensures that a fraction of a microbial population will 
survive conditions that are lethal to the majority of the population, and is considered to 
boost the fitness of the species (Avery, 2006; Booth, 2002; Kussell and Leibler, 2005). 
 
Intrapopulation variation can be achieved through stable genetic changes (such as 
random, spontaneous mutations or genome rearrangements), or through variations in 
cellular parameters that do not involve changes in the genome.  The term ‘phenotypic 
heterogeneity’ or ‘phenotypic variation’ is used to describe cell-to-cell variation in an 
isogenic population.  This type of variability is usually due to reversible, unstable or 
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metastable changes that are typically not inherited by the variant’s progeny (Avery, 
2006; Dhar and McKinney, 2007).  There are two alternative models of how phenotype 
switching may be initiated: a stochastic model where switching occurs without direct 
sensing of the environment, and an alternative model where switching is induced by 
signals generated in response to environmental factors (Balaban et al., 2004; Kussell 
and Leibler, 2005). 
 
A genetically clonal microbial population can exhibit considerable phenotypic variation.  
For example, individual cells of pathogenic organisms can exhibit varying degrees of 
virulence, variable expression of cell-surface antigens and differential sensitivity to 
stress and antimicrobial treatments.  Sources of phenotypic heterogeneity include 
progression through the cell cycle, epigenetic modifications (that are metastably 
inherited and do not involve changes in the DNA sequence of the organism), ageing 
linked to cell division, mitochondrial activity, individual cell growth rates and 
stochastic variation (Avery, 2006; Sumner and Avery, 2002).  Biological processes such 
as gene expression are inherently stochastic, or ‘noisy’ (Kaern et al., 2005).  Stochastic 
variation in the levels of gene products contributes to phenotypic heterogeneity in 
microbial populations (Avery, 2006; Dhar and McKinney, 2007; Sumner and Avery, 
2002). 
 
The differential behaviour of individual cells is typically masked in conventional 
studies of microbial populations, which rely on bulk-scale measurements and report 
values averaged across large numbers of cells.  However, recent technological advances 
have enabled the analysis of microbial behaviour at single-cell resolution, providing 
fundamental insights into the processes governing cell-to-cell variability (Avery, 2006; 
Brehm-Stecher and Johnson, 2004; Dhar and McKinney, 2007). 
 
Microbial populations benefit from the creation of variant subpopulations that are better 
equipped to persist in different environments.  Individual cells can switch to a 
phenotype that renders them tolerant to stress (Avery, 2006; Kussell and Leibler, 2005).  
Phenotypic variation in the expression of virulence factors or antigenic surface proteins 
enables cells to escape recognition by the host’s immune system and avoid activation of 
host defence mechanisms (Avery, 2006; Balaban, 2011; McAdams and Arkin, 1999). 
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Phenotypic heterogeneity in clonal populations is linked to the persistence of bacterial 
subpopulations under selective pressures such as antibiotic treatment.  Stochastically 
determined differences in growth rate or in the expression of a specific enzyme, for 
example, may result in a subpopulation of bacteria that show differential antibiotic 
susceptibility (Barry et al., 2009). 
 
2.9.5 Drug Tolerance 
 
Bacteria that are normally susceptible to antibiotics can be resistant to their action 
(Levin and Rozen, 2006).  This phenomenon is referred to as phenotypic drug 
resistance, or drug tolerance, a non-genotypic, reversible resistance to a drug.  Drug 
tolerant bacteria are genetically susceptible to antibiotics, and their progeny are fully 
susceptible to antibiotics (Gengenbacher and Kaufmann, 2012; Jayaraman, 2008; Zhang 
et al., 2012).  In contrast, genotypic drug resistance is an inheritable resistance to a drug 
resulting from genetic mutations or acquisition of external resistance-encoding genes 
(Levin and Rozen, 2006). 
 
In general, non-growing and slow-growing bacteria are less sensitive to killing by 
antibiotics, a property termed ‘drug indifference’ (Jayaraman, 2008; Levin and Rozen, 
2006; McDermott, 1958).  Drug indifference is a population-wide property that reflects 
the reduced sensitivity of non-replicating and slowly dividing bacteria to antibiotics.  
Unlike the drug tolerance induced when a subset of a dividing microbial population 
ceases replication it has no specific mechanistic basis (Jayaraman, 2008).  Drug 
indifference is a subtype of drug tolerance (Connolly et al., 2007). 
 
When a genetically homogeneous bacterial population is exposed to a lethal 
concentration of antibiotics, the majority of the population is killed, but a small fraction 
of the population survives (Dhar and McKinney, 2007).  Part of the reason for this can 
be attributed to the physiological state and physical structure of the bacterial cells 
(Levin and Rozen, 2006). 
 
This phenomenon was first described by Gladys Hobby and co-workers in 1942.  They 
investigated the action of penicillin on pneumococci, hemolytic streptococci and 
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staphylococci and observed that the number of organisms decreased at a constant rate 
until 99% of the organisms were killed.  They also studied the effect of growth on the 
activity of penicillin against hemolytic streptococci and found that it was only effective 
when active multiplication took place (Hobby et al., 1942). 
 
This property was further investigated by Joseph Bigger in 1944.  He treated cultures of 
staphylococci with penicillin and found that a fraction of cells (of the order of 10-6 or 
less) survived.  These cells were termed ‘persisters.’  Upon removal of the penicillin 
persisters were able to divide and their descendants were no more resistant to penicillin 
than the original population, but formed a new subpopulation of persisters.  Bigger 
proposed that persisters were insensitive to the action of penicillin because they are in a 
‘dormant, non-dividing phase, similar to that of bacteria in the lag phase of the growth 
curve,’ and penicillin kills dividing bacteria.  He found no evidence that the production 
of persisters was due to the presence of penicillin (Bigger, 1944). 
 
Although this phenomenon has been known for over sixty years, little progress has been 
made in understanding the mechanisms behind persister formation and the potential 
clinical implications (such as their contribution to antibiotic treatment failure) (Dhar and 
McKinney, 2007; Levin and Rozen, 2006).  Persisters are difficult to study because of 
the low frequency of these cells (10-6–10-4 in Escherichia coli (E. coli)) in a microbial 
population, and because this is a temporary phenotype that is metastable and rapidly lost 
on subculture (Dhar and McKinney, 2007; Keren et al., 2004).  It is likely that in most 
infections small numbers of persisters can be removed by the immune system, but for 
immunocompromised patients or infections that require relatively low numbers of 
bacteria to progress (such as tuberculosis), drug tolerance poses a major threat and may 
cause the disease to reactivate (Balaban, 2011). 
 
Persisters may contribute to the difficulty in treating bacterial infections such as 
tuberculosis, necessitating lengthy chemotherapy to eliminate the subpopulation of M. 
tuberculosis that is tolerant to antimycobacterial drugs (Dhar and McKinney, 2007; 
Stewart et al., 2003).  It is unclear whether this population is identical to the bacterial 
population that persists during latent infection, although it is possible that bacilli in both 
populations are non-replicating or slow-growing (Stewart et al., 2003). 
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Drug tolerant tubercle bacilli have been identified in vitro.  Hu et al. (2000) developed a 
model of drug-induced persistence.  In this model a 100-day-old microaerophilic 
stationary phase M. tuberculosis culture was treated with a high dose of rifampicin.  A 
subpopulation of cells was found to be rifampicin-tolerant.  These persistent bacilli were 
not immediately culturable on agar plates but showed ongoing transcriptional 
(metabolic) activity and could be resuscitated with fresh broth in the absence of RIF. 
 
M. tuberculosis persister cells have been isolated from in vitro cultures.  Low numbers 
of persisters were present during the lag and early exponential phases, with their 
numbers rising sharply at late exponential and stationary phases to make up 
approximately 1% of the population.  It was suggested that persister formation is 
governed by both deterministic and stochastic mechanisms.  The number of persister 
cells rises sharply as the population density increases indicating a deterministic 
component.  This density-dependent increase in persister formation may be caused by 
nutrient depletion.  The transcription profile of persisters was obtained and showed 
down-regulation in energy metabolism and biosynthetic pathways, consistent with a 
degree of dormancy.  The transcriptome of persisters was then compared to the 
transcriptomes obtained for several in vitro models of dormancy (or NRP).  The authors 
identified five genes that are up-regulated in all of the models and may represent a core 
dormancy or NRP response (Keren et al., 2011). 
 
The study of drug tolerance has largely focused on bacteria with slowed growth and 
reduced metabolic activity.  However, actively growing mycobacteria may also develop 
multidrug tolerance following exposure to the macrophage environment.  A recent study 
has shown that bacterial efflux pumps that are required for intracellular growth mediate 
the drug tolerance of replicating bacilli in cultured macrophages.  This population may 
contribute to the difficulty in treating tuberculosis infection and the development of 
drugs that target these bacteria could shorten the duration of treatment (Adams et al., 
2011). 
 
The efficacy of anti-TB drugs in vitro is not matched in vivo.  M. tuberculosis is killed 
by bactericidal drugs (such as INH and RIF) within a few days in vitro, but the same 
combination requires months for bacteria living in host tissues, despite adequate 
penetration of the drugs to the site of infection.  It has been proposed that the 
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persistence of tubercle bacilli in the face of chemotherapy is due to the physiological 
heterogeneity of the bacterial population in tissues (McKinney, 2000). 
 
Tuberculosis chemotherapy must target a mixed population of mycobacteria.  Mitchison 
(1979) hypothesized that tuberculous lesions consist of four different subpopulations of 
tubercle bacilli: organisms that are growing continuously, organisms in an acid 
environment, organisms with short periods of active metabolism or growth and dormant 
organisms.  Actively growing bacteria are killed primarily by INH, but in the case of 
INH resistance, this population is killed by RIF and SM.  Bacilli in acidic environments 
are killed by PZA and bacilli that have spurts of metabolism are killed by RIF.  The 
dormant population is not killed by any drug. 
 
Current front-line antimycobacterial drugs primarily target cellular processes involved 
in cell growth and division, such as cell wall biogenesis and DNA replication.  
Consequently, these drugs are highly effective against actively growing bacilli, but are 
less potent against bacteria that are non-replicating or slow-growing (McKinney, 2000).  
RIF and PZA are important sterilizing drugs that are able to kill non-replicating bacilli, 
but there may still be persister populations that are not killed by these drugs  (Zhang, 
2005).  Persisters may be responsible for the difficulty in treating both acute and latent 
infections (Keren et al., 2011), and these cells form a subpopulation of organisms from 
which clinical relapses can arise (Davies, 2010). 
 
Bigger (1944) proposed that intermittent drug dosing, which allows persisters to resume 
growth and become drug-susceptible again once the antibiotics are removed, might be 
an effective way to eradicate persisters and sterilize infection.  However, while this 
approach is successful in vitro, it is potentially more difficult to achieve in a clinical 
setting, with the optimal pulse-dosing regimen likely to vary from patient to patient.  
The emergence of drug resistance is also a risk with intermittent dosing, especially 
when bacterial levels are high (Lewis, 2007; Zhang et al., 2012). 
 
The effective elimination of persister cells may be required to improve treatment of TB.  
This could be achieved by a combination of approaches that specifically target 
persisters such as intermittent drug dosing, the development of new drugs, the use of 
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appropriate drug combinations, and combined chemotherapy and immunotherapy 
(Zhang et al., 2012). 
 
The mechanisms of mycobacterial persistence are still not well understood.  A better 
understanding of the fundamental biology of persistence is required to suggest new 
strategies for targeting persistent bacteria (Munoz-Elias et al., 2005; Stewart et al., 
2003). 
 70 
6 78$94:8$*)8.+7&'4..*#/+&1+;&5$<=8$9&/4#+"#$4%8)$*&#5+8#'+
>%(/+2%48$:4#$+
 
3.1 Introduction 
 
The use of mathematics in the life sciences has become more and more widespread as 
this field has become more quantitative (Murray, 2002).  New technologies, particularly 
the technological advances in molecular biology and the advent of high-throughput 
genomic/proteomic technologies, have resulted in an explosion in experimental data.  
However, the vast amounts of data generated through these techniques are insufficient 
on their own to advance our knowledge of how complex biological systems function 
(Stark et al., 2003a; Stark et al., 2003b; Yates et al., 2001). 
 
The complexity of biological systems necessitates an interdisciplinary approach and the 
use of quantitative methods (mathematical modelling, computer simulation, statistical 
analysis) alongside traditional experimental methods.  The unifying goal of this 
collaborative effort is the elucidation of the underlying biological processes that give 
rise to a particular observed phenomenon (Murray, 2002). 
 
Mathematical models can help us to better understand complex biological systems, 
providing insights into their behaviour and allowing us to identify key parameters or 
mechanisms.  Mathematical models use equations and/or rules to describe known 
characteristics of a system, integrating existing knowledge of biological processes into a 
cohesive structure (Kirschner et al., 2005; Kirschner and Linderman, 2009).  These 
models and simulations are driven by empirical observations and generate specific, 
explicitly testable predictions that motivate new experiments.  The results from these 
experiments can then be used to refine the model.  This iterative process of model 
construction and experimental validation is a crucial feature of a systems biology 
approach (Young et al., 2008). 
 
Mathematical modelling provides experimentalists with an additional, complementary 
tool for studying biological systems (Kirschner and Linderman, 2009).  Once a 
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mathematical model is formulated it can easily be manipulated to explore different 
interactions and rates in the system, in effect serving as a ‘virtual laboratory’ to 
supplement in vivo and in vitro work (Yates et al., 2001), and allowing us to perform 
experiments that are impractical or infeasible using other approaches (Kirschner, 2007; 
Kirschner et al., 2010; Marino et al., 2011b). 
 
In this chapter we describe some of the approaches used to model host-pathogen 
interactions and review existing models of tuberculosis infection.  We also describe 
basic pharmacokinetic and pharmacodynamic concepts and look at general models that 
describe the concentration of a drug in the body, and models relating drug concentration 
in the blood (plasma or serum) to effect. 
 
3.2 Modelling Host-Pathogen Interactions 
 
The host response to infectious disease involves complex, interdependent interactions 
between host and pathogen that occur across different length and time scales (Marino et 
al., 2011b).  A systems biology framework that integrates modelling and experimental 
techniques is required to gain insight into the interplay between the various components 
(Kirschner et al., 2010; Marino et al., 2011b) and unravel the mechanisms that govern 
the behaviour of host-pathogen interactions (Lin et al., 2005). 
 
Experimental biology has made substantial contributions to our understanding of the 
immune system, microbial pathogens and the interactions that occur between the two.  
However, there are a number of limitations to using a purely experimental approach to 
study host-pathogen interactions.  These include the number and cost of experiments 
required to fully explore all the potential interactions between individual elements and 
the various outcomes, the time required to carry out the experiments and the difficulty 
in integrating data obtained from multiple sources across length and time scales in a 
comprehensive view (Kirschner and Linderman, 2009; Marino et al., 2011b).  Studies in 
animals and humans typically focus on only one or two factors at a time giving a limited 
understanding of the system as a whole.  One of the main challenges in tuberculosis 
research is that granuloma formation is particularly difficult to mimic in an 
experimental setting as granulomas cannot be created or maintained in vitro (Kirschner 
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et al., 2010).  The trafficking of cells between different organs is also difficult to 
reproduce (Kirschner et al., 2005). 
 
Mathematical models allow the integration of host and pathogen into a single system in 
which each element can be monitored and varied simultaneously to determine its role in 
infection dynamics (Kirschner et al., 2005) thus helping us to identify factors that have 
a major impact on the outcome of infection (Marino et al., 2011b).  Models can be used 
to address open questions about host-pathogen interactions that may be experimentally 
intractable, e.g. they can be used to describe compartmentalized processes (Kirschner et 
al., 2005; Marino et al., 2011b).  Simulations of experiments can be performed 
generating hypotheses and making predictions that can then be tested in an experimental 
setting (Lin et al., 2005).  They can also be used to investigate the effect of drug 
treatment or vaccination in a ‘virtual clinical trial’ (Kirschner et al., 2010; Lin et al., 
2005). 
 
Mathematical modelling of within-host-pathogen interactions has largely focused on 
host-viral interactions, with relatively few exploring host-bacterial interactions 
(Kirschner, 2007).  Mathematical models have been used to study the infection 
dynamics of HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus 
(CMV) (Perelson, 2002) and human T-lymphotropic virus (HTLV) (Nowak and May, 
2000). 
 
3.2.1 Within-host Population Dynamics 
 
Ecological principles have frequently been used to describe the within-host dynamics of 
infection.  The interactions between pathogenic organisms (viruses, bacteria or 
parasites) and the host immune system can be considered to be a predator-prey system, 
with immune cells acting as the predators and the pathogen acting as the prey (Wodarz, 
2006). 
 
In these models pathogen dynamics are often described by equations of the type 
 
 dxdt = ax ! bxy   (3.1) 
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where x  is the pathogen density, y  is the density of immune cells, a  is the pathogen 
growth rate and b  is the rate of killing of the pathogen by immune cells (Alizon and 
van Baalen, 2008).  This is the equation for prey dynamics in the Lotka-Volterra 
predator-prey model. 
 
The killing function is usually modelled by a mass action term that is proportional to the 
product of the two population densities.  However, the exact form of the killing function 
can affect the outcome of the host-pathogen interactions (Pilyugin and Antia, 2000), and 
different killing functions may be used (Handel et al., 2009).  It is often assumed that 
the rate at which the pathogen is killed saturates as the pathogen load increases giving 
the killing function 
 
 !b xx + h
"
#$
%
&' y   (3.2) 
 
where h  is the value of x  when the killing rate is half its maximum value.  This 
equation takes into account the handling time of immune cells. 
 
Various equations have been used to model the dynamics of the immune system (Alizon 
and van Baalen, 2008).  One form for the equation of the immune cells is 
 
 dydy = s + cxy ! dy   (3.3) 
 
where s  is the baseline production of immune cells, c  is the proliferation rate of 
immune cells due to the presence of the pathogen or its antigens and d  is the death rate 
of the immune cells. 
 
Other forms for the equation describing the generation of the immune response include 
 
 dydt = s + cx ! dy   (3.4) 
 
 74 
where the pathogen stimulates the growth of the immune response at rate c  (Alizon and 
van Baalen, 2005; Bonhoeffer and Nowak, 1994; Fenton et al., 2006).  A density 
dependent response for the growth of immune cells has also been used 
 
 dydt = s + cy
x
x + k
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where k  is the value of x  when the proliferation rate is half its maximum value.  In this 
case the pathogen stimulates the proliferation of immune cells at a rate that is 
proportional to the density of the pathogen at low densities and saturates at high 
pathogen densities (Antia et al., 1996; Antia et al., 1994).  The source term s  may or 
may not be included in these equations. 
 
3.2.2 Models of HIV Infection 
 
HIV is a retrovirus that infects cells expressing the cell-surface molecule CD4 (namely 
CD4+ T cells, macrophages and dendritic cells), leading to their slow depletion and the 
gradual loss of immune competence.  HIV-positive individuals are susceptible to 
infection with opportunistic pathogens, various lymphomas and several rare cancers. 
 
Immediately after an individual is infected with HIV the amount of virus detected in the 
blood rises dramatically as an adaptive immune response is initiated.  This acute phase 
of infection is characterized by influenza-like symptoms, a high viral load and a marked 
decrease in the number of circulating CD4+ T cells.  After a few weeks to months 
symptoms have usually passed and the viral load declines as antibodies against HIV and 
HIV specific cytotoxic T lymphocytes control infection, but do not eliminate the virus.  
The initial acute phase is followed by a chronic, asymptomatic phase, during which the 
viral load remains relatively stable.  Most individuals infected with HIV eventually 
develop acquired immune deficiency syndrome (AIDS) following a prolonged period of 
clinical latency.  However, the virus continues to replicate and infect new cells during 
this period resulting in a gradual decline in the function and numbers of CD4+ T cells.  
A patient is said to have AIDS when CD4+ T cell counts fall below 200 cells/µl of 
blood (the normal value is about 1200 cells/µl) (Murphy et al., 2008; Perelson and 
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Nelson, 1999).  HIV takes on average about ten years to advance from initial infection 
to AIDS (Perelson, 2002). 
 
HIV represents a success story for the mathematical modelling of host-pathogen 
interactions (Perelson, 2002).  Mathematical models have had a substantial impact on 
our thinking of HIV infection and helped to shape our understanding of T cell and viral 
dynamics (Perelson and Nelson, 1999; Velasco-Hernandez et al., 2002). 
 
Before the use of mathematical modelling by the HIV research community it was 
believed that the replication rate of the virus during the chronic phase was very slow.  
The apparent quiescence of disease during this period and the slow progression to AIDS 
suggested that the dynamics of HIV infection would also be slow.  However, 
mathematical models combined with appropriate experiments have shown that HIV is a 
dynamic disease (Perelson and Nelson, 1999), with virions being produced and cleared 
at a rapid rate (Ho et al., 1995; Perelson et al., 1996; Wei et al., 1995). 
 
The rapid replication of HIV has important implications for drug therapy.  Each 
replication carries the possibility of a mutation, so treatment with a single drug is 
doomed to fail because of the high probability of mutations conferring resistance to 
antiviral drugs.  Thus combination therapy is required to treat HIV infection (Coffin, 
1995; Perelson and Nelson, 1999). 
 
3.2.3 Basic Model of Virus Infection 
 
The basic model of virus infection consists of three variables: a population of 
uninfected cells (more specifically cells susceptible to infection, or target cells 
(Perelson, 2002)), x , a population of infected cells, y , and free virus particles (virions), 
v .  Uninfected cells are produced at rate !  and die at rate dx .  They are infected by 
free virus particles at rate !xv .  The death rate of infected cells is ay .  Virions are 
produced by infected cells at rate ky  and are cleared at rate uv .  This gives the 
following system of ordinary differential equations (ODEs) (Nowak and Bangham, 
1996; Nowak and May, 2000): 
 
 76 
 dxdt = ! " dx " #xv   (3.6) 
 dydt = !xv " ay   (3.7) 
 dvdt = ky ! uv   (3.8) 
 
This model has been used to study HIV, HBV and HCV infection (Perelson, 2002), as 
well as the effect of drug treatment on viral dynamics (Bonhoeffer et al., 1997). 
 
The basic model of virus dynamics can be extended to include the effect of a CTL 
response.  The population of virus specific CTLs is denoted by the variable z .  This 
population can be modelled in different ways.  The simplest model, a self-regulating 
immune response, is given by 
 
 dxdt = ! " dx " #xv   (3.9) 
 dydt = !xv " ay " pyz   (3.10) 
 dvdt = ky ! uv   (3.11) 
 dzdt = c ! bz   (3.12) 
 
CTLs are produced at rate c  and die at rate bz .  Infected cells are killed by CTLs at rate 
pyz  (Nowak and May, 2000). 
 
For a linear immune response, where CTLs are produced at a rate proportional to the 
number of infected cells, the dynamics for the CTL population z  are given by 
 
 dzdt = cy ! bz   (3.13) 
 
CTLs may also be produced at a rate that is proportional to the number of infected cells 
and the number of CTLs to give (Nowak and Bangham, 1996; Nowak and May, 2000) 
 77 
 
 dzdt = cyz ! bz   (3.14) 
 
These models are similar to the classical susceptible-infected-recovered (SIR) models of 
epidemiology, where susceptible and infected individuals are replaced by uninfected 
and infected cells.  They describe the spread, or ‘transmission,’ of the infectious agent 
from cell to cell (Nowak and May, 2000), and can be used to model infections such as 
malaria (Anderson et al., 1989; Hetzel and Anderson, 1996). 
 
3.3 Models of Tuberculosis Infection 
 
A number of models describing host-pathogen interactions during tuberculosis infection 
have been developed over the last twenty years. 
 
Antia et al. (1996) developed simple ODE models for the within-host dynamics of 
mycobacterial infection analogous to predator-prey interactions.  The aim was to 
investigate the mechanisms that allow the long-term persistence of M. tuberculosis in 
the host and how this affects the immune response.  The first model describes the 
dynamics of the bacteria and the specific immune response to the bacteria (T cells) 
shortly after infection: 
 
 
dP
dt = rP ! hPX
dX
dt = a + sX
P
k + P
"
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%
&' ! dX
  (3.15) 
 
where P  is the density of bacteria, X  is the density of immune cells, r  is the growth 
rate of bacteria, h  is the rate of killing of bacteria by immune cells, a  is the migration 
rate of immune cells from the thymus, s  is the maximum proliferation rate of immune 
cells due to bacteria, k  is the value of P  when the proliferation rate is half its 
maximum value and d  is the death rate of the immune cells. 
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A dormant stage (analogous to a refuge in ecology) where bacteria are sequestered from 
the immune response is then incorporated into the model.  It is assumed that bacteria 
switch between growth and dormant stages at constant rates, f  and g .  Let Q  represent 
the density of bacteria in a dormant stage.  Then the equations that describe the 
dynamics are now 
 
 
dP
dt = rP ! hPX ! fP + gQ
dQ
dt = fP ! gQ
dX
dt = a + sX
P
k + P
"
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%
&' ! dX
  (3.16) 
 
The long-term dynamics of persistent infection are also considered.  Bacterial 
persistence may lead to clonal deletion of specific immune cells in the thymus.  Immune 
cells also have a limited proliferative capacity, undergoing only a certain number of cell 
divisions (the Hayflick limit), after which they die.  The immune response equation is 
modified to include antigen-dependent deletion of specific T cells in the thymus and the 
Hayflick limit to T cell proliferation.  This model predicts that the persistence of M. 
tuberculosis may be the result of the bacteria having a slow growth rate or a dormant 
stage.  The long-term persistence of bacteria may also lead to the loss of specific 
immunity due to the deletion of T cells arriving from the thymus and the exhaustion of 
T cells reaching the Hayflick limit. 
 
Denise Kirschner and co-workers have developed a series of mathematical and 
computational models to describe the host immune response to M. tuberculosis 
infection (Marino et al., 2011b).  Different mathematical approaches are employed to 
explore the dynamics of bacteria and various components of the immune system 
(including macrophages, T cells, cytokines and chemokines) during the course of 
infection. 
 
Several ODE models have been developed to describe the temporal behaviour of 
different populations in the lung (Marino et al., 2007; Sud et al., 2006; Wigginton and 
Kirschner, 2001) and in the lung and lymph node (Marino and Kirschner, 2004; Marino 
et al., 2010; Marino et al., 2004).  These models consist of a system of nonlinear ODEs.  
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Partial differential equations (PDEs) were used to model spatial and temporal aspects of 
the early innate immune response to M. tuberculosis in the lung (Gammack et al., 
2004).  In these differential equation models the populations are represented by 
continuous variables which interact in a deterministic manner. 
 
A metapopulation approach (a coarse-grid discrete, spatial model) was used to extend 
the model of Wigginton and Kirschner (2001) to a spatio-temporal model that describes 
the dynamics of granuloma formation and maintenance in the lung (Ganguli et al., 
2005).  The metapopulation framework is utilized as a way of incorporating spatial 
heterogeneity into population models.  The spatial domain is discretized into a lattice of 
compartments, each containing subpopulations of the different model components.  
Local interactions in each compartment and the migration of subpopulations between 
adjacent compartments are described by ODEs.  Agent-based models (ABMs) were also 
used to simulate granuloma formation in the lung (Ray et al., 2009; Segovia-Juarez et 
al., 2004).  These models incorporate both discrete agents and continuous variables.  
Individual agents reside in a defined environment and interact with one another and 
their environment according to a set of rules.  The rules that govern the behaviour of the 
discrete entities are stochastic.  A hybrid multi-compartment model consisting of an 
ABM for the lung compartment and a system of ODEs for the lymph node compartment 
has also been developed (Marino et al., 2011a). 
 
3.3.1 Model 1 
 
Wigginton and Kirschner (2001) developed an ODE model of human tuberculosis 
infection in the lung.  This is the first paper to explore the immune response to a 
specific bacterial pathogen in detail.  The aim of the model is to identify the 
mechanisms of host immunity that are responsible for different disease trajectories. 
 
The reference space for the model is bronchoalveolar lavage (BAL) fluid, which has 
been shown to be an acceptable qualitative (but not necessarily quantitative) predictor 
of immune responses in lung tissue.  Tuberculosis is a disease that primarily manifests 
in the lung parenchyma, rather than the airways.  However, in the human system 
experiments are limited to BAL, pleural fluid or peripheral blood mononuclear cell 
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(PBMC) measurements. 
 
The model describes the temporal dynamics of twelve different populations: three 
macrophage populations (resting, activated and chronically infected), three CD4+ T cell 
populations (Th0, Th1 and Th2), four cytokines (IFN-", IL-12, IL-10, and IL-4), and 
two bacterial populations (intracellular and extracellular mycobacteria) (!"#$%&' +)().  
Parameters that govern the interactions between the different populations may vary 
from individual to individual and over time within an individual.  The parameter space 
is explored to assess which parameters affect the outcome of infection.  Changes in only 
certain parameters lead to different disease outcomes. 
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Figure 3.1 Schematic diagram of the cellular and bacterial dynamics in the lung in the model of 
Wigginton and Kirschner (2001). 
 
The possible outcomes of this model are primary disease, latency, clearance and 
reactivation.  The bacterial load is used as a marker of disease progression.  Primary 
disease is characterized by uncontrolled bacterial growth and latent infection by low and 
controlled bacterial numbers.  Model predictions are within experimentally observed 
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ranges, which exhibit large variability.  The model predicts that macrophage function 
(activation, infection and death rates of resting macrophages and bactericidal ability of 
activated macrophages), and T cell effector functions (killing of infected macrophages 
via cytotoxic activity or Fas/Fas-L induced apoptosis) play a key role in determining 
infection outcome.  Extra sources of IFN-!  (from CD8+ T cells or NK cells) and the 
level of IL-4 production by Th0 cells can also affect the disease trajectory. 
 
This model indicates that the immune response must be properly regulated (by IL-4 or 
IL-10) to minimize tissue damage.  Tissue damage is defined by the effector cell 
activity to TB killing ratio.  IFN-!  levels beyond what is needed to control infection 
lead to tissue damage. 
 
The model is used to perform virtual cytokine deletion and depletion experiments that 
determine which elements control the establishment and maintenance of latency.  
IFN-!  and IL-12 deletion models lead to active disease indicating that these two 
cytokines are required to achieve latency.  IL-10 deletion leads to lower bacterial levels 
than in the positive control, but cell and cytokine populations undergo oscillations 
suggesting a less stable steady state.  The model predicts that IL-10 stabilizes the 
system, making reactivation more likely in its absence.  This prediction was later 
confirmed by experimental work (Lin et al., 2005; Marino et al., 2011b).  Using IL-10 
KO mice Higgins et al., 2009 showed that a lack of IL-10 leads to decreased control 
over the inflammatory response and eventually to disease progression, bacterial 
multiplication and morbidity.  IFN-!  depletion leads to a switch from latency to active 
disease.  The system is able to maintain latency following IL-12 depletion, but the 
bacterial load is higher and the cellular activation level is lower.  IL-10 depletion leads 
to an increase in macrophage activation and IFN-!  production resulting in a lower 
bacterial load.  Once bacterial numbers fall, the immune response returns to equilibrium 
at a lower level.  There is also a large increase in IL-4 to compensate for the lack of 
IL-10, regulating the immune response and limiting tissue damage. 
 
3.3.2 Model 2 
 
The model of Wigginton and Kirschner (2001) assumes that antigen presentation occurs 
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at the site of infection in the lung.  Marino and Kirschner (2004) extend the model of 
Wigginton and Kirschner (2001) to two compartments: the lung and the peripheral 
draining lymph node (DLN).  This ODE model captures the trafficking of dendritic cells 
(DCs) from the site of infection (the lung) to secondary lymphoid tissue (the DLN), T 
cell priming and activation in the DLN following antigen presentation by DCs, and the 
migration of Th precursor cells (Th0) from the DLN to the lung.  The model includes 
five new variables: four in the DLN (naïve T cells, Th0, IL-12 and mature DCs) and one 
in the lung (immature DCs), and has seventeen variables in total.  A schematic diagram 
of the cellular and bacterial dynamics in the lung and DLN is shown in !"#$%&' +)*.  
This model is able to simulate the different infection outcomes: primary TB, latency, 
reactivation and clearance.  Volumetric measuring units (cells per cm3 of tissue) are 
used in both the lung and lymph node. 
 
The model predicts that a delay in DC trafficking to the DLN or in the migration of Th 
precursor cells from the DLN to the site of infection can affect the ability of the host to 
contain infection.  The rate of bacterial uptake by IDCs is also important in controlling 
infection.  Macrophage function (activation and infection rates of resting macrophages 
and bacterial killing by resting and activated macrophages), T cell effector functions 
and extra sources of IFN-!  production (by CD8+ T cells and NK cells) are still 
important determinants of infection outcome.  However, IL-4 production by Th0 cells in 
the lung and the death rate of resting macrophages are no longer important.  Th1/Th2 
differentiation rates can also affect the course of disease.  A more virulent strain of 
mycobacteria (with a higher extracellular growth rate) causes a more rapid progression 
to disease. 
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Figure 3.2 Schematic diagram of the cellular and bacterial dynamics in the lung and lymph node in the 
model of Marino and Kirschner (2004).  The new terms and processes in this model (compared with the 
model of Wigginton and Kirschner (2001)) are shown in blue. 
 
3.3.3 Model 3 
 
Sud et al. (2006) updated the model of Wigginton and Kirschner (2001) to examine the 
contribution of CD8+ T cells to the host immune response to M. tuberculosis in the 
lung.  The model includes four new variables: three subsets of CD8+ T cells (null or 
non-polarized (T80), cytokine producing (T8) and cytotoxic (TC)) and the cytokine 
TNF-#, and has a total of sixteen variables (!"#$%&'+)+). 
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Figure 3.3 Schematic diagram of the cellular and bacterial dynamics in the lung in the model of Sud et 
al. (2006).  The new terms and processes in this model are shown in green, and terms that were 
introduced in Marino and Kirschner (2004) are shown in blue. 
 
This model predicts that CD8+ T cells, in particular cytotoxic T cells, are key factors in 
the immune response to TB.  The rate of killing of infected macrophages by cytotoxic 
activity is important in determining the outcome of infection.  The model also predicts 
that the level of macrophage activation is influential in distinguishing between different 
disease trajectories, and that the production of IFN-!  and IL-12 affects the ability of 
the host to control infection.  Parameters that inhibit a type 1 response (e.g. inhibition of 
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IFN-!  action by IL-4 and inhibition of IL-12 production by IL-10) have a negative 
effect on the establishment of latency.  Extracellular and intracellular bacterial growth 
rates, the rate of bacterial killing by macrophages, the rate of bursting of infected 
macrophages and the turnover of bacteria from intracellular to extracellular due to the 
natural death of infected macrophages can all affect the disease trajectory. 
 
The model predicts that TNF-!  production beyond a threshold level leads to tissue 
damage.  Inhibition of macrophage and T cell recruitment by IL-10 and IFN-!  induced 
apoptosis of T cells play an important role in controlling immunopathology. 
 
The deletion of TNF-! , IFN-! or IL-12 leads to active disease.  Depletion of any of 
these cytokines also leads to a switch from latency to disease.  IL-10 deletion or 
depletion leads to similar results as latent TB.  TNF-!  deletion and depletion results in 
a faster progression to disease.  Virtual T cell deletion and depletion experiments are 
carried out to explore the role of different T cell subsets in controlling infection.  The 
deletion of CD4+ or CD8+ T cells leads to active disease.  When either cytotoxic or 
cytokine producing CD8+ T cells are removed individually latency is still achieved.  
However, the deletion of cytotoxic T cells leads to oscillations in bacterial numbers (a 
less stable steady state), while removing cytokine producing T cells results in a higher 
bacterial load.  The model is also used to investigate dynamic changes in CD8+ T cell 
effector functions, and suggests a differential contribution for CD8+ cells that are 
cytotoxic as compared with those that produce IFN-! .  If cytotoxic CD8+ cells appear 
in the lung first and decline as cytokine producing CD8+ cells are introduced into the 
system later in infection latency can be achieved, but with oscillations in bacterial 
numbers and a higher bacterial load.  If cytokine producing cells appear first followed 
by cytotoxic cells a more stable latent state is achieved (at higher bacterial numbers than 
normal latency levels).  Infection can be cleared if cytokine producing cells are 
decreased more slowly. 
 
The model predicts the minimum level of effector memory Th1 and CD8+ T cells 
required in the lungs to provide effective protection following vaccination.  For Th1 or 
cytotoxic CD8+ T cells (with a small number of Th1 cells) 10% of peak values that lead 
to latency need to be present in the lung to offer protection.  For cytokine producing 
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CD8+ T cells 75% of peak values need to be present to clear a challenge infection.  A 
combination of Th1 and cytotoxic CD8+ T cells provided the most effective protection 
with 4% and 2% of peak values, respectively, and no cytokine producing CD8+ cells 
required.  It was also determined that the memory T cells need to be present in the lung 
at the time of infection, or arrive in the lungs by one day postchallenge for the vaccine 
to be effective. 
 
3.3.4 Model 4 
 
Marino et al. (2010) merged the two models of Marino and Kirschner (2004) and Sud et 
al. (2006).  This updated two-compartment model consists of thirty-two variables, 
including two new populations in the lung (!"#$%&'+),) and eleven new populations in 
the lymph node (!"#$%&' +)-).  Th2 cells and IL-4 are not modelled in this system.  
Alternatively activated macrophages (AAM) are introduced into the model alongside 
classically activated macrophages (CAM) (similar to a study by Day et al. (2009)).  
AAM are activated by IL-4 and IL-13 (Th2 type cytokines) and play a role in humoral 
responses to parasites and extracellular pathogens.  They are classified as anti-
inflammatory macrophages (Gordon, 2003).  The macrophage populations in the lung 
and lymph node now consist of resting or uncommitted macrophages, CAM, AAM and 
infected macrophages.  Mature dendritic cells are also included in the lung, while 
immature dendritic cells, four effector T cell populations and three cytokines (TNF-! , 
IFN- !  and IL-10) are added to the lymph node compartment.  Bacteria are not 
modelled explicitly in this model; time courses of bacteria in the lung and lymph node 
are used as input functions. 
 
This paper focuses on the effects of TNF-!  and IL-10 on the macrophage and dendritic 
cell populations in the lung and lymph node.  The results indicate that TNF-!  plays a 
major role in the recruitment of macrophages and dendritic cells to the lungs.  IL-10 
affects the balance of AAM and CAM in the lung and lymph node. 
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Figure 3.4 Schematic diagram of the cellular dynamics in the lymph node in the model of Marino et al. 
(2010).  The new terms and processes in this model are shown in purple, and terms that were introduced 
in Marino and Kirschner (2004) are shown in blue. 
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Figure 3.5 Schematic diagram of the cellular dynamics in the lung in the model of Marino et al. 
(2010).  The new terms and processes in this model are shown in purple.  Terms that were introduced in 
Marino and Kirschner (2004) are shown in blue, and terms that were introduced in Sud et al. (2006) are 
shown in green. 
 
3.3.5 Model 5 
 
Segovia-Juarez et al. (2004) developed an agent-based model of granuloma formation 
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in the lung during M. tuberculosis infection.  This model captures both spatial and 
temporal aspects of the host immune response at the local site of infection.  Individual 
cells (macrophages, T cells) display spatial and temporal heterogeneity (Gammack et 
al., 2005).  Granuolma formation and maintenance may play a key role in the host 
ability to contain infection, so an understanding of the processes involved in granuloma 
formation will help elucidate some of the mechanisms involved in host-pathogen 
interactions. 
 
The model consists of the environment where entities reside (a cross-section of alveolar 
tissue), the entities of the model (discrete macrophage and T cell agents and continuous 
chemokine and bacteria variables), the rules governing the dynamics of the system 
(biological interactions of the entities), and the time-scales on which the rules are 
executed.  The possible outcomes of this model are clearance, small, solid granulomas 
(bacterial containment) and large, necrotic granulomas (bacterial dissemination).  
Chemokine diffusion and decay, macrophage recruitment, T cell recruitment and 
movement, and macrophage activation by T cells can influence infection outcome.  
Increased recruitment of macrophages to the site of infection was found to increase 
bacterial load and has a detrimental effect on the host.  The model also predicts that a 
slow intracellular bacterial growth rate facilitates the survival of M. tuberculosis. 
 
Other groups have developed models of TB infection that are based on the ODE models 
of Kirschner’s group (Day et al., 2009; Friedman et al., 2008; Magombedze et al., 
2006b; Magombedze et al., 2009), and extended them to include the effect of drug 
treatment (Goutelle et al., 2011; Magombedze et al., 2006a).  Day et al. (2009) built on 
some of this work to consider the population of AAM (the dominant macrophage 
population in healthy lung tissue) and determine the first time CAM become the 
dominant macrophage type.  Warrender et al. (2006) attempt to capture spatial effects 
and inherently stochastic processes to describe early events in M. tuberculosis infection. 
 
Mathematical models of co-infection with HIV have also been developed (Bauer et al., 
2008; Kirschner, 1999; Magombedze et al., 2008), as well as models of treatment 
during co-infection (Magombedze et al., 2010). 
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3.4 Mathematical Modelling of Drug Treatment 
 
Many diseases, including tuberculosis, require the use of drugs to be eliminated or 
ameliorated.  However, drugs have the potential to cause harm and must be 
administered at a dose that will be therapeutic but not toxic.  When designing a novel 
drug it is therefore important to be able to predict its pharmacological, therapeutic and 
toxic effects. 
 
A number of factors play a role in determining the activity of an administered drug.  
Successful drug therapy requires the establishment of a dosing regimen (dose and 
dosing interval) that provides an effective concentration of drug in the body and 
achieves the desired therapeutic effect.  To find the optimal dosing regimen we must 
understand the effects of the drug on the body, the mechanism of action of the drug, and 
what the body does to the drug (Jambhekar and Breen, 2009). 
 
Numerous models have been developed to study the effect of drug treatment on virus 
dynamics and bacterial dynamics. 
 
3.4.1 Pharmacokinetics 
 
Pharmacokinetics is the branch of pharmacology concerned with the kinetics of a drug 
and/or its metabolites in the body.  Pharmacokinetics is divided into several categories 
of study: liberation, absorption, distribution, metabolism, excretion and toxicity 
(LADMET) (Ruiz-Garcia et al., 2008). 
 
Liberation refers to the release of the drug from its pharmaceutical form.  Absorption is 
the process by which a drug moves from the site of administration to the systemic 
circulation.  The extent of a drug’s bioavailability is the proportion of the administered 
dose that is absorbed into the circulation.  This may be low because of incomplete 
absorption or because the drug is metabolized before reaching the bloodstream.  Drug 
absorption depends on the physiochemical properties of a drug, such as lipophilicity 
(lipid solubility), and the pH at the absorption site.  For a drug administered 
intravascularly there is no absorption phase.  A drug administered orally must pass from 
the gastrointestinal tract to the bloodstream.  Distribution refers to the reversible transfer 
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of a drug to and from the bloodstream.  Once a drug is in the systemic circulation 
(immediately for intravenous administration and after the absorption step for 
extravascular administration) it is distributed to all tissues.  The rate and extent of drug 
distribution depends on how well tissues and/or organs are perfused with blood, the 
binding of the drug to plasma proteins and tissue components and the permeability of 
tissue membranes to the drug molecule.  Metabolism is the conversion of one chemical 
species to another.  Elimination is the irreversible loss of a drug from the bloodstream.  
This can occur via metabolism and/or excretion.  Excretion is the loss of a drug in a 
chemically unchanged form.  The principal organs involved in drug elimination are the 
kidney and the liver.  The kidney is the primary site for the removal of unaltered drugs 
and metabolites.  The liver is the primary site for metabolism.  The lungs may also be an 
important route of elimination for substances of high vapour pressure such as gaseous 
anaesthetics and alcohol (Jambhekar and Breen, 2009).  Toxicity refers to the harmful 
effects of a drug. 
 
We usually measure the concentration of a drug in blood (plasma or serum) or the 
amount of drug removed in urine (excretion data).  The minimum effective 
concentration (MEC), or minimum inhibitory concentration (MIC), is the minimum 
plasma or serum concentration required to produce a therapeutic effect.  The minimum 
toxic concentration (MTC) is the minimum plasma or serum concentration at which the 
drug has a toxic effect.  The therapeutic range is the plasma or serum concentration 
range within which a drug produces a therapeutic effect, but is not toxic.  The onset of 
action is the time at which an administered drug reaches the therapeutic range and 
begins to produce an effect.  The termination of action is the time at which the drug 
concentration falls below the MEC.  The duration of action is the time from the onset of 
action to the termination of action i.e. the time range within which the plasma or serum 
concentration is equal to or above the MEC (Jambhekar and Breen, 2009). 
 
A drug can be administered via intravascular (intravenous, intra-arterial) or 
extravascular (oral, intramuscular, subcutaneous, sublingual or buccal, rectal, 
transdermal, inhalation) routes. !"#$%&'+). shows a plot of plasma concentration versus 
time for a drug administered extravascularly and a drug administered intravascularly.  
Drugs administered intravascularly have no absorption phase, an immediate onset of 
action and the entire administered dose is available to produce pharmacological effects.  
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For a drug administered extravascularly there is an absorption phase, the onset of action 
is not immediate and the entire administered dose may not always reach the general 
circulation (i.e. incomplete absorption) (Jambhekar and Breen, 2009). 
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Figure 3.6 Plot of plasma concentration versus time for a single dose of a drug administered by an 
extravascular route (left) (equations (3.28) - (3.32)) and an intravascular route (right) (equations (3.19) - 
(3.22)).  This figure is adapted from (Jambhekar and Breen, 2009). 
 
For intravenous administration the amount of drug that reaches the systemic circulation 
is equal to the dose: 
 
Dose = X0 = AUC( )0
! KV    (3.17) 
 
where AUC( )0
!  is the area under the curve of plasma drug concentration from time 
t = 0  to t = ! , K  is the first-order elimination constant and V  is the drug’s apparent 
volume of distribution.  The volume of distribution is the apparent volume into which a 
given mass of a drug would need to be diluted to give the observed concentration 
(Jambhekar and Breen, 2009). 
 
For extravascular administration the amount of drug reaching the circulation is equal to 
the product of the dose administered and the extent of bioavailability, F : 
 
F  !  Dose = FX0 = F AUC( )0
" KV    (3.18) 
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3.4.1.1 Pharmacokinetic Modelling 
 
The change in the concentration of a drug in the body over time can be described 
mathematically.  The processes of absorption, distribution, metabolism and excretion 
(ADME processes) are usually assumed to be first-order in nature with drug transfer in 
the body mediated by passive diffusion.  The majority of therapeutic drugs are 
eliminated by a first-order process, i.e. the rate of elimination is proportional to the 
concentration of the drug. 
 
An important concept in pharmacokinetics is that of mathematically interconnected 
compartments.  The selection of a compartment model depends on the distribution 
characteristics of a drug following its administration.  In general, the slower the 
distribution of a drug in the body, the greater the number of compartments required to 
characterize the plasma concentration versus time data.  If a drug is rapidly distributed 
in the body, a one-compartment model can be used (Jambhekar and Breen, 2009). 
 
The terms rapid and slow distribution refer to the time taken for a drug to reach 
distribution equilibrium in the body.  Distribution equilibrium means that the rate of 
drug transfer from the blood to various organs and tissues and the rate of drug transfer 
from the organs and tissues back into the blood are equal.  Rapid distribution suggests 
that distribution equilibrium is attained instantaneously following administration and 
that all organs and tissues behave in a similar way towards the drug.  Slow distribution 
suggests that distribution equilibrium is attained in a finite time and that the vasculature, 
tissues and organs do not behave in a similar way towards the drug.  In this case we 
consider the body to be comprised of two or more compartments.  These compartments 
do not correspond to physiologically defined spaces (e.g. the liver is not a 
compartment). 
 
Highly perfused systems such as the liver, kidney and blood should be in rapid 
distribution equilibrium with the blood and can be pooled in one compartment (the 
central compartment).  Systems that are not highly perfused such as muscle, lean tissue, 
fatty tissue, bones, cartilage etc. are pooled in another compartment (the tissue or 
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peripheral compartment).  In this type of model the rates of drug transfer from the 
central compartment to the peripheral compartment and back to the central compartment 
become equal at a time greater than zero.  The amount of drug distributed in different 
tissues may be different.  Changes in drug concentration in the blood (which can be 
sampled) reflect changes in drug concentrations in other tissues (which cannot be 
sampled) (Jambhekar and Breen, 2009). 
 
The compartment concept is utilized in pharmacokinetics when it is necessary to 
describe plasma concentration versus time data adequately and accurately.  This allows 
us to obtain estimates of selected fundamental pharmacokinetic parameters such as the 
apparent volume of distribution, the elimination half-life and the elimination rate 
constant of a drug.  The knowledge of these parameters and the selection of an 
appropriate model enable the calculation of a dosage regimen that will provide the 
desired plasma concentration and duration of action for an administered drug. 
 
The selection of an appropriate model depends on the distribution characteristics of the 
drug and the route of administration (Jambhekar and Breen, 2009). 
 
3.4.1.1.1 Intravenous Bolus Administration 
 
One-compartment Model 
 !"#$%&'+)/ shows a plot of plasma concentration versus time for a drug administered 
intravenously.  The drug is administered intravenously so there is no absorption phase.  
A one-compartment model can be used to characterize the data as distribution 
equilibrium is achieved instantaneously.  In this case it is not possible to distinguish 
between distribution and elimination (Jambhekar and Breen, 2009). 
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Figure 3.7 Rectilinear (left) and semi-logarithmic (right) plots of plasma concentration versus time for 
a drug administered as an intravenous bolus dose (equations (3.19) - (3.22)).  This figure is adapted from 
(Jambhekar and Breen, 2009). 
 
The change in the amount (mass) of drug in the body over time can be described by the 
following differential equation: 
 
dX
dt = !KX    (3.19) 
 
where X  is the amount (mass) of drug in the body (blood) at time t  and K  is the first-
order elimination rate constant. 
 
This equation can be solved to give 
 
X = X0 exp !Kt( )    (3.20) 
 
where X0  is the amount of drug in the body at time t = 0 . 
 
We usually measure the concentration of a drug in the blood (plasma or serum) so we 
need to find a relationship between the concentration, C , and the amount of the drug, 
X .  We define the apparent volume of distribution, V .  Then we have the following 
relationship 
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Cp =
X
V    (3.21) 
 
Dividing equation (3.20) by V  we get 
 
Cp = Cp( )0 exp !Kt( )    (3.22) 
 
where Cp  is the concentration of drug in the plasma at time t  and Cp( )0  is the 
concentration at time t = 0  (Jambhekar and Breen, 2009). 
 
Two-compartment Model 
 !"#$%&'+)0 shows a plot of plasma concentration versus time for a drug that is slowly 
distributed in the body following the administration of an intravenous bolus dose of a 
drug.  There are two phases in the concentration versus time data: a distribution phase 
and a post-distribution phase.  The time at which the plot becomes a straight line 
represents the occurrence of distribution equilibrium.  This suggests that the drug is 
distributed slowly in the body and a two-compartment model is required to characterize 
the data (Jambhekar and Breen, 2009). 
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Figure 3.8 Rectilinear (left) and semi-logarithmic (right) plots of plasma concentration versus time for 
a drug administered as an intravenous bolus dose that is distributed slowly in the body (equations (3.23) -
(3.26)).  This figure is adapted from (Jambhekar and Breen, 2009). 
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The change in the amount of drug in the central compartment is given by: 
 
dXC
dt = K21Xp ! K12XC ! K10XC    (3.23) 
 
where XC  is the amount of drug in the central compartment, XP  is the amount of drug 
in the peripheral compartment, K21  and K12  are the apparent first-order inter-
compartmental distribution or transfer rate constants and K10  is the apparent first-order 
elimination constant from the central compartment. 
 
The change in the amount of drug in the peripheral compartment is given by: 
 
dXP
dt = K12XC ! K21Xp    (3.24) 
 
These equations can be solved to give 
 
XC =
X0 ! " K21( )
! " #
exp "!t( ) + X0 K21 " #( )
! " #
exp "#t( )   (3.25) 
 
where !  is a parameter associated with drug distribution and !  is a parameter 
associated with the post-distribution phase. 
 
The concentration of drug in plasma is given by: 
 
CP =
XC
VC
=
X0 ! " K21( )
VC ! " #( )
exp "!t( ) + X0 K21 " #( )VC ! " #( )
exp "#t( )
  (3.26) 
 
where VC  is the apparent volume of distribution for the central compartment 
(Jambhekar and Breen, 2009).  Equation (3.26) can be written as 
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CP = Aexp !"t( ) + Bexp !#t( )    (3.27) 
 
3.4.1.1.2 Extravascular Administration 
 
One-compartment Model 
 !"#$%&'+)1 shows a plot of plasma concentration versus time for a drug administered 
extravascularly.  The plasma concentration versus time profile has two phases: 
absorption and elimination.  However, there is only one phase in the post-absorption 
period so the data can be described with a one-compartment model (Jambhekar and 
Breen, 2009). 
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Figure 3.9 Rectilinear (left) and semi-logarithmic (right) plots of plasma concentration versus time for 
a drug administered by an extravasular route (equations (3.28) - (3.32)).  This figure is adapted from 
(Jambhekar and Breen, 2009). 
 
The rate of change in the amount of drug at the site of administration is given by 
 
dXa
dt = !KaXa    (3.28) 
 
where Xa  is the amount (mass) of absorbable drug in the gastrointestinal tract or at the 
site of administration and Ka  is the first-order absorption rate constant. 
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Equation (3.28) can be solved to give 
 
Xa = Xa( )t=0 exp !Kat( ) = FX0 exp !Kat( )    (3.29) 
 
where Xa( )t=0 = FX0  is the amount of absorbable drug at the absorption site present at 
time t = 0  ( X0  is the administered dose and F  is the fraction of the administered dose 
that is absorbed into the systemic circulation). 
 
The change in the amount of drug in the blood over time is given by 
 
dX
dt = KaXa ! KX    (3.30) 
 
where X  is the amount (mass) of drug in the body (blood) and K  is the first-order 
elimination rate constant. 
 
Equation (3.30) has solution 
 
X = Ka Xa( )t=0Ka ! K( )
exp !Kt( )! exp !Kat( )"# $%
= KaFX0Ka ! K( )
exp !Kt( )! exp !Kat( )"# $%
   (3.31) 
 
Using equation (3.21) we obtain the following equation for the concentration of drug in 
the blood (plasma) at time t . 
 
Cp =
Ka Xa( )t=0
V Ka ! K( )
exp !Kt( )! exp !Kat( )"# $%
= KaFX0V Ka ! K( )
exp !Kt( )! exp !Kat( )"# $%
   (3.32) 
 
where V  is the apparent volume of distribution (Jambhekar and Breen, 2009). 
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Two-compartment Model 
 
The plasma concentration versus time data has three phases: absorption, distribution and 
post-distribution.  A two-compartment model is required to characterize the data.  The 
equation for the concentration of drug in plasma will contain three exponential terms, 
one for each phase (Jambhekar and Breen, 2009). 
 
3.4.2 Pharmacodynamics 
 
Pharmacodynamics is the branch of pharmacology concerned with the biochemical and 
physiological effects of drugs and their mechanisms of action (Drusano, 2004). 
 
The majority of drugs either mimic, alter or inhibit normal physiological/biochemical 
processes or inhibit pathological processes in animals, or inhibit vital processes of 
parasites and microorganisms (Lees et al., 2004).  The term chemotherapy is used to 
describe the use of chemicals to inhibit the growth of microorganisms or cancer cells 
(Rang et al., 1998).  Antimicrobial agents may be cell wall synthesis inhibitors, nucleic 
acid synthesis inhibitors, protein synthesis inhibitors or energy inhibitors (Zhang, 2005). 
 
Drug molecules must exert some chemical influence on one or more constituents of 
cells in order to produce a pharmacological response (Rang et al., 1998).  Most drugs 
act by binding specific molecular targets (target sites) in body tissues, parasites or 
microorganisms (Lees et al., 2004).  The pharmacological effect of a drug occurs when 
the drug reaches and interacts with a molecule for which it has affinity (Pallasch, 1988).  
Protein molecules are commonly involved as primary drug targets.  Protein targets 
include enzymes, carrier molecules, ion channels and receptors.  Targets for 
chemotherapeutic drugs include DNA and cell wall constituents as well as proteins 
(Rang et al., 1998). 
 
According to the occupancy theory, the drug effect is a function of the binding of drug 
to the receptor and drug-induced activation of the receptor, and propagation of this 
initial receptor activation into the observed pharmacological effect, where the intensity 
of the pharmacological effect is proportional to the number of receptor sites occupied by 
drug (Macheras and Iliadis, 2006). 
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Drug-receptor interactions can be represented by 
 
 
D + R konkoff! "!!# !!! DR  
 
where D  is the drug (ligand), R  is the receptor, DR  is the drug-receptor complex, kon  
is the association rate constant and koff  is the dissociation rate. 
 
Using the law of mass action, which states that the rate of a reaction is proportional to 
the product of the concentration of the reactants (Murray, 2002), we can write the 
following equation for the rate of change of the drug-receptor complex: 
 
d DR[ ]
dt = kon D[ ] R[ ]! koff DR[ ]    (3.33) 
 
where D[ ]  is the concentration of free (unbound) drug at the site of action, R[ ]  is the 
concentration of free receptor and DR[ ]  is the concentration of occupied receptors. 
 
The total concentration of receptors, RT , can be written as RT = R[ ] + DR[ ]  so that 
RT ! DR[ ]  is the concentration of free receptor.  Substituting this expression into 
equation (3.33) we obtain 
 
d DR[ ]
dt = kon RT ! DR[ ]( ) D[ ]! koff DR[ ]    (3.34) 
 
At equilibrium, 
d DR[ ]
dt = 0
!
"#
$
%&
, equation (3.34) gives 
 
DR[ ] = RT D[ ]Kd + D[ ]
   (3.35) 
 
or 
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DR[ ]
RT
=
D[ ]
Kd + D[ ]
   (3.36) 
 
where Kd  is the dissociation constant 
koff
kon
 (Csajka and Verotta, 2006; Norman, 1979).  
Kd  is equal to the concentration of drug required to occupy half of the receptors (Rang 
et al., 1998). 
 
The translation of receptor action into the ultimate pharmacological response is known 
as transduction.  The binding of a drug to its target site initiates a cascade of 
biochemical and/or electrophysiological events that results in an observable biological 
response (Danhof et al., 2005). 
 
The transduction function z DR[ ]RT
!
"#
$
%&
 relates receptor occupancy to pharmacological 
effect E  
 
E = z DR[ ]RT
!
"#
$
%&
= z D[ ]Kd + D[ ]
!
"#
$
%&
   (3.37) 
 
Assuming that the response produced by the drug is proportional to the fraction of 
occupied receptors 
DR[ ]
RT
 we obtain 
 
E = EmaxCEC50 +C
   (3.38) 
 
where C  is the concentration of drug at the site of action , Emax  is the maximum effect 
and EC50  is the concentration of drug required to produce half the maximum effect 
(Csajka and Verotta, 2006). 
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3.4.2.1 Pharmacodynamic Modelling 
 
Pharmacodynamic models describe the relationship between the response (or effect) 
produced by a drug and drug concentration in the plasma. 
 
The most commonly used pharmacodynamic model for describing concentration-effect 
relationships is the sigmoid Emax  model (!"#$%&'+)(2), which is an empirical function 
for describing nonlinear concentration-effect relationships.  The effect of a drug is 
described by the following equation: 
 
E = EmaxC
n
EC50( )n +Cn
   (3.39) 
 
where the intensity of the pharmacological effect E  is a function of the concentration 
C  with maximum effect Emax .  EC50  is the concentration of drug that will produce 
one-half of the maximum effect.  This corresponds to a Hill function with a Hill-
coefficient of n  (Derendorf and Meibohm, 1999; Handel et al., 2009). 
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Figure 3.10 Plot of effect versus drug concentration in plasma for different values of n in the sigmoid 
Emax model. 
 
This model is based on the law of mass action and classical receptor occupancy theory 
(Csajka and Verotta, 2006).  The parameter EC50 , which characterizes the potency of 
the drug, is a function of receptor affinity.  Emax , which reflects the efficacy or intrinsic 
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activity of the drug, is a function of receptor density.  n  is the number of drug 
molecules combining with each receptor molecule (Danhof et al., 2005; Derendorf and 
Meibohm, 1999).  Although n  can be derived from receptor theory, in practice it is 
merely used to provide a better fit to data (Derendorf et al., 2000). 
 
3.5 Antimicrobial Chemotherapy 
 
Antimicrobial pharmacodynamics aims to link a measure of drug exposure to the 
observed microbiological or clinical effect.  Measures of the activity of the drug (for 
example, the minimum inhibitory concentration (MIC) for a specified pathogen) are 
normally available (Drusano, 2004), and dose and drug selection are mostly based on 
the static MIC and the antibiotic plasma concentration.  As a result, several efficacy 
indices or surrogate markers have been defined to describe the antimicrobial activity of 
different drugs which take into account both pharmacokinetic and pharmacodynamic 
information (Mueller et al., 2004). 
 
Antibiotics are often divided into two classes: those that exhibit time-dependent killing 
(e.g ! -lactams) and those that exhibit concentration-dependent killing (e.g. 
aminoglycosides and fluoroquinolones).  For those that exhibit time-dependent killing, 
their effect depends on the length of time that the bacteria are exposed to the drug.  
Their effect increases with increasing concentrations until the maximum kill rate is 
reached.  After this point higher drug concentrations will not produce an increase in 
effect.  The rate of killing is maximized at a low multiple of the MIC.  For antibiotics 
that exhibit concentration-dependent killing, the rate of bacterial killing increases with 
increasing concentrations (Drusano, 2007; Mueller et al., 2004). 
 
The most frequently used pharmacodynamic parameters for the evaluation of the 
efficacy of anti-infective agents are the time above MIC ( T  >MIC), the peak 
concentration-to-MIC ratio (Cmax  /MIC) and the area under the concentration-time 
curve-to-MIC ratio (AUC/MIC).   T  >MIC is the most used parameter for time-
dependent antibiotics, and Cmax  /MIC and AUC>MIC are the most used parameters for 
concentration-dependent antibiotics (Mueller et al., 2004). 
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Although these parameters are useful predictors of the efficacy of a drug, they only 
provide limited information on the complex interactions that occur between drug, host 
and pathogen in vivo (Mueller et al., 2004). 
 
3.5.1 Population Dynamics 
 
Mathematical models of antibiotic treatment typically focus on the dynamics of the drug 
and bacterial population, and neglect the role played by the immune system in clearing 
infection (Handel et al., 2009).  The simplest models of antimicrobial chemotherapy 
consist of a population of drug-susceptible bacteria, S , and the concentration of a given 
antibiotic, C .  For simplicity, a one-compartment pharmacokinetic model (as described 
in Section 3.4.1.1.1) may be used to model the concentration of the drug.  The effect of 
the drug on the bacteria is given by the following equation: 
 
dS
dt = gS ! Sf (C)    (3.40) 
 
where g  is the net growth rate of the bacterial population.  A sigmoid Emax  model is 
often used for f C( ) , so f (C) = EmaxC
n
EC50( )n +Cn
 (as described in Section 3.4.2.1).  A drug 
resistant population can also be included in these models, and the model can be 
extended to incorporate multidrug treatment (e.g. Lipsitch and Levin, 1997). 
 
Antimicrobial drugs can also inhibit bacterial growth.  This effect can be combined with 
a killing term to give: 
 
dS
dt = gSfg (C)! Sf (C)    (3.41) 
 
where fg (C) = 1!
Cng
EC50g( )ng +Cng
.  EC50g  is the concentration of drug that will produce 
one-half of the maximum effect and ng  is the Hill-coefficient (e.g. Goutelle et al., 
2011). 
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3.5.2 Classification of PK/PD Models 
 
Integrated PK/PD models can be classified into four different groups depending on the 
way in which the measured pharmacokinetic and pharmacodynamic data are related to 
one another.  These include direct link versus indirect link models, direct response 
versus indirect response models, time-variant versus time-invariant models and soft link 
versus hard link models (Derendorf et al., 2000; Derendorf and Meibohm, 1999). 
 
For direct link models the measured drug concentration in plasma and the effect site 
concentration are directly linked.  Equilibrium between both concentrations is assumed 
to be achieved rapidly.  In these models the measured concentrations can serve as an 
input function in the pharmacodynamic model.  Indirect link models are required if 
there is a temporal dissociation between the time courses of concentration and effect.  
The observed delay in the concentration-effect relationship is most likely caused by a 
distributional delay between the concentrations in plasma and at the effect site. 
 
For direct response models the observed effect is directly related to the effect site 
concentration without time lag.  Temporal dissociation between the time courses of 
concentration and effect might also be caused by an indirect response mechanism where 
the observed effect is not directly linked to effect site concentration but is secondary to 
intermediary response steps (Derendorf et al., 2000; Derendorf and Meibohm, 1999). 
 
For time-invariant PK/PD models pharmacodynamic model parameters remain constant 
over time.  Most drugs follow this rule, but for some drugs pharmacodynamic 
parameters undergo time-dependent changes resulting in changes in effect intensities 
without changes in drug concentrations at the effect site.  A decrease in effect intensity 
at concentrations that earlier produced a greater effect is related to drug tolerance. 
 
PK/PD models can also differ in the way they are established and utilize clinical 
measurements of concentration of effect and data regarding mechanisms of action.  Soft 
link models use measurements of concentration and effect to define the link between 
pharmacokinetics and pharmacodynamics.  In contrast, hard link models use 
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pharmacokinetic data and additional information on the mechanisms of action of the 
drug to predict the time course of effect (Derendorf et al., 2000; Derendorf and 
Meibohm, 1999).  
 
Pharmacokinetic and pharmacodynamic equations have been used to model the effect of 
drug treatment during tuberculosis infection.  Goutelle et al. (2011) extended the model 
of Marino and Kirschner (2004) to include the effect of treatment with rifampicin.  A 
three-compartment PK model (Goutelle et al., 2009) is used to describe the 
concentration of the drug in the absorptive compartment, the central compartment, the 
pulmonary epithelial lining fluid compartment and the pulmonary alveolar cell 
compartment.  It is assumed that the drug kills the bacteria and inhibits bacterial growth.  
The authors also developed a simpler model that does not include immune system 
dynamics.  In addition, mathematical models have been used to investigate the 
emergence of drug resistance during tuberculosis treatment (Lipsitch and Levin, 1998). '
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4.1 Introduction 
 
The protective response to M. tuberculosis is complex and involves many components 
of the immune system  (Flynn and Chan, 2001a).  The aim of this work is to develop a 
mathematical model that represents the basic processes of the immune response to 
tuberculosis and allows us to predict the outcome of infection at the individual level 
(Wigginton and Kirschner, 2001), both in the presence and absence of drug treatment. 
 
In this chapter a mathematical model of human tuberculosis infection in the lung and 
nearest draining lymph node (DLN) is developed, based on the models of Wigginton 
and Kirschner (2001), Marino and Kirschner (2004) and Sud et al. (2006).  The model 
describes the temporal dynamics of the major elements of the host immune response 
and the pathogen M. tuberculosis, including populations of immune cells, cytokines and 
extracellular and intracellular bacteria. 
 
This type of model is very complicated and involves many variables and parameters.  
There is a lot of uncertainty with respect to the parameter values.  The focus in this 
chapter is to explore the dependence of disease outcome on model parameters.  This 
approach is used to identify components of the system that affect the outcome of 
infection. 
 
4.2 Mathematical Model 
 
The model is constructed by extending the model of Sud et al. (2006) to two 
compartments: the lung and the peripheral draining lymph node, similar to the model 
developed by Marino and Kirschner (2004).  This gives a more complete description of 
the dynamics of the immune system during M. tuberculosis infection.  This model 
contains twenty-one variables.  Six new variables are added to the model of Sud et al. 
(2006): one in the lung (immature dendritic cells) and five in the DLN (naïve CD4+ and 
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CD8+ T cells, non-polarized CD4+ and CD8+ T cells and mature dendritic cells).  
These new populations are also found in the model of Marino et al. (2010) (which 
includes a number of other variables), but the forms of the equations for the new 
populations follow the model of Marino and Kirschner (2004).  Only one population of 
effector CD8+ T cells is included in the model presented in this chapter (rather than two 
different populations), which display both cytotoxic and cytokine-producing 
capabilities.  Cytokine production in the DLN is not included in the model. 
 
The lung compartment includes three macrophage populations (resting, infected and 
activated), three CD4+ lymphocyte populations (T helper precursor (Th0), T helper 1 
(Th1) and T helper 2 (Th2)), two CD8+ lymphocyte populations (non-polarized (T80) 
and cytotoxic or effector (TC)), five cytokines (tumor necrosis factor-!  (TNF-! ), 
interferon- !  (IFN- ! ), interleukin-12 (IL-12), IL-10 and IL-4), two bacterial 
populations (extracellular and intracellular) and immature dendritic cells (IDCs).  The 
DLN compartment includes naïve CD4+ T cells, naïve CD8+ T cells, Th precursors, 
precursor CD8+ T cells, and mature dendritic cells (MDCs).  A descriptive diagram of 
the bacterial and cellular dynamics is shown in !"#$%&' ,)(.  All model variables and 
their initial condition are listed in 3456&'(. 
 
The intracellular bacterial population consists of bacteria found within infected 
macrophages.  All other bacteria are considered extracellular, including bacteria found 
within resting or activated macrophages.  Extracellular bacteria are vulnerable to direct 
killing by resting or activated macrophages (and immature dendritic cells), while 
intracellular bacteria are only killed when their host macrophage dies (Wigginton and 
Kirschner, 2001). 
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Figure 4.1 Schematic diagram of the cellular dynamics in the lung and lymph node.  Terms in the 
original Wigginton and Kirschner (2001) model are shown in black.  Those that were introduced in 
Marino and Kirschner (2004) are shown in blue, those introduced in Sud et al. (2006) are shown in green, 
and those introduced in Marino et al. (2010) are shown in purple. 
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Cellular populations (dendritic cells, macrophages and T lymphocytes) are measured in 
cells/cm3 of tissue (or cells/mL).  Bacterial populations are measured in bacteria/cm3 of 
tissue.  Cytokine concentrations are measured in pg/mL. 
 
Table 1 Model variables and initial conditions. 
Variable Description Initial condition Units 
MR  Density of resting macrophages 3 $ 105 cells/cm3 
MI  Density of infected macrophages 0 cells/cm3 
MA  Density of activated macrophages 0 cells/cm3 
F!  Concentration of TNF-" 0 pg/mL 
I!  Concentration of IFN-! 0 pg/mL 
I12  Concentration of IL-12 0 pg/mL 
I10  Concentration of IL-10 0 pg/mL 
I4  Concentration of IL-4 0 pg/mL 
T
40
L  Density of Th precursors in the lung 0 cells/cm3 
T1  Density of Th1 cells 0 cells/cm3 
T2  Density of Th2 cells 0 cells/cm3 
T
80
L  Density of TC precursors in the lung 0 cells/cm3 
TC  Density of effector CD8+ T cells 0 cells/cm3 
BE  Density of extracellular bacteria 25 bacteria/cm3 
BI  Density of intracellular bacteria 0 bacteria/cm3 
N4  Density of naïve CD4+ T cells 1000 cells/cm3 
N8  Density of naïve CD8+ T cells 1000 cells/cm3 
T40LN  Density of Th precursors in the DLN  0 cells/cm3 
T80LN  Density of TC precursors in the DLN 0 cells/cm3 
MDC  Density of mature dendritic cells 0 cells/cm3 
IDC  Density of immature dendritic cells 5 $ 104 cells/cm3 
 
4.2.1 Model Description 
 
Macrophage dynamics are described in equations (4.1) - (4.3) (Sud et al., 2006).  
Resting macrophages are normally present in the lungs of healthy individuals and 
undergo constant turnover.  There is a source of newly differentiated cells coming into 
the site srM( )  and a natural death of cells that stay the remainder of their life span 
(Wigginton and Kirschner, 2001) at rate µMR .  In the absence of infection the 
macrophage population remains at the equilibrium value of srM / µMR . 
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During the course of infection additional resting macrophages are recruited to the site of 
infection in the lung.  Activated and infected macrophages release chemokines that 
promote the migration of macrophages at rates ! 4A  and w2! 4A  (with 0 < w2 < 1 ), 
respectively.  Resting macrophages are also recruited in a TNF-! -dependent manner at 
a rate of sr4B .  This process is down-regulated by IL-10 (Sud et al., 2006). 
 
Macrophage activation occurs at a maximum rate of k3  in response to signals from 
IFN-!  and either bacteria or TNF-! .  Here BT = BE + wBI  (with 0 ! w ! 1) to account 
for the reduced contribution of intracellular bacteria to antigen stimulation.  TNF-!  is 
scaled by a factor !  because of the difference in measurement units between bacteria 
and TNF-! .  Macrophage activation induced by IFN-!  is inhibited by IL-4.  Activated 
macrophages are deactivated by IL-10 at a maximum rate of k4 .  Activated 
macrophages undergo natural death at rate µMA  (Sud et al., 2006). 
 
Resting macrophages become chronically infected at a maximum rate of k2 .  This is 
dependent on the extracellular bacterial load.  Infected macrophages are cleared via 
several different mechanisms: bursting, apoptosis (programmed cell death), cytotoxic 
activity and natural death (at rate µMI ) (Sud et al., 2006).  We assume that macrophages 
have an average maximal intracellular bacterial carrying capacity or multiplicity of 
infection (MOI) of N , so the carrying capacity for the entire population of infected 
macrophages is given by NMI .  Infected macrophages may burst when their 
intracellular bacterial load exceeds their carrying capacity.  When the number of 
intracellular bacteria is equal to NMI  the rate of death due to bursting will be one-half 
of the maximum rate of k17 .  This mechanism is described by a Hill process, with the 
Hill co-efficient estimated to be equal to two (Wigginton and Kirschner, 2001).  
Infected macrophages can also be eliminated by T cell-mediated immune responses.  
Cytotoxic CD8+ T cells and Th1 cells can induce apoptosis in infected macrophages via 
the Fas-FasL apoptotic pathway at a maximum rate of k14A .  This depends on the 
effector cell to target ratio TC +w3T1( ) :MI  and is half-maximal when this ratio is equal 
to c4 .  The contribution from Th1 cells is less than that from cytotoxic CD8 cells so 
Th1 numbers are scaled 0 < w3 < 1( ) .  Apoptosis can also be induced by TNF-!  at a 
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maximum rate of k14B .  This process is inhibited by IL-10.  Cytotoxic killing by CD8+ 
T cells and Th1 cells occurs at a maximum rate of k52 .  The cytotoxic activity of Th1 
cells is less than that of cytotoxic CD8 cells so their numbers are scaled 0 < w1 < 1( )  
(Sud et al., 2006).  CD8+ T cells depend indirectly on CD4+ T cells for their cytotoxic 
capability (Serbina et al., 2001). 
 
dMR
dt = srM +! 4A MA +w2MI( )+ sr4B
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Cytokine dynamics in the lung are described in equations (4.4) - (4.8) (Sud et al., 2006).  
TNF- !  is secreted by infected macrophages at a rate of ! 30  and by activated 
macrophages at a maximum rate of ! 31  in response to IFN-!  or bacteria.  This process 
is down-regulated by IL-4 and IL-10.  Th1 cells and cytotoxic CD8+ T cells also 
produce TNF-!  at a rate of ! 32  and ! 33 , respectively.  TNF-!  decays at a rate of 
µF! . 
 
Th1 cells and CD8+ T cells produce IFN-!  in response to antigen presentation by 
activated macrophages at a maximum rate of !5A  and !5B , respectively.  Th0 and T80 
cells also produce IFN-!  at a maximum rate of ! 7  in response to IL-12.  This process 
is inhibited by IL-10.  Infected macrophages secrete IFN-!  at a rate of !5C .  We 
include an extra source term, sg , to account for other sources of IFN-! , such as !"  T 
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cells, natural killer cells and natural killer T cells.  This production is governed by IL-12 
and the total bacterial load.  IFN-!  decays at rate µI!  (Sud et al., 2006). 
 
Resting macrophages produce IL-12 at a maximum rate of !23  in response to bacteria.  
IL-12 is also produced by activated macrophages at a maximum rate of !8 .  This 
process is opposed by IL-10.  IDCs in the lung produce IL-12 at a maximum rate of s12 .  
This process depends on the extracellular bacterial load (Ebner et al., 2001; Sousa et al., 
1997).  IL-12 decays at rate µI12  (Sud et al., 2006). 
 
IL-10 is produced by infected macrophages at a maximum rate of !7 .  This process is 
inhibited by IFN-!  and IL-10.  Th1 cells, Th2 cells and CD8+ T cells produce IL-10 at 
a rate of !16 , !17  and !18 , respectively.  IL-10 decays at rate µI10 . 
 
IL-4 is produced by Th0 cells at a rate of !11  and by Th2 cells at a rate of !12 .  IL-4 
decays at a rate of µI10  (Sud et al., 2006). 
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dt =!11T40
L +!12T2 ! µI 4I4   (4.8) 
 
The lymphocyte population in the lung consists of CD4+ subpopulations (Th precursor, 
Th1 and Th2 cells), and CD8+ subpopulations (precursor and cytotoxic T cells).  T cell 
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dynamics at the site of M. tuberculosis infection in the lung are given by equations (4.9) 
- (4.13) (Marino and Kirschner, 2004; Sud et al., 2006).  Th0, Th1 and Th2 cells die 
naturally at rates µT 40 , µT1  and µT 2 , respectively.  T80 and effector CD8+ T cells die 
at rates µT 80  and µTC , respectively.  Th precursor and T80 cells migrate to the lung 
from the draining lymph node in a TNF-! -independent manner at a maximum rate of 
! A"A  and ! B"B , respectively.  This process is induced by chemokines released by 
activated and infected macrophages.  They are also recruited to the site of infection in a 
TNF-! -dependent manner at a maximum rate of 1!" A( )#A  for Th precursors and a 
maximum rate of 1!" B( )#B  for T80 cells.  This process is inhibited by IL-10 (Marino 
et al., 2010; Sud et al., 2006).  Th0 and T80 cells can proliferate in the lung at a 
maximum rate of ! 2A  and ! 2B , respectively, in response to signals from activated 
macrophages (Sud et al., 2006).  We assume that all T cells arrive in the lung as 
precursor or non-polarized (Th0, T80) cells and differentiate into the different subtypes 
in the lung (Marino and Kirschner, 2004). 
 
Th0 cells can differentiate into either Th1 or Th2 cells at a maximum rate of k6A  and 
k7 , respectively.  Th1 differentiation is dependent on signals from both IL-12 and 
IFN-! .  This process is inhibited by IL-4 and IL-10.  Th2 differentiation is induced by 
IL-4 and opposed by IFN-! .  IFN-!  induced apoptosis of Th1 cells in the presence of 
activated macrophages occurs at a maximum rate of µT !  (Sud et al., 2006). 
 
T80 cells can differentiate into cytotoxic cells at a maximum rate of k6B .  These cells 
are capable of lysing infected macrophages and secreting cytokines.  This process is 
induced by IL-12 and IFN-!  and down-regulated by IL-4 and IL-10.  Cytotoxic CD8+ 
T cells undergo IFN-!  induced apoptosis at a maximum rate of µTc!  (Sud et al., 2006).  
!  represents the scaling factor between the lung and lymph node compartments 
(Marino et al., 2010). 
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Bacterial dynamics are described in equations (4.14) and (4.15) (Sud et al., 2006).  
Extracellular bacteria follow a logistic growth equation with a maximum growth rate of 
!20  and carrying capacity Nmax .  The turnover of bacteria from intracellular to 
extracellular due to the natural death of infected macrophages is given by the term 
µI BI .  Extracellular bacteria are internalized and killed by activated and resting 
macrophages at a rate of k15  and k18 , respectively.  Extracellular bacteria become 
intracellular when their host macrophage becomes chronically infected and carries one-
half of its maximal carrying capacity, N / 2  bacteria.  Bursting of infected macrophages 
(at rate k17 ) results in the release of their intracellular bacterial load.  Fas-FasL induced 
apoptosis k14A( )  releases a proportion of intracellular bacteria, shown by the multiplier 
N fracc , and TNF-!  induced apoptosis k14B( )  releases a proportion shown by the 
multiplier N fraca .  We assume that CTL activity k52( )  kills all intracellular bacteria and 
does not add to the extracellular bacterial population (Sud et al., 2006).  Extracellular 
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bacteria are taken up by immature dendritic cells at rate !12  (Marino and Kirschner, 
2004). 
 
Intracellular bacterial growth is described by a Hill equation accounting for the maximal 
carrying capacity of infected macrophages.  Intracellular bacteria grow at a maximum 
rate of !19 .  Growth occurs near the maximum rate of !19  until the intracellular 
bacterial population reaches the carrying capacity of the chronically infected 
macrophage population, NMI .  When this capacity is reached, bacterial growth is 
reduced (Wigginton and Kirschner, 2001). 
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T cells undergo development in the thymus.  Mature T cells leave the thymus, enter the 
bloodstream and then leave the bloodstream to migrate through peripheral lymphoid 
organs (where they may encounter their specific foreign antigen and become activated) 
(Murphy et al., 2008).  Naïve T cells continuously re-circulate between blood and 
peripheral lymphoid tissues.  Naïve T cell dynamics are given by equations (4.16) and 
(4.17) (Marino and Kirschner, 2004).  A constant amount of naïve CD4+ T cells 
migrate in from the thymus, sN 4 , and a variable amount proportional to the number 
present migrate out at rate !1A .  These cells are also recruited to the DLN by mature 
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dendritic cells at rate ! 2A , and undergo natural death at rate µN 4 .  Naïve CD4+ T cells 
differentiate into Th precursor cells at a rate of ! 4A  in response to antigen presentation 
by mature dendritic cells.  Naïve CD8+ T cell dynamics are regulated by similar 
mechanisms: migration from the thymus ( sN 8  term), recruitment by MDCs (! 2B  term), 
migration out of the DLN (!1B  term), differentiation to T80 cells (! 4B  term) and natural 
death (µN 8  term). 
 
dN4
dt = sN 4 +!2AMDC ! "1AN4 ! µN 4N4 !! 4AN4MDC  (4.16) 
dN8
dt = sN8 +!2BMDC ! "1BN8 ! µN8N8 !! 4BN8MDC  (4.17) 
 
The dynamics of Th precursor and T80 cells in the draining lymph node are governed 
by equation (4.18) and equation (4.19), respectively (Marino and Kirschner, 2004).  The 
proliferation and death of Th precursor and T80 cells is described by a logistic growth 
term with a maximum carrying capacity of !A  and !B , respectively.  A percentage !A  
of Th precursor cells and !B  of T80 cells migrate into the blood (and eventually enter 
the site of infection in the lung). 
 
dT40LN
dt = ! 4AN4MDC +!5AT40
LN 1! T40
LN
"A
"
#$
%
&'
!#AT40LN  (4.18) 
dT80LN
dt = ! 4BN8MDC +!5BT80
LN 1! T80
LN
"B
"
#$
%
&'
!#BT80LN  (4.19) 
 
Dendritic cell population dynamics are described in equation (4.20) and equation (4.21) 
(Marino and Kirschner, 2004).  Following bacterial uptake immature dendritic cells 
(IDCs) mature and migrate from the lung to the lymph node at a maximum rate of !10 .  
This term is scaled by a constant factor 1/!  because of the different compartmental 
measuring units of the lung and the DLN.  Mature dendritic cells (MDCs) die naturally 
at a rate of µMDC . 
 
Immature dendritic cells are normally present in the lung and undergo a natural 
turnover.  There is a source of new cells migrating into the site, sIDC , and a natural death 
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of cells at rate µIDC .  In the absence of infection the immature dendritic cell population 
should remain at an equilibrium value of sIDC / µIDC .  Immature dendritic cells are 
recruited to the lung at a maximum rate of !8  in response to extracellular bacteria 
(Marino and Kirschner, 2004). 
 
dMDC
dt =
!10IDC
"
BE
BE +!11
#
$%
&
'(
) µMDCMDC   (4.20) 
dIDC
dt = sIDC +!8IDC
BE
BE +!9
!
"#
$
%&
'!10IDC
BE
BE +!11
!
"#
$
%&
' µIDCIDC  (4.21) 
 
4.2.2 Model Parameters 
 
The 137 parameters used in the model are listed in the 788&9:"; (3456&' ,).  The 
majority of parameter values were adopted from Marino and Kirschner (2004) and Sud 
et al. (2006).  Parameter values in the DLN and those describing the trafficking of cells 
between the DLN and lung were based on parameter values in Marino and Kirschner 
(2004).  Parameters in the lung were mostly based on those in Sud et al. (2006), with 
some obtained from Marino and Kirschner (2004). 
 
This model contains thirteen parameters that are not included in the models of Marino 
and Kirschner (2004) and Sud et al. (2006).  Most (eight) of these new parameters 
describe the dynamics of CD8+ T cells in the lymph node.  These dynamics are the 
same as the CD4+ T cell dynamics described in Marino and Kirschner (2004), so these 
parameter values were chosen based on the equivalent parameters for CD4+ T cells.  
Other new parameters in the model describe the migration of precursor T cells into the 
lung.  These include the maximum contribution of activated and chronically infected 
macrophages to Th0 migration into the lung ! A( ) , the maximum contribution of 
activated and chronically infected macrophages to precursor CD8+ T cell migration into 
the lung ! B( ) , and the effect of activated and chronically infected macrophages on Th0 
and CD8+ T cells migration into the lung (the half-saturation constants ! 6A  and ! 6B ).  
! 6A  and ! 6B  were based on a similar parameter (for activated macrophages) in Marino 
and Kirschner (2004).  It is assumed that the maximum contribution of macrophages 
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and TNF-!  to Th0 and precursor CD8+ T cell migration into the lung are equal, so ! A  
and ! B  are set to 0.5.  A carrying capacity for the extracellular bacterial population 
Nmax( )  was also included in the model and this parameter value was taken from Goutelle 
et al. (2011). 
 
Values for many of the parameters in the models of Marino and Kirschner (2004) and 
Sud et al. (2006) were estimated from published and unpublished experimental data 
from human, mouse, rabbit and nonhuman primate models of TB, with human (or 
nonhuman primate) derived data used when possible.  However, parameter values in the 
DLN were more difficult to estimate, and those for DCs were estimated based on 
similar rates for macrophages (Marino and Kirschner, 2004).  Mathematical estimation 
was used in the absence of data (Marino and Kirschner, 2004; Sud et al., 2006). 
 
The lack of experimental data (especially time course data) for humans makes 
parameter estimation difficult.  Experimental data used to estimate parameter values 
often contains significant variability, while some parameters cannot be estimated from 
experimental data.  Marino and Kirschner (2004) and Sud et al. (2006) performed 
uncertainty and sensitivity analyses to evaluate all the parameters in their model and 
obtain order of magnitude estimates for parameters for which there are a range of values 
and parameters for which no experimental data are available (e.g. rates in the DLN) 
(Wigginton and Kirschner, 2001). 
 
Detailed uncertainty and sensitivity analyses were performed by Marino and Kirschner 
(2004) and Sud et al. (2006) to assess how variations in parameter values affect the 
model output and to identify the critical parameters of the system.  The purpose of 
uncertainty analysis is to investigate the uncertainty in the model output due to 
uncertainty in parameter inputs.  Sensitivity analysis is performed to quantify how input 
uncertainty impacts model outcome (Marino et al., 2008). 
 
Latin hypercube sampling (LHS) is combined with partial rank correlation (PRC) to 
assess the sensitivity of outcome variables to parameter variation (Marino et al., 2008).  
LHS is a stratified Monte Carlo sampling method that allows simultaneous, random and 
evenly distributed sampling of each parameter over a defined range (Sud et al., 2006).  
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LHS involves the generation of a matrix that consists of N  rows corresponding to the 
number of simulations and k  columns corresponding to the number of varied 
parameters.  N  model solutions are then simulated using each combination of 
parameter values.  Partial rank correlation is performed to calculate the correlation 
coefficient between the k  parameters and the outcome values.  The partial rank 
correlation coefficient (PRCC) is a measure for nonlinear but monotonic relationships 
between inputs and outputs.  Each PRCC value has an associated p -value that 
determines the significance of the correlation.  Even small correlations may be 
significant (Gammack et al., 2005; Marino et al., 2008). 
 
The model in Marino and Kirschner (2004) contains more than seventy parameters.  
Seventeen of these parameters were found to be influential in distinguishing between 
infection outcomes after performing uncertainty and sensitivity analyses over specified 
parameter ranges.  The model predicts that the percentage of Th0 cells migrating out of 
the DLN into the blood, the source term for IDCs and the rate of IDC migration from 
the lung to the DLN can affect the ability of the host to contain infection.  The rate of 
bacterial uptake by IDCs, the rates of killing of extracellular bacteria by resting and 
activated macrophages and the rate of T cell killing of infected macrophages (cytotoxic 
activity and apoptosis) are also important in controlling infection.  Other critical 
parameters include the extracellular bacterial growth rate, activation and infection rates 
of resting macrophages, the rate of macrophage deactivation, the rate of T cell 
activation by MDCs, the death rate of MDCs, the rate of IFN-!  production by extra 
sources (CD8+ T cells and NK cells) and the rate of IL-12 production by MDCs in the 
DLN.  Th1 and Th2 differentiation rates can also affect the course of disease. 
 
The model in Sud et al. (2006) consists of more than 100 parameters that govern rates 
and interactions between various components.  Changes in only twenty of these 
parameters were found to be influential in distinguishing between infection outcomes 
after performing uncertainty and sensitivity analyses.  The model predicts that the rate 
of macrophage activation, the strength of the IFN-!  signal and the strength of the 
signal from bacteria (half-saturation constants for macrophage activation) are important 
in determining the outcome of infection.  The effect of activated macrophages on 
IFN-!  production by Th1 cells (half-saturation constant), the rate of IFN-!  production 
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by cytokine producing CD8+ T cells, the effect of activated macrophages on IFN-!  
production by cytokine producing CD8+ T cells, the rate of IFN-!  production by other 
sources (NK cells) and the effect of bacteria on IFN-!  production by other sources can 
affect the ability of the host to control infection.  The rate of IL-12 production by resting 
macrophages, the effect of bacteria on IL-12 production by resting macrophages and the 
effect of bacteria on IL-12 production by other sources (DCs) are also influential in 
distinguishing between different disease trajectories.  The inhibition of IFN-!  effects 
by IL-4, the inhibition of IL-12 production by IL-10 and the rate of IL-10 production by 
CD8+ T cells (cytotoxic and cytokine producing) are also critical.  Extracellular and 
intracellular bacterial growth rates, the rate of killing of infected macrophages by 
cytotoxic activity, the rate of killing of extracellular bacteria by resting macrophages, 
the rate of bursting of infected macrophages and the turnover of bacteria from 
intracellular to extracellular due to the natural death of infected macrophages can all 
affect the disease trajectory. 
 
4.2.3 Computer Simulations 
 
Calculations were performed using MATLAB® version R2011b (The MathWorks, Inc., 
Natick, MA, USA).  The system of nonlinear ODEs is solved using the built-in ODE 
solver ode15s.  ode15s is a variable-order solver for stiff ODEs based on the numerical 
differentiation formulas. 
 
4.3 Results 
 
 
The model presented in Section 4.2.1 is able to simulate different infection outcomes: 
primary tuberculosis (or active disease), latent tuberculosis and clearance, depending on 
the choice of parameter values.  These parameter sets are not unique, and each outcome 
can be achieved with different combinations of parameters.  Extracellular bacterial load 
is used as a marker of disease progression (Marino and Kirschner, 2004; Sud et al., 
2006; Wigginton and Kirschner, 2001). 
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Clearance is considered to be achieved when the density of both extra- and intracellular 
bacteria is less than 1x10-3 bacteria/cm3 of tissue, which is roughly equivalent to less 
than one bacterium in human lungs.  The mass of human lung tissue is of the order of 
1x102 g (Joachim et al., 1978), so its volume is of the order of 1x102 cm3. 
 
Active disease is characterized by out of control growth of bacteria up to carrying 
capacity and high levels of immune system activity, including macrophage activation, 
IFN-!  production and T cell differentiation (3456&'*).  !"#$%&',)* shows the dynamics 
of bacteria and immune system variables during active disease.  The particular set of 
parameters used that lead to primary TB are given in the 788&9:"; (3456&',).  During 
active disease the extracellular bacterial load is higher than the intracellular bacterial 
load.  The maximum bacterial load is reached after approximately 450 days. 
 
Latent tuberculosis is characterized by levels of both intra- and extracellular bacteria 
much lower than the carrying capacity, and some immune system activity (3456&' *).  !"#$%&',)+ shows the dynamics during latent TB.  The latency in this case is obtained 
using the active disease parameters but increasing the maximum rate of killing of 
infected macrophages by cytotoxic activity, k52( ) .  The early stages of latency (the first 
150 days or so) are similar to primary TB.  Bacterial numbers grow relatively 
unchecked during this time while an adaptive immune response is initiated in the DLN.  
Once adaptive immunity develops and activated T cells migrate to the lung the infection 
can be contained due to the increased efficiency of cytotoxic activity.  There is low 
level background immunity present to respond to persistent bacteria (Wigginton and 
Kirschner, 2001), and the number of T cells in the lymph node is greater than the 
number of T cells in the lungs.  During latent TB most mycobacteria are found within 
chronically infected macrophages (or other refuge site) and the intracellular bacterial 
load is 1000-fold less than during active disease.  The extracellular bacterial load is low 
indicating that the infection is being controlled. 
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Figure 4.2 Dynamics of bacteria, macrophages, T cells, cytokines and dendritic cells during active 
disease.  Initial conditions are given in Table 1 and parameter values are given in the Appendix (Table 4). 
 
 
 
 
 
 
 125 
Table 2 Values of model variables after 2000 days for active disease and latency (three significant 
figures). 
Variable Description Active disease Latency Units 
MR  Density of resting macrophages 2.52 x 104 3.12 x 105 cells/cm3 
MI  Density of infected macrophages 4.69 x 105 50.1 cells/cm3 
MA  Density of activated macrophages 1490 15.9 cells/cm3 
F!  Concentration of TNF-" 1350 0.296 pg/mL 
I!  Concentration of IFN-! 6730 29.1 pg/mL 
I12  Concentration of IL-12 320 36.0 pg/mL 
I10  Concentration of IL-10 1520 3.38 pg/mL 
I4  Concentration of IL-4 7.93 0.401 pg/mL 
T
40
L  Density of Th precursors in the lung 4.39 x 104 220 cells/cm3 
T1  Density of Th1 cells 9.82 x 104 193 cells/cm3 
T2  Density of Th2 cells 3.13 1.56 cells/cm3 
T
80
L  Density of TC precursors in the lung 4.39 x 104 2220 cells/cm3 
TC  Density of effector CD8+ T cells 1.02 x 105 193 cells/cm3 
BE  Density of extracellular bacteria 9.55 x 108 55.9 bacteria/cm3 
BI  Density of intracellular bacteria 2.77 x 107 1690 bacteria/cm3 
N4  Density of naïve CD4+ T cells 1350 8090 cells/cm3 
N8  Density of naïve CD8+ T cells 1350 8090 cells/cm3 
T40LN  Density of Th precursors in the DLN  1.06 x 105 2.72 x 104 cells/cm3 
T80LN  Density of TC precursors in the DLN 1.06 x 105 2.72 x 104 cells/cm3 
MDC  Density of mature dendritic cells 2.50 x 104 275 cells/cm3 
IDC  Density of immature dendritic cells 2.50 x 104 4.95 x 104 cells/cm3 
 
Model simulations give results similar to those obtained by Marino and Kirschner 
(2004) and Sud et al. (2006).  For active TB, the dynamics observed in the lung are 
similar to those observed in Sud et al. (2006).  The dynamics of naïve T cells and DCs 
in the DLN are similar to Marino and Kirschner (2004), but for this particular parameter 
set higher numbers of lymphocytes (precursor T cells) are predicted in the DLN than in 
their simulation.  For latency, the dynamics observed in the lung are different.  The 
steady state values are comparable with those predicted by Sud et al. (2006), but the 
initial stages of infection (before the infection is controlled) are different because of the 
time delay before activated T cells arrive in the lung following T cell priming in the 
DLN.  Dynamics of naïve T cells and DCs in the DLN are similar to Marino and 
Kirschner (2004), but the background level of immune activity is higher, with higher 
numbers of precursor T cells in the lung and DLN. 
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Figure 4.3 Dynamics of bacteria, macrophages, T cells, cytokines and dendritic cells during latent 
tuberculosis.  Initial conditions are given in Table 1 and parameter values are given in the Appendix 
(Table 4) except the maximum rate of killing of infected macrophages by cytotoxic activity, k52, is 
increased to 0.5 days-1. 
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4.3.1 Sensitivity Analysis 
 
This model contains 137 parameters that could affect the outcome of infection.  In order 
to assess the sensitivity of the model to changes in parameters, the average percentage 
change in extracellular bacterial load was calculated when each parameter was 
increased and decreased by a factor of two from the baseline values used to simulate 
latent TB. 
 
It is observed that changing the majority of parameters in the model by a factor of two 
does not lead to a significant change in the extracellular bacterial load 2000 days after 
infection.  Changes in 21 parameters led to a change of over 10% in extracellular 
bacterial load, while changes in only 6 parameters led to a change of over 100%.  These 
include parameters that govern the rate of killing of infected macrophages by cytotoxic 
activity, ( k52  and c52 ), the source term for immature dendritic cells, sIDC( ) , the net 
proliferation rate of precursor CD8+ T cells in the DLN, ! 5B( ) , the proportion of 
precursor CD8+ T cells migrating into the blood, !B( ) , and the contribution of 
macrophages to precursor CD8+ T cell migration into the lung ! B( ) . 
 
4.3.2 Parameter Dependence 
 
The disease model presented contains a large number of parameters that could 
potentially affect the outcome of M. tuberculosis infection.  In order to gain an insight 
into the role of key players in the outcome of disease, this section focuses on variation 
of groups of parameters relating to specific mechanisms, such as immune system killing 
rates and bacterial growth rates. 
 
Parameters describing immune system killing rates are combined so that we can assess 
the overall contribution of the immune system to disease trajectory.  These rates can be 
divided into innate and adaptive immune system killing rates, allowing us to determine 
the differential contribution of innate and adaptive immunity in determining the 
outcome of M. tuberculosis infection.  Similarly, the influence of extracellular and 
intracellular bacterial growth rates can be evaluated, both together and separately.  
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Parameters are changed from the baseline values used to simulate latent tuberculosis 
(parameter values in the 788&9:"; (3456&',) with k52 = 0.5 ). 
 
The model is used to investigate how the strength (or efficiency) of the immune system 
affects the infection outcome, and to explore the roles played by innate and adaptive 
immunity in fighting infection.  !"#$%&',),A shows the extracellular bacterial dynamics 
as all the immune system killing rates are varied.  These include the rate of killing of 
extracellular bacteria by resting macrophages, k18( ) , the uptake rate of extracellular 
bacteria by immature dendritic cells, !12( ) , the rate of killing of extracellular bacteria 
by activated macrophages, k15( ) , the maximum rate of Fas-FasL induced apoptosis of 
chronically infected macrophages, k14A( ) , the maximum rate of TNF- !  induced 
apoptosis of chronically infected macrophages, k14B( ) , and the maximum rate of 
cytotoxic killing of chronically infected macrophages, k52( ) .  Parameter values are 
changed so that the ratios k14A / k52 , k14B / k52 , k15 / k52 , !12 / k52  and k18 / k52  remain 
constant and are the same as in the 788&9:"; (3456&',) with k52 = 0.5 .  k52  is varied 
over the range 1x10-4 – 1x103 days-1.  This affects all the immune system killing rates 
and hence the overall strength of the immune system.  All other parameter values are 
left unchanged.  As expected, it is possible to clear the infection by increasing the 
strength of the immune response (in terms of the rates of killing).  Intermediate strength 
of immunity gives rise to latency and a weaker immune response leads to a transition 
from latency to active disease as the immune system can no longer control the infection.  
However, while bacterial load can be cleared by a strong immune response, this may 
lead to host-mediated lung tissue damage (Flynn and Chan, 2001a; Sud et al., 2006). 
 
The result of changing innate immune system killing parameters (without altering the 
strength of adaptive immunity) is shown in !"#$%&' ,),B.  Effective innate immunity 
consists of the rate of killing of extracellular bacteria by resting macrophages, k18( ) , 
and the uptake rate of extracellular bacteria by immature dendritic cells, !12( ) .  
Parameter values are changed so that the ratio k18 /!12  remains the same as in the 788&9:"; (3456&' ,), and !12  is varied over the range 1x10-9 – 1x10-4 days-1.  If we 
increase the strength of innate immunity the infection can be cleared.  This may 
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represent the scenario where an individual is exposed to bacteria and is able to clear 
infection with no memory of that response (PPD-negative), i.e. bacteria are eliminated 
by innate immunity before an adaptive immune response is initiated (Marino and 
Kirschner, 2004; Sud et al., 2006; Wigginton and Kirschner, 2001).  If we decrease the 
strength of the innate response the infection can still be controlled (latent tuberculosis), 
as the adaptive immune system is able to compensate for weaker innate immunity. 
 !"#$%&',),C shows the result of changing adaptive immune system killing parameters 
(without changing innate immunity).  Adaptive immunity consists of the rate of killing 
of extracellular bacteria by activated macrophages, k15( ) , the rate of Fas-FasL induced 
apoptosis of chronically infected macrophages, k14A( ) , the rate of TNF-!  induced 
apoptosis of chronically infected macrophages, k14B( ) , and the rate of cytotoxic killing 
of chronically infected macrophages, k52( ) .  In this figure parameter values are changed 
so that the ratios k14A / k52 , k14B / k52  and k15 / k52  remain the same as in the 788&9:"; 
(3456&' ,) with k52 = 0.5 .  k52  is varied over the range 1x10-4 – 1x103 days-1.  If the 
strength of the adaptive immune system is increased we remain in a latent state, but the 
extracellular bacterial load is lower.  The infection cannot be cleared for the range of 
parameters considered.  If we decrease the strength of adaptive immunity we transition 
from latency to active disease.  These results suggest that innate immunity is essential 
for the clearance of infection while adaptive immunity controls latency. 
 
Bacterial growth rates are influential in determining the outcome of infection.  Plots in !"#$%&' ,),D show the result of changing the maximum extracellular !20( )  and 
intracellular !19( )  bacterial growth rates.  Parameter values are changed so that the ratio 
!19 /! 20  remains the same as in the 788&9:"; (3456&' ,), and ! 20  is varied over the 
range 1x10-6 – 1x101 days-1.  If we increase the bacterial growth rates we transition from 
latency to active disease, as the immune system cannot contain bacterial replication.  If 
we decrease the bacterial growth rates we remain in a latent state, but the level of 
extracellular bacteria becomes very low, and is not cleared within 2000 days.  This may 
be because if the bacterial growth rates are very low the bacterial load is too small to 
stimulate the immune system enough to clear the infection. 
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Figure 4.4 Extracellular bacterial load dependence on killing and growth rates. (A) Varying immune 
system killing rates (rate of killing of extracellular bacteria by resting macrophages, (k18), uptake rate of 
extracellular bacteria by immature dendritic cells, (!12), rate of killing of extracellular bacteria by 
activated macrophages, (k15), maximum rate of Fas-FasL induced apoptosis of chronically infected 
macrophages, (k14A), maximum rate of TNF-" induced apoptosis of chronically infected macrophages, 
(k14B) and maximum rate of cytotoxic killing of chronically infected macrophages, (k52)).  Parameter 
values are changed so that the ratios k14A/k52, k14B/k52, k15/k52, !12/k52 and k18/k52 are the same as in the 
Appendix (Table 4) with k52=0.5.  k52 is varied over the range 1x10-4 – 1x103 days-1.  (B) Varying innate 
immune system killing rates (k18 and !12).  Parameter values are changed so that the ratio k18/!12 is the 
same as in the Appendix (Table 4).  !12 is varied over the range 1x10-9 – 1x10-4 days-1.  (C) Varying 
adaptive immune system killing rates (k15, k14A, k14B and k52).  Parameter values are changed so that the 
ratios k14A/k52, k14B/k52 and k15/k52 are the same as in the Appendix (Table 4) with k52=0.5.  k52 is varied 
over the range 1x10-4 – 1x103 days-1.  (D) Varying the maximum extracellular ("20) and intracellular ("19) 
bacterial growth rates.  Parameter values are changed so that the ratio "19/"20 is the same as in the 
Appendix (Table 4).  "20 is varied over the range 1x10-6 – 1x101 days-1.  (E) Varying the maximum 
extracellular bacterial growth rate over the range 1x10-6 – 1x101 days-1.  (F) Varying the maximum 
intracellular bacterial growth rate over the range 1x10-6 – 1x101 days-1. 
 
Increasing the growth rate of either extracellular bacteria or intracellular bacteria leads 
to active disease (!"#$%&',),E and !"#$%&',),
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sensitive to changes in the intracellular bacterial growth rate, falling to very low levels 
for low intracellular bacterial growth rates (!"#$%&',),F).  In this figure ! 20  and !19  are 
varied over the range 1x10-6 – 1x101 days-1. 
 
In order to obtain further insight into the interplay between different sets of parameters, 
the model is also used to study the effect of varying two different parameters or sets of 
parameters simultaneously, and the possible trade-offs that exist between these 
parameters.  !"#$%&',)- shows the extracellular bacterial load 2000 days after infection, 
which allows us to characterize the long-term fixed point behaviour of the system and 
determine the outcome of infection. 
 !"#$%&',)-A shows the extracellular bacterial load after 2000 days as extracellular and 
intracellular bacterial growth rates and immune system killing rates are varied.  
Parameter values are changed so that the ratios k14A / k52 , k14B / k52 , k15 / k52 , !12 / k52 , 
k18 / k52  and !19 /! 20  are the same as in the 788&9:"; (3456&',) with k52 = 0.5 .  k52  is 
varied over the range 1x10-4 – 1x103 days-1 and ! 20  is varied over the range 1x10
-6 – 
1x101 days-1.  If the bacterial growth rates are low and the immune system is weak the 
simulation gives latent disease.  For low levels of bacterial growth, it is possible to clear 
the infection with a strong immune response.  As expected, when bacterial replication 
rates are increased a stronger immune response is needed to contain or clear the 
infection.  If the bacterial growth rates are high and the immune response is not very 
strong, the system progresses to active disease.  As the strength of the immune response 
increases we transition from active disease to latency.  There are certain bacterial 
growth rates in this region where the infection can be cleared if the immune response is 
strong enough. 
 
The result of changing adaptive and innate immune system killing rates is shown in !"#$%&' ,)-B.  Parameter values are changed so that the ratios k14A / k52 , k14B / k52 , 
k15 / k52  and k18 /!12  are the same as in the 788&9:"; (3456&',) with k52 = 0.5 .  k52  is 
varied over the range 1x10-4 – 1x103 days-1 and !12  varied over the range 1x10
-9 – 
1x10-4 days-1.  At low levels of innate and adaptive immunity the simulation gives 
active disease.  It is possible to clear the infection with a strong innate immune 
response, even if the adaptive immune response is weak.  However, for a low level of 
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innate immunity it is only possible to control the infection (latent tuberculosis) with a 
strong adaptive immune response, but not to clear the infection for the range of 
parameters considered. 
 !"#$%&',)-C shows a somewhat symmetric effect of the intracellular and extracellular 
bacterial growth rates on the extracellular bacteria load.  In this figure ! 20  and !19  are 
varied over the range 1x10-4 – 1x101 days-1.  Interestingly, we observe that if either the 
intra- or extracellular bacterial growth rate is high, the simulation gives active disease.  
If both growth rates are low we get latent tuberculosis. 
 
The interplay between growth and immune killing parameters reveals some differential 
roles of intra- versus extracellular bacterial growth.  The result of changing the 
extracellular bacterial growth rate and immune system killing rates is shown in !"#$%&',)-D.  Parameter values are changed so that the ratios k14A / k52 , k14B / k52 , k15 / k52 , 
!12 / k52  and k18 / k52  are the same as in the 788&9:"; (3456&',) with k52 = 0.5 .  k52  is 
varied over the range 1x10-4 – 1x103 days-1  and ! 20  is varied over the range 1x10
-6 – 
1x101 days-1.  At low levels of immunity the simulation gives active disease, 
irrespective of the extracellular bacterial growth rate.  For low extracellular bacterial 
growth rates we transition from active disease to latency as the strength of the immune 
response increases.  It is possible to clear infection if the immune response is strong.  If 
the extracellular bacterial growth rate is high the simulation gives active disease, even if 
the immune response is strong. 
 !"#$%&' ,)-E shows the extracellular bacterial load when the intracellular bacterial 
growth rate and immune system killing rates are varied.  Parameter values are changed 
so that the ratios k14A / k52 , k14B / k52 , k15 / k52 , !12 / k52  and k18 / k52  are the same as in 
the 788&9:"; (3456&' ,) with k52 = 0.5 .  k52  is varied over the range 1x10-4 – 1x103 
days-1  and !19  is varied over the range 1x10
-6 – 1x101 days-1.  These results are similar 
to those in !"#$%&',)-A.  At low levels of intracellular bacterial growth and immunity 
the simulation gives latent tuberculosis.  At these growth rates it is possible to clear the 
infection with a strong immune response.  If the intracellular bacterial growth rate is 
high the simulation gives active disease, unless the immune response is very strong.  
We transition from active disease to latency as the strength of the immune response 
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increases.  The infection can be cleared for some bacterial growth rates if the immune 
response is strong enough. 
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Figure 4.5 Extracellular bacterial load after 2000 days of infection.  (A) Varying bacterial growth rates 
and immune system killing rates.  ‘Bacterial growth’ includes the maximum extracellular ("20) and 
intracellular ("19) bacterial growth rates.  ‘Immunity’ includes the rate of killing of extracellular bacteria 
by resting macrophages, (k18), the uptake rate of extracellular bacteria by immature dendritic cells, (!12), 
the rate of killing of extracellular bacteria by activated macrophages, (k15), the maximum rate of Fas-FasL 
induced apoptosis of chronically infected macrophages, (k14A), the maximum rate of TNF-" induced 
apoptosis of chronically infected macrophages, (k14B) and the maximum rate of cytotoxic killing of 
chronically infected macrophages, (k52).  Parameter values are changed so that the ratios "19/"20, k14A/k52, 
k14B/k52, k15/k52, !12/k52 and k18/k52 are the same as in the Appendix (Table 4) with k52=0.5.  k52 is varied 
over the range 1x10-4 – 1x103 days-1 and "20 is varied over the range 1x10-6 – 1x101 days-1.  (B) Varying 
adaptive and innate immune system killing rates.  ‘Adaptive immunity’ includes k15, k14A, k14B and k52 and 
‘innate immunity’ includes k18 and !12.  Parameter values are changed so that the ratios k14A/k52, k14B/k52, 
k15/k52 and k18/!12 are the same as in the Appendix (Table 4) with k52=0.5.  k52 is varied over the range 
1x10-4 – 1x103 days-1 and !12 is varied over the range 1x10-9 – 1x10-4 days-1.  (C) Varying the maximum 
intracellular (‘BI growth’) and extracellular (‘BE growth’) bacterial growth rates.  "20 and "19 are varied 
over the range 1x10-4 – 1x101 days-1.  (D) Varying the maximum rate of extracellular bacterial growth 
(‘BE growth’) and immune system killing rates (‘immunity’).  "20 is varied over the range 1x10-6 – 1x101 
days-1.  (E) Varying the maximum rate of intracellular bacterial growth (‘BI growth’) and immune system 
killing rates (‘immunity’).  "19 is varied over the range 1x10-6 – 1x101 days-1.  Baseline parameter values 
and the corresponding extracellular bacterial load are marked with an asterisk. 
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4.3.3 Dependence on Initial Conditions 
 
The outcome of infection (active disease, latent TB or clearance) is dependent on the 
initial conditions, as well as the model parameters.  The model is used to investigate 
how different initial conditions affect the dynamics of the system.  The initial level of 
immune cells is varied over the range 1x10-3 – 1x1010 cells/cm3 and the initial number 
of bacteria is varied over the range 1x10-3 – 1x1010 bacteria/cm3.  The parameter values 
remain unchanged from the baseline values used to simulate latent tuberculosis. 
 
The size of the initial bacterial inoculum (i.e. the initial number of extracellular 
bacteria) can affect the outcome of exposure to M. tuberculosis (!"#$%&',).A).  If the 
initial number of extracellular bacteria is above a certain value, the simulation gives 
active disease.  If the initial number of extracellular bacteria is very low, the infection 
can quickly be cleared.  For intermediate numbers of extracellular bacteria the 
simulation gives latent tuberculosis.  These observations suggest that for this parameter 
set the model has multiple stable steady states. 
 
The initial number of immune cells can also determine the outcome of infection.  The 
effect of changing the initial number of effector T cells (Th1 cells and effector CD8+ T 
cells) is shown in !"#$%&' ,).B.  If the initial number of effector T cells is high the 
infection is cleared.  This can be considered to be equivalent to an immediate T cell 
memory response resulting from vaccination (or previous exposure to mycobacterial 
antigens).  If the initial number of effector T cells is low the simulation still gives latent 
disease, as the number of T cells will increase to the necessary level as the infection 
progresses. 
 
Plots in !"#$%&',).C show the extracellular bacterial dynamics when the initial number 
of resting macrophages is changed.  These results indicate that if the initial number of 
resting macrophages is high the system progresses to active disease.  Resting 
macrophages are able to kill extracellular bacteria so we might expect that increasing 
the number of these cells would help to clear infection.  However, macrophages play a 
dual role during M. tuberculosis infection: in their activated state they are able to kill 
bacteria, but in their resting state they are the preferred location for bacterial growth 
(Ray et al., 2009).  If the number of resting macrophages is high more extracellular 
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bacteria are internalized leading to more chronically infected macrophages (where 
bacteria grow at a faster rate than in the extracellular spaces) and active disease.  This 
effect was also observed in the agent-based model of granuloma formation developed 
by Segovia-Juarez et al. (2004).  This model predicts that high numbers of resting 
macrophages at the site of infection, particularly early in infection, increases the 
bacterial load.  The authors suggest that too many resting macrophages provide shelter 
to bacteria and crowd the granuloma, thus preventing the cell-cell interactions that lead 
to macrophage activation and control of infection.  If the initial number of resting 
macrophages is low the simulation gives latent tuberculosis.  !"#$%&',).D shows that 
for the particular parameter set used, the initial number of immature dendritic cells does 
not affect the outcome of infection. 
 !"#$%&' ,).E shows the extracellular bacterial load after 1000 days when the initial 
number of effector T cells (Th1 and effector CD8+ T cells) and the initial bacterial 
inoculum are varied.  If the initial number of extracellular bacteria is very low it is 
possible to clear infection, even if the initial number of effector T cells is low.  If the 
initial number of extracellular bacteria is high the system progresses to active disease, 
irrespective of the initial number of effector T cells.  The result of changing the initial 
number of effector CD8+ T cells and Th1 cells is shown in !"#$%&',).F.  It is possible 
to clear the infection with a high initial number of Th1 cells, even if the number of 
CD8+ effector cells is low.  However, infection cannot be cleared if the initial number 
of CD8+ T cells is high but the initial number of Th1 cells is too low.  This suggests 
that there must be a minimum number of Th1 cells present for the infection to be 
cleared. 
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Figure 4.6 Dynamics of extracellular bacterial load as initial levels of bacteria and cells are varied over 
the range 1x10-3 – 1x1010 bacteria/cm3 or cells/cm3. (A) Initial concentration of extracellular bacteria.  (B) 
Initial concentration of effector T cells (Th1 cells and effector CD8+ T cells).  (C) Initial concentration of 
resting macrophages.  (D) Initial concentration of immature dendritic cells.  Extracellular bacterial load 
after 1000 days as two different initial conditions are varied.  (E) Initial concentrations of effector T cells 
(Th1 cells and effector CD8+ T cells) and extracellular bacteria.  (F) Initial concentrations of effector 
CD8+ T cells and Th1 cells.  Parameter values are given in the Appendix (Table 4) with k52=0.5. 
 
The number of positive steady states of this system, which may correspond to different 
disease outcomes, depends on the choice of parameter values.  !"#$%&' ,)/ shows the 
number of disease outcomes that can be achieved with different initial bacterial 
inoculums for different parameter sets (the parameter sets used in !"#$%&',)-A, !"#$%&',)-B and !"#$%&',)-C).  These outcomes include clearance as it was defined previously 
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(which may not be actual fixed points of the system, but could be more relevant 
physiologically).  This figure shows that multiple stable solutions exist for a large range 
of parameter values, and that the outcome of M. tuberculosis infection depends on the 
state of the system at the time of exposure. 
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Figure 4.7 Number of possible disease outcomes after 2000 days of infection when the initial bacterial 
inoculum is varied over the range 1x10-3 – 1x1010 bacteria/cm3.  (A) Varying bacterial growth rates and 
immune system killing rates.  ‘Bacterial growth’ includes the maximum extracellular ("20) and 
intracellular ("19) bacterial growth rates.  ‘Immunity’ includes the rate of killing of extracellular bacteria 
by resting macrophages, (k18), the uptake rate of extracellular bacteria by immature dendritic cells, (!12), 
the rate of killing of extracellular bacteria by activated macrophages, (k15), the maximum rate of Fas-FasL 
induced apoptosis of chronically infected macrophages, (k14A), the maximum rate of TNF-" induced 
apoptosis of chronically infected macrophages, (k14B) and the maximum rate of cytotoxic killing of 
chronically infected macrophages, (k52).  Parameter values are changed so that the ratios "19/"20, k14A/k52, 
k14B/k52, k15/k52, !12/k52 and k18/k52 are the same as in the Appendix (Table 4) with k52=0.5.  k52 is varied 
over the range 1x10-4 – 1x103 days-1 and "20 is varied over the range 1x10-6 – 1x101 days-1.  (B) Varying 
adaptive and innate immune system killing rates.  ‘Adaptive immunity’ includes k15, k14A, k14B and k52 and 
‘innate immunity’ includes k18 and !12.  Parameter values are changed so that the ratios k14A/k52, k14B/k52, 
k15/k52 and k18/!12 are the same as in the Appendix (Table 4) with k52=0.5.  k52 is varied over the range 
1x10-4 – 1x103 days-1 and !12 is varied over the range 1x10-9 – 1x10-4 days-1.  (C) Varying the maximum 
intracellular (‘BI growth’) and extracellular (‘BE growth’) bacterial growth rates.  "20 and "19 are varied 
over the range 1x10-4 – 1x101 days-1.  Baseline parameter values and the corresponding number of disease 
outcomes are marked with an asterisk. 
 
This model is too complicated for a full bifurcation analysis, but these results combined 
with the results in Section 4.3.2 (!"#$%&' ,), and !"#$%&' ,)-) show a glimpse of 
bifurcations taking place in the system.  In Section 4.3.2 parameters were varied in a 
constrained manner, similar to a bifurcation parameter.  The number of stable steady 
states varies as certain parameters, (including the uptake rate of extracellular bacteria by 
immature dendritic cells, !12( ) , the maximum rate of cytotoxic killing of chronically 
infected macrophages, k52( ) , the maximum extracellular !20( )  and intracellular !19( )  
bacterial growth rates), are varied. 
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4.3.4 Virtual Deletion and Depletion Experiments 
 
Experimental studies use genetic knockouts (KOs) or mutations, or depletion 
experiments to analyse the effects of different components of the immune system on 
disease progression.  These studies have contributed significantly to our understanding 
of the host immune response to TB.  Mathematical models allow us to mimic gene KO 
or depletion experiments quickly and easily through virtual deletion and depletion 
experiments.  Virtual deletion experiments mimic KO experiments.  For deletion 
experiments a component is removed from the system at day zero before infection is 
simulated.  This helps us to identify elements of the system that control the 
establishment of latency.  Depletion experiments involve the removal of an element 
after latency has been achieved.  This helps us to determine which elements control the 
maintenance of latency.  Depletion experiments can mimic antibody-mediated 
neutralization studies (Sud et al., 2006; Wigginton and Kirschner, 2001). 
 
The results of virtual deletion experiments are shown in !"#$%&',)0.  The deletion of 
TNF-! , IFN-!  or IL-12 leads to active disease.  The deletion of IL-10 results in lower 
bacterial levels than in the positive control (!"#$%&' ,)+), but leads to oscillatory 
behaviour.  This implies that latency may be a less stable state in the absence of IL-10.  
This phenomenon was observed by Wigginton and Kirschner (2001).  The deletion of 
CD4+ or CD8+ T cells also leads to active disease. 
 
The results of the virtual depletion experiments are shown in !"#$%&' ,)1.  Each 
component is removed at day 500 after latency has been achieved.  The depletion of 
TNF-! , IFN-!  or IL-12 results in a shift from latency to active disease.  The depletion 
of IL-10 leads to a decrease in bacterial load, but again the population undergoes minor 
oscillations (as observed by Wigginton and Kirschner (2001)).  The depletion of either 
CD4+ or CD8+ T cells once latency has been achieved also leads to active disease.  
Following the depletion of a component, the bacterial population reaches the same 
steady state value that is achieved following the deletion of the component (!"#$%&',)0). 
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Steady depletion of TNF-!  could mimic the use of monoclonal anti-TNF antibody for 
the treatment of rheumatoid arthritis or Crohn’s disease.  Steady depletion of CD4+ T 
cells could mimic HIV infection, which frequently leads to reactivation TB. 
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Figure 4.8 Virtual deletion experiments.  (A) Effect on extracellular bacterial load when CD4+ and 
CD8+ T cells are deleted.  (B) Effect on extracellular bacterial load when TNF-", IFN-!, IL-12 and IL-10 
are deleted.  Latency (wild-type) is used as a positive control. 
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Figure 4.9 Virtual depletion experiments.  (A) Effect on extracellular bacterial load when CD4+ and 
CD8+ T cells are depleted.  (B) Effect on extracellular bacterial load when TNF-", IFN-!, IL-12 and 
IL-10 are depleted.  Latency (wild-type) is used as a positive control. 
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4.4 Conclusion 
 
In this chapter a model of human TB infection was presented that builds on the models 
of Marino and Kirschner (2004) and Sud et al. (2006).  The model incorporates two 
compartments: the lung and the peripheral draining lymph node, and is able to simulate 
different infection outcomes – clearance, active TB and latency – depending on the 
choice of parameters.  Model simulations give results that are consistent with those 
obtained by Marino and Kirschner (2004) and Sud et al. (2006). 
 
The model predicts a differential role for innate and adaptive immune responses in 
fighting infection.  Clearance is achieved by enhancing the innate immune response 
(killing of extracellular bacteria by macrophages and bacterial uptake by IDCs), while 
the establishment and maintenance of latency depends on the adaptive immune response 
(cytotoxic killing of infected macrophages, Fas/Fas-L-induced apoptosis of infected 
macrophages, TNF- ! -induced apoptosis of infected macrophages and killing of 
extracellular bacteria by activated macrophages).  Clearance is often a rapid event that 
does not require T cell priming in the DLN.  If bacteria are able to escape killing by the 
innate immune system, infection can still be controlled by a sufficiently high level of 
adaptive immunity.  These results suggest that the use of immunotherapy to enhance the 
innate immune response may be an effective way to fight tuberculosis infection and 
prevent latency, especially when the initial inoculum is low (Finlay and Hancock, 
2004).  The use of immunotherapy to enhance the immune response (e.g. cytokine 
therapy to increase levels of Th1 cytokines such as IL-2 or IFN-! , or the use of 
monoclonal antibodies to down-regulate the Th2 response) has been proposed to target 
bacteria that are resistant to antimycobacterial agents, such as those responsible for 
MDR-TB and XDR-TB (Barnes, 2003) and persister cells (Zhang et al., 2012).  
However, this may also lead to increased pathology so a balance needs to be struck 
between the increase in microbial killing and the prevention of tissue damage. 
 
Extracellular and intracellular bacterial growth rates, which contribute to the virulence 
of bacteria, are also important determinants of infection outcome.  Simulation results 
suggest that the intracellular bacterial growth rate may be more important.  Intracellular 
bacteria are shielded from both the innate immune system and antibodies so it is 
difficult to clear infection when the intracellular population is high.  This might explain 
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why pathogens like M. tuberculosis and Salmonella have evolved ways of surviving and 
growing inside macrophages.  It is difficult to clear infection once M. tuberculosis 
becomes established within macrophages. 
 
The outcome of infection may also depend on initial conditions.  This is due to the 
underlying multistability observed in the model.  For some parameter regimes different 
disease trajectories are possible depending on the state of the system at the onset of 
infection.  A high bacterial inoculum often results in active disease, while high levels of 
effector T cells at the site of infection can lead to clearance.  Interestingly, increasing 
the initial number of resting macrophages is detrimental to the host as they provide 
additional cells for infection by extracellular bacteria (Kirschner et al., 2005; Segovia-
Juarez et al., 2004).  It is typically assumed that disease and latency are distinct 
outcomes that are achieved with distinct parameter values (Marino and Kirschner, 2004; 
Sud et al., 2006).  Here it is observed that different disease trajectories could co-exist as 
stable solutions of the model, and only the history of the system dictates the disease 
outcome. 
 
While this model is complicated and includes various components of the immune 
system, many simplifications and assumptions have been made.  For example, this 
model does not include cytokine production by dendritic cells or T cells in the DLN, 
and antigen presentation by macrophages is ignored.  If macrophages are able to present 
antigen to T cells efficiently, this omission may affect the outcome of the model.  
Increased antigen presentation would lead to an increase in T cell activation and effector 
functions, and help protect the host against disease.  It is also assumed that T cell 
differentiation into different subsets (i.e. the differentiation of Th0 cells into Th1 or Th2 
cells and the differentiation of precursor CD8+ T cells into effector cells) only occurs at 
the site of infection in the lung and does not occur in the DLN.  However, T cell 
differentiation typically occurs in secondary lymphoid tissue (Murphy et al., 2008).  
Spatial aspects of the immune response have also been neglected, specifically the 
process of granuloma formation, which is thought to play a key role in determining the 
outcome of infection.  An agent-based model of granuloma formation has shown that 
the spatial distribution of different types of immune cells (macrophages and T cells) in a 
developing granuloma affects its size and function, and ultimately the progression of 
disease within the host (Segovia-Juarez et al., 2004). 
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This model can be modified to include antigen presentation by macrophages and T cell 
differentiation and cytokine production in the DLN.  These processes have been 
incorporated into other models of tuberculosis infection (Marino et al., 2010).  Future 
studies might also include other populations of immune cells, such as neutrophils, !"  T 
cells or B cells, and this model could be extended to include the development of 
immunological memory.  The addition of immunological memory could allow us to 
determine the minimum level of memory cells that is required to provide effective 
protection, and can be used to predict the effects of vaccination and suggest new 
vaccine strategies.  Such a model can also be used to predict the response of individuals 
to re-challenge, i.e. whether infected individuals treated with antibiotics succumb to 
disease following re-challenge with a new infection.  This could involve the addition of 
central and effector memory CD4+ and CD8+ T cells.  Non-polarized T cells in the lung 
and DLN can differentiate into central memory cells, and effector T cells in the lung can 
differentiate into effector memory cells (Lanzavecchia and Sallusto, 2000). 
 
The bacterial population is assumed to be homogeneous, with bacteria in an active state 
(replicating at a constant rate) throughout the course of infection.  Latency is achieved 
by efficient killing of bacteria by the immune system, a ‘dynamic’ equilibrium.  It may 
be that infected tissue consists of a heterogeneous population of bacteria in different 
metabolic and replicative states, and that the physiological state of the bacilli plays a 
role in establishing and maintaining latent infection (Munoz-Elias et al., 2005).  Future 
work could incorporate a state of non-replicating persistence or infrequent replicative 
cycles into the model to investigate the significance of bacterial replication dynamics in 
determining infection outcome. 
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5.1 Introduction 
 
In this chapter the tuberculosis infection model described in Chapter 4 is modified to 
incorporate the effect of drug treatment.  Pharmacokinetic and pharmacodynamic 
(PK/PD) models are used to describe the kinetics of the drug in the body and the 
therapeutic effect of the drug. 
 
This treatment model is based on the work of Goutelle et al. (2011), who combined 
PK/PD models with the model of Marino and Kirschner (2004).  It is assumed that in 
the absence of acquired drug resistance and drug tolerance both primary and latent 
tuberculosis can be treated with a single drug.  This work considers the use of 
rifampicin (rifampin; RIF) to treat infection.  Rifampicin is one of the most powerful 
bactericidal drugs.  It is active against all populations of tubercle bacilli, including non-
replicating bacilli (Gumbo et al., 2007a), and rapidly diffuses into all tissues and fluids, 
so is able to act on both extra- and intracellular bacteria (World Health Organization, 
2010b). 
 
The aim of this work is to develop a model that allows us to predict the outcome, or 
success, of anti-TB chemotherapy.  The model is used to explore a number of factors 
that may affect the outcome and length of treatment, including variability in 
pharmacokinetic and pharmacodynamic parameters, different treatment regimens and 
patient non-adherence. 
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5.2 Mathematical Model 
 
5.2.1 Pharmacokinetic Model 
 
The pharmacokinetic model published in Goutelle et al. (2009) and Goutelle et al. 
(2011) is used to describe the concentration of the drug in the plasma, epithelial lining 
fluid (ELF) and alveolar cells (AC). 
 
Anti-TB drugs (including rifampicin) are administered orally, so the kinetics of the drug 
in the body can be described by the following three-compartment pharmacokinetic 
model (Goutelle et al., 2011; Goutelle et al., 2009): 
 
dXA
dt = !KAXA   (5.1) 
 
dX1
dt = KAXA !KEX1 !K12X1 + K21X2   (5.2) 
 
dX2
dt = K12X1 !K21X2 !K23X2 !K32X3   (5.3) 
 
dX3
dt = K23X2 !K32X3   (5.4) 
 
where XA  is the amount of drug at the absorption site, X1  is the amount of drug in the 
central compartment (plasma), X2  is the amount of drug in the pulmonary epithelial 
lining fluid (ELF) compartment and X3  is the amount of drug in the pulmonary alveolar 
cell (AC) compartment. KA  is the absorptive rate constant, KE  is the elimination rate 
constant from the central compartment, K12  is the rate of transfer from X1  to X2 , K21  
is the rate of transfer from X2  to X1 , K23  is the rate of transfer from X2  to X3  and K32  
is the rate of transfer from X3  to X2 .  A scheme of this model is shown in !"#$%&'-)(. 
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Figure 5.1 Scheme of three-compartment pharmacokinetic model following oral administration of dose 
X0. 
 
The drug concentrations in the central, ELF and AC compartments are given by: 
 
C1 =
X1
VC
  (5.5) 
 
CELF =
X2
VELF
  (5.6) 
 
CCELL =
X3
VCELL
  (5.7) 
 
where C1  is the concentration of the drug in the central compartment, CELF  is the 
concentration of the drug in the ELF compartment and CCELL  is the concentration of the 
drug in the AC compartment.  VC , VELF  and VCELL  are the apparent volumes of 
distribution of the central, ELF and AC compartments, respectively.  A dose of X0  is 
administered every T  days (the dosing interval). 
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5.2.2 Pharmacodynamic Model 
 
The pharmacodynamic model published in Goutelle et al. (2011) is used to describe the 
effect of the drug on the bacterial populations.  The drug is bactericidal against 
extracellular and intracellular bacteria and inhibits bacterial growth.  The drug in the 
epithelial lining fluid acts on extracellular bacteria, while the drug in alveolar cells acts 
on intracellular bacteria. 
 
In order to model the effect of the drug on bacteria we incorporate pharmacodynamic 
equations into the equations describing bacterial dynamics (equations (4.14) and (4.15)). 
(Goutelle et al., 2011).  Extracellular bacteria are acted on by the drug in the epithelial 
lining fluid, CELF , while intracellular bacteria are acted on by the drug in alveolar cells, 
CCELL .  Extracellular bacteria are killed at a maximum rate of Kkmax(E ) .  EC50k! k  is the 
concentration of drug required to achieve half-maximal killing.  Intracellular bacteria 
are killed at a maximum rate of Kkmax(I )  with half-maximal killing achieved at a 
concentration of EC50k!k .  ! k  is the Hill co-efficient.  The drug also inhibits the growth 
of bacteria.  EC50g!g  is the half-saturation concentration for the effect on growth and ! g  
is the Hill co-efficient.  The equations for the bacterial populations are now given by 
(!"#$%&'-)*): 
 
dBE
dt =! 20BE 1"
BE
Nmax
#
$%
&
'(
1" CELF
!g
EC50g!g +CELF!g
#
$
%
&
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with new terms shown in red.  The equations for all other populations are as described 
in Chapter 4 (equations (4.1) - (4.13) and (4.16) - (4.21)).  The drug treatment model is 
obtained by combining these equations with the PK model (equations (5.1) - (5.7)).  
Pharmacokinetic and pharmacodynamic parameter values are given in 3456&'+.  These 
parameters are obtained from Goutelle et al. (2011) with oral bioavailability arbitrarily 
fixed at 100% (Goutelle et al., 2009).  It is assumed that the drug is more effective 
against extracellular bacteria than intracellular bacteria. 
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Figure 5.2 Schematic diagram showing bacterial dynamics in the lung during drug treatment.  All other 
cellular populations remain unchanged.  The effect of the drug on the bacterial populations is shown in 
red. 
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Table 3 Pharmacokinetic and pharmacodynamic parameter values. 
Name Description Value Unit Reference 
EC50g
! g  Half-saturation constant, RIF concentration for effect on growth 1.932 mg/L (Goutelle et al., 2011) 
! g  Hill co-efficient for effect on growth 0.361  (Goutelle et al., 2011) 
Kkmax(E )  Maximum kill rate of RIF on BE 0.576 1/hour (Goutelle et al., 2011) 
EC50 k! k  
Half-saturation constant, RIF 
concentration for effect on killing 7.652 mg/L (Goutelle et al., 2011) 
! k  Hill co-efficient for effect on killing 1.388  (Goutelle et al., 2011) 
Kkmax( I )  Maximum kill rate of RIF on BI 0.0504 1/hour (Goutelle et al., 2011) 
KA  Absorption rate constant 2.00 1/hour (Goutelle et al., 2011) 
KE  
Elimination rate constant from the central 
compartment 1.18 1/hour (Goutelle et al., 2011) 
K12  Transfer rate from X1 to X2 39.43 1/hour (Goutelle et al., 2011) 
K21  Transfer rate from X2 to X1 19.29 1/hour (Goutelle et al., 2011) 
K23  Transfer rate from X2 to X3 46.01 1/hour (Goutelle et al., 2011) 
K32  Transfer rate from X3 to X2 22.18 1/hour (Goutelle et al., 2011) 
V1  Apparent volume of distribution of central compartment 5.31 L (Goutelle et al., 2011) 
V2  Apparent volume of distribution of ELF compartment 78.0 L (Goutelle et al., 2011) 
V3  Apparent volume of distribution of AC compartment 27.09 L (Goutelle et al., 2011) 
X0  Dose 600 mg (Goutelle et al., 2011) 
F  Extent of bioavailability 1  (Goutelle et al., 2009) T  Dosing interval 1 days (Goutelle et al., 2011)  
5.3 Results 
 
The disease model is used to simulate active disease.  We run the simulation for 500 
days, (so a high bacterial load is achieved), and then introduce the drug into the system.  
A 600mg dose is administered once every twenty-four hours.  The pharmacokinetic and 
pharmacodynamic parameters are given in 3456&'+. 
 !"#$%&'-)+ shows the result of successful treatment of active disease (!"#$%&'-)+A) and 
latent tuberculosis (!"#$%&'-)+B), leading to the elimination of bacteria.  The short-term 
bacterial dynamics are shown in !"#$%&'-),.  For active disease, the infection is cleared 
after approximately 150 days of treatment.  The intracellular population takes longer to 
clear than the extracellular population.  Extracellular bacteria are killed within 110 days.  
Once infection is cleared resting macrophages, immature dendritic cells and naïve T 
cells reach their equilibrium value (consistent with the levels detected in healthy 
individuals (Marino and Kirschner, 2004)) and all other cell and cytokine populations 
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fall to zero.  Using the same treatment regimen a latent infection can be cleared in less 
time than active disease as the bacterial load is smaller.  The infection is cleared after 
approximately eighty-five days of treatment.  The extracellular bacteria are killed within 
fifty-five days.  The pharmacokinetic profiles of rifampicin in the central compartment 
(plasma), ELF and AC compartments over the first five days of treatment are shown in !"#$%&'-)-. 
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Figure 5.3 Dynamics of extracellular and intracellular bacteria following treatment of (A) active 
disease and (B) latent tuberculosis.  Treatment is started 500 days post infection.  Parameter values are 
given in the Appendix (Table 4) and Table 3, with k52=0.5 in (B). 
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Figure 5.4 Dynamics of extracellular and intracellular bacteria following treatment of (A) active 
disease and (B) latent tuberculosis over the first twenty-eight days of treatment.  Parameter values are 
given in the Appendix (Table 4) and Table 3, with k52=0.5 in (B). 
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Figure 5.5 Concentration-time profiles in central, ELF and AC compartments over the first five days of 
rifampicin treatment following one 600mg dose per day. 
 
5.3.1 Parameter Dependence 
 
The outcome of drug treatment is governed by pharmacokinetic and pharmacodynamic 
parameters.  We investigate how modifying these parameters affects the result of anti-
TB chemotherapy. 
 
The effect of changing the maximum kill rate of extracellular Kkmax(E )( )  and 
intracellular Kkmax(I )( )  bacteria by RIF is shown in !"#$%&' -).A and !"#$%&' -).B, 
respectively.  If we increase the rate of killing of extracellular or intracellular bacteria 
by the drug the time taken to clear the infection decreases.  The impact of increasing 
these killing rates saturates at high Kkmax(E )  and Kkmax(I )  (due to the form of the 
pharmacodynamic model).  If either Kkmax(E )  or Kkmax(I )  is too low the infection cannot 
be cleared within 1000 days of treatment.  Kkmax(E )  and Kkmax(I )  are varied over the 
range 1x10-3 – 1x103 days-1.  Similarly, the median effective concentration for RIF 
killing, EC50k( ) , will also affect the outcome of treatment. 
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Figure 5.6 Time to clear infection when varying (A) the maximum rate of killing of extracellular 
bacteria by the drug (Kkmax(E)) over the range 1x10-3 – 1x103 days-1; (B) the maximum rate of killing of 
intracellular bacteria by the drug (Kkmax(I)) over the range 1x10-3 – 1x103 days-1; (C) the dose (X0) over the 
range 1x10-3 – 1x104 mg and (D) the dose and dosing interval (T) such that the dose/day remains constant 
at 600mg/day. 
 
The drug treatment model is also used to investigate different treatment regimens.  
Successful drug therapy requires the establishment of a dosing regimen (dose and 
dosing interval) that provides an effective concentration of drug in the body and 
achieves the desired therapeutic effect.  The result of changing the dose of the drug 
X0( )  is shown in !"#$%&'-).C.  The dose is varied over the range 1x10-3 – 1x104 mg.  
The antibacterial effect of RIF is concentration dependent (Goutelle et al., 2009; 
Gumbo et al., 2007a), so we can reduce the time needed to clear the infection by 
increasing the daily dose.  This leads to an increase in the concentration of RIF in the 
central, ELF and AC compartments (!"#$%&'-)/).  If the dose falls below a certain level 
the infection cannot be cleared within 1000 days of treatment as the concentration of 
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RIF in the body is too low.  The effect of increasing the dose is less significant at higher 
doses, as the killing rates saturate at high doses.  It may be beneficial to use a higher 
dose of RIF during anti-TB chemotherapy (for example 900mg or 1200mg), but its 
toxic effects at high concentrations need to be considered. 
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Figure 5.7 Concentration-time profiles in central, ELF and AC compartments over the first five days of 
rifampicin treatment varying the dose (X0) over the range 1x10-3 – 1x104 mg. 
 
The major adverse side effects of RIF therapy can be divided into two types, 
hepatoxicity and immunoallergenicity (Aristoff et al., 2010).  RIF is well tolerated by 
most patients at the current standard daily dose of 600mg (Aristoff et al., 2010; World 
Health Organization, 2010b).  However, few studies have used higher daily doses and 
there is limited safety and toxicity data in the literature (van Ingen et al., 2011; Kreis et 
al., 1976; Peloquin, 2003; Favez et al., 1972).  In contrast, intermittent therapy (once or 
twice weekly) with higher doses (900-1800mg) is associated with the ‘influenza-like 
syndrome’ (fever, chills and malaise) that can arise from RIF sensitization and antibody 
production.  Some patients also developed thrombocytopenia, haemolysis or renal 
failure (van Ingen et al., 2011; Aristoff et al., 2010; Grosset and Leventis, 1983; Pujet et 
al., 1974; Peloquin, 2003; Girling, 1977).  The influenza-like syndrome rarely occurs 
when RIF is given daily (Grosset and Leventis, 1983; Girling, 1977).  Nevertheless, 
these findings may have prevented further research into the use of high-dose RIF to 
treat tuberculosis (van Ingen et al., 2011). 
 !"#$%&'-).D shows the effect of changing the dose and dosing interval T( )  such that the 
dose/day remains constant at 600mg/day.  If we increase the frequency of drug intake 
(i.e. decrease the dosing interval) and decrease the dose, it takes less time to clear the 
infection.  The results show that it is favourable to change the dosing regimen from a 
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dose of 600mg taken once per day to a dose of 300mg taken two times per day.  This 
reduces the required length of treatment by approximately twenty days.  The 
pharmacokinetic profiles in the central (plasma), ELF and AC compartments over the 
first five days of therapy for a dose of 600mg once per day and a dose of 300mg twice 
per day are shown in !"#$%&'-)- and !"#$%&'-)0, respectively.  However, there is little 
benefit in increasing the frequency further.  If the dosing interval is too great the 
infection cannot be cleared within 1000 days of treatment.  The short-term dynamics of 
the drug in the body affect the outcome of treatment, and when the dosing interval is 
long the drug is able to decay in between doses and treatment becomes less efficient.  
The value of EC50k , the median effective concentration for RIF killing, also plays a role 
in determining the outcome of treatment.  At higher doses the concentration of the drug 
in the AC compartment reaches levels that are greater than the value of EC50k  used in 
these simulations so the intracellular bacterial killing rate begins to saturate and there is 
no benefit in using a higher dose when the dosing interval is long. 
 
It has been demonstrated that the bactericidal efficacy of rifampicin in an aerosol 
infection model of TB in mice correlates best with the area under the plasma 
concentration-time curve-to-minimum inhibitory concentration ratio (AUC/MIC) 
(Jayaram et al., 2003).  Numerical integration shows that the AUC over twenty-four 
hours at steady-state for the different treatment regimens in !"#$%&'-).D are equal. 
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Figure 5.8 Concentration-time profiles in central, ELF and AC compartments over the first five days of 
rifampicin treatment following two 300mg doses per day. 
 
Pharmacokinetic parameters vary from individual to individual and can affect the 
outcome of drug treatment.  !"#$%&'-)1 shows the extracellular bacterial dynamics when 
pharmacokinetic parameters are varied. The corresponding pharmacokinetic profiles in 
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the central, ELF and AC compartments over the first five days of treatment are shown 
in !"#$%&'-)(2 - !"#$%&'-)(-.  These figures show that in order to clear infection the 
concentration of drug in both the ELF and AC compartments must be high enough to 
eliminate the extra- and intracellular bacterial populations.  Individual PK parameters 
affect the distribution of the drug into the different compartments, resulting in variable 
drug exposure and drug effect (Goutelle et al., 2011). 
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Figure 5.9 Dynamics of extracellular bacterial load varying (A) the absorption rate constant (KA) over 
the range 1x10-4 – 1x104 days-1; (B) the elimination rate constant from the central compartment (KE) over 
the range 1x10-2 – 1x104 days-1; (C) the rate of transfer from X1 to X2 (K12) over the range 1x10-2 – 1x104 
days-1; (D) the rate of transfer from X2 to X1 (K21) over the range 1x10-2 – 1x104 days-1; (E) the rate of 
transfer from X2 to X3 (K23) over the range 1x10-2 – 1x104 days-1 and (F) the rate of transfer from X3 to X2 
(K32) over the range 1x10-2 – 1x104 days-1. 
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If the absorption rate constant KA( )  is too low the infection cannot be cleared as there is 
not enough drug reaching the central compartment (and subsequently the ELF and AC 
compartments where it needs to act) (!"#$%&'-)1A and !"#$%&'-)(2).  We can also see 
that if the elimination rate constant KE( )  is too high the infection cannot be cleared 
because the concentration of RIF in the plasma is too low (!"#$%&' -)1B).  The 
pharmacokinetic profiles of the drug over the first five days of treatment (!"#$%&'-)(() 
show that when the elimination rate constant is high the drug decays rapidly between 
doses and there is little drug accumulation in the body.  When the elimination rate 
constant is low the drug is able to accumulate sufficiently in the different compartments 
to clear infection.  KA  is varied over the range 1x10-4 – 1x104 days-1 and KE  is varied 
over the range 1x10-2 – 1x104 days-1. 
 
0 1 2 3 4 5
0
2
4
6
8
10
12
14
Days of treatment
Co
nc
en
tra
tio
n 
(m
g/
L)
Central compartment
0 1 2 3 4 5
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
Days of treatment
Co
nc
en
tra
tio
n 
(m
g/
L)
Pulmonary epithelial lining fluid compartment
0 1 2 3 4 5
0
2
4
6
8
10
12
Days of treatment
Co
nc
en
tra
tio
n 
(m
g/
L)
Pulmonary alveolar cell compartment
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
 
 
log
10
(K
A 
(d
ay
s?
1 ))
?4
?3
?2
?1
0
1
2
3
4
 
Figure 5.10 Concentration-time profiles in central, ELF and AC compartments over the first five days 
of rifampicin treatment varying the absorption rate constant (KA) over the range 1x10-4 – 1x104 days-1. 
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Figure 5.11 Concentration-time profiles in central, ELF and AC compartments over the first five days 
of rifampicin treatment varying the elimination rate constant from the central compartment (KE) over the 
range 1x10-2 – 1x104 days-1. 
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The rates of transfer between the central X1( ) , ELF X2( )  and AC X3( )  compartments 
are also important in determining the outcome of treatment.  !"#$%&' -)1C shows the 
effect of varying the rate of transfer from X1  to X2  K12( ) .  If K12  is too low the 
infection cannot be cleared as the drug does not accumulate in the ELF compartment 
and the concentration of RIF is too low to kill the extracellular bacteria (!"#$%&'-)(*).  
The concentration of RIF in the ELF compartment will also affect the concentration of 
RIF in the AC compartment, and the ability of the drug to eliminate the intracellular 
bacterial population.  The effect of changing the rate of transfer from X2  to X1  K21( )  is 
shown in !"#$%&' -)1D.  If K21  is too high the infection cannot be cleared as the 
concentration of RIF in the ELF compartment, and subsequently the AC compartment, 
becomes too low.  When K21  is low the drug is able to accumulate in the ELF and AC 
compartments and the infection can be cleared (!"#$%&' -)(+).  If the rate of transfer 
from X2  to X3  K23( )  is too low the infection cannot be cleared as the concentration of 
RIF in the AC compartment is too low to kill the intracellular bacteria (!"#$%&'-)1E).  
The drug in the AC compartment is able to reach sufficient levels when K23  is high 
(!"#$%&'-)(,).  !"#$%&'-)1F shows the effect of varying the rate of transfer from X3  to 
X2  K32( ) .  If K32  is too low the infection cannot be cleared as the concentration of RIF 
in the ELF compartment is too low and the population of extracellular bacteria cannot 
be killed.  If K32  is too high the concentration of RIF in the AC compartment becomes 
too low to clear the infection (!"#$%&'-)(-).  K12 , K21 , K23  and K32  are varied over the 
range 1x10-2 – 1x104 days-1.  The model appears to be more sensitive to changes in the 
rates of transfer between the ELF and AC compartments, highlighting the importance of 
achieving an effective concentration in the AC compartment. 
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Figure 5.12 Concentration-time profiles in central, ELF and AC compartments over the first five days 
of rifampicin treatment varying the rate of transfer from X1 to X2 (K12) over the range 1x10-2 – 1x104 
days-1. 
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Figure 5.13 Concentration-time profiles in central, ELF and AC compartments over the first five days 
of rifampicin treatment varying the rate of transfer from X2 to X1 (K21) over the range 1x10-2 – 1x104 
days-1. 
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Figure 5.14 Concentration-time profiles in central, ELF and AC compartments over the first five days 
of rifampicin treatment varying the rate of transfer from X2 to X3 (K23) over the range 1x10-2 – 1x104 
days-1. 
 
 158 
0 1 2 3 4 5
0
5
10
15
20
25
Days of treatment
Co
nc
en
tra
tio
n 
(m
g/
L)
Central compartment
0 1 2 3 4 5
0
0.5
1
1.5
2
2.5
3
3.5
Days of treatment
Co
nc
en
tra
tio
n 
(m
g/
L)
Pulmonary epithelial lining fluid compartment
0 1 2 3 4 5
0
20
40
60
80
100
120
Days of treatment
Co
nc
en
tra
tio
n 
(m
g/
L)
Pulmonary alveolar cell compartment
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
 
 
log
10
(K
32
 (d
ay
s?
1 ))
?2
?1
0
1
2
3
4
 
Figure 5.15 Concentration-time profiles in central, ELF and AC compartments over the first five days 
of rifampicin treatment varying the rate of transfer from X3 to X2 (K32) over the range 1x10-2 – 1x104 
days-1. 
 !"#$%&' -)(. shows the extracellular bacterial load after 1000 days of treatment when 
two different parameters or sets of parameters are changed simultaneously.  The effect 
of changing the rates of killing of extracellular and intracellular bacteria by RIF 
(Kkmax(E )  and Kkmax( I ) , respectively) is shown in !"#$%&' -)(.A.  Kkmax(E )  and Kkmax( I )  
are varied over the range 1x10-3 – 1x103 days-1.  In order to clear the infection the rate 
of killing of both extracellular and intracellular bacteria needs to be above a certain 
level, i.e. the drug must be effective against both extra- and intracellular bacteria.  If the 
rate of killing of either extracellular or intracellular bacteria is low the infection cannot 
be cleared within 1000 days of treatment. 
 !"#$%&' -)(.B shows the result of changing the rates of killing of extracellular and 
intracellular bacteria by RIF and the maximum growth rates of extracellular ! 20( )  and 
intracellular !19( )  bacteria.  Parameter values are changed so that the ratio 
Kkmax( I ) /Kkmax(E )  remains constant and is the same as in 3456&'+, and the ratio !19 /! 20  
remains constant and is the same as in the 788&9:"; (3456&',).  Kkmax(E )  is varied over 
the range 1x10-3 – 1x103 days-1 and ! 20  is varied over the range 1x10
-4 – 1x101 days-1.  
If bacterial growth rates are high, we need higher rates of killing by the drug to control 
bacterial replication and clear the infection.  Slower growing bacteria can be eliminated 
with a less efficient drug. 
 
The result of changing the rates of killing of extracellular and intracellular bacteria by 
RIF and the immune system killing rates is shown in !"#$%&'-)(.C.  Immune system 
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killing rates include the rate of killing of extracellular bacteria by resting macrophages, 
k18( ) , the uptake rate of extracellular bacteria by immature dendritic cells, !12( ) , the 
rate of killing of extracellular bacteria by activated macrophages, k15( ) , the maximum 
rate of Fas-FasL induced apoptosis of chronically infected macrophages, k14A( ) , the 
maximum rate of TNF-!  induced apoptosis of chronically infected macrophages, 
k14B( ) , and the maximum rate of cytotoxic killing of chronically infected macrophages, 
k52( ) .  Parameter values are changed so that the ratios k14A / k52 , k14B / k52 , k15 / k52 , 
!12 / k52  and k18 / k52  remain constant and are the same as in the 788&9:"; (3456&',), 
and the ratio Kkmax( I ) /Kkmax(E )  is the same as in 3456&'+.  k52  is varied over the range 
1x10-4 – 1x103 days-1 and Kkmax(E )  is varied over the range 1x10-3 – 1x103 days-1.  If the 
rate of killing by the drug is low and the immune response is weak the infection cannot 
be cleared within 1000 days of treatment.  If the rate of killing due to the drug is high 
enough (i.e. if the drug is efficient enough) it is possible to clear infection even when 
the immune response is weak.  The infection can also be cleared if the immune response 
is strong enough. 
 !"#$%&' -)(.D shows the result of varying the rates of killing of extracellular and 
intracellular bacteria by RIF and the dose of the drug.  Parameter values are changed so 
that the ratio Kkmax( I ) /Kkmax(E )  is the same as in 3456&'+, with Kkmax(E )  varied over the 
range 1x10-3 – 1x103 days-1.  The dose is varied over the range 1x10-1 – 1x104 mg.  
When a lower dose of RIF is administered the concentration of drug in the body is 
lower and a higher rate of killing is needed to clear infection. 
 !"#$%&'-)(.E shows the result of changing the effect of the drug on bacterial growth 
EC50g( )  and the rates of killing of extracellular and intracellular bacteria by RIF.  
Parameter values are changed so that the ratio Kkmax( I ) /Kkmax(E )  is the same as in as in 3456&' +, with Kkmax(E )  varied over the range 1x10-3 – 1x103 days-1.  EC50g  is varied 
over the range 1x10-10 – 1x104 mg/L.  At certain intermediate killing rates it is possible 
to clear the infection by decreasing EC50g , i.e. increasing the effect of the drug on 
bacterial growth.  At high and low killing rates EC50g  does not affect the success of the 
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treatment.  However, it can reduce the time required to clear the infection when 
treatment is successful. 
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Figure 5.16 Extracellular bacterial load after 1000 days of treatment.  (A) Varying the rates of killing 
of bacteria by the drug.  ‘Efficacy of drug against BI’ is the maximum rate of killing of intracellular 
bacteria by the drug (Kkmax(I)) and ‘Efficacy of drug against BE’ is the maximum rate of killing of 
extracellular bacteria by the drug (Kkmax(E)).  Kkmax(E) and Kkmax(I) are varied over the range 1x10-3 – 1x103 
days-1.  (B) Varying the rates of killing of bacteria by the drug and bacterial growth rates.  ‘Efficacy of 
drug’ includes Kkmax(E) and Kkmax(I).  ‘Bacterial growth’ includes the maximum extracellular ("20) and 
intracellular ("19) bacterial growth rates.  Parameter values are changed so that the ratio Kkmax(I)/Kkmax(E) is 
the same as in Table 3 and the ratio "19/"20 is the same as in the Appendix (Table 4).  Kkmax(E) is varied 
over the range 1x10-3 – 1x103 days-1 and "20 is varied over the range 1x10-4 – 1x101 days-1.  (C) Varying 
the rates of killing of bacteria by the drug (‘Efficacy of drug’) and immune system killing rates.  
‘Immunity’ includes the rate of killing of extracellular bacteria by resting macrophages, (k18), the uptake 
rate of extracellular bacteria by immature dendritic cells, (!12), the rate of killing of extracellular bacteria 
by activated macrophages, (k15), the maximum rate of Fas-FasL induced apoptosis of chronically infected 
macrophages, (k14A), the maximum rate of TNF-" induced apoptosis of chronically infected macrophges, 
(k14B) and the maximum rate of cytotoxic killing of chronically infected macrophages, (k52).  Parameter 
values are changed so that the ratio Kkmax(I)/Kkmax(E) is the same as in Table 3 and the ratios k14A/k52, 
k14B/k52, k15/k52, !12/k52 and k18/k52 are the same as in the Appendix (Table 4).  k52 is varied over the range 
1x10-4 – 1x103 days-1.  (D) Varying the daily dose and the rates of killing of bacteria by the drug 
(‘Efficacy of drug’).  The dose is varied over the range 1x10-1 – 1x104 mg.  (E) Varying the half-
saturation constant EC50g (‘Effect of drug on bacterial growth’) and the rates of killing of bacteria by the 
drug (‘Efficacy of drug’).  EC50g is varied over the range 1x10-10 – 1x104 mg/L.  Baseline parameter 
values and the corresponding extracellular bacterial load are marked with an asterisk. 
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5.3.2 Non-adherence 
 
Non-adherence to a prescribed dosing regimen that is known to be effective can 
increase the length of treatment and is associated with poor treatment outcome.  In this 
work the effect of two different types of non-adherence are explored.  !"#$%&' -)(/ 
shows how patient non-compliance affects the time required to clear infection for two 
different dosing regimens, a dose of 600mg taken once per day and a dose of 300mg 
taken twice per day.  In !"#$%&'-)(/A it is assumed that each dose is taken with some 
probability p .  As expected, as the probability of taking each dose falls, the average 
time to clear the infection increases.  Infection cannot be cleared within 1000 days when 
the probability of taking each dose is too low, (below 0.4).  These results also show that 
a dosing regimen that consists of two 300mg doses per day is slightly more robust to 
missed doses than one that consists of a single daily dose of 600mg.  When this dosing 
regimen is used infection can still be cleared within 1000 days in some cases when 
p = 0.5 , but it is never cleared for a dose of 600mg taken once per day. 
 
Now suppose that each dose X0  should be taken at time Tdose , but the patient takes the 
dose at some time T1  such that T1 = Tdose +T! , where T  is the dosing interval and !  is 
a random number chosen from a Gaussian distribution with mean zero and variance ! 2 .  
If a patient takes all of their prescribed doses, but does not take them at the right time 
(so any particular dose may be taken either early or late), infection is still cleared 
(!"#$%&' -)(/B).  However, as the variance ! 2( )  increases, the average time to clear 
infection increases.  This increase is more significant for the dosing regimen that 
consists of a dose of 300mg taken twice per day, than for the one that consists of a dose 
of 600mg taken once per day.  This implies that for this dosing regimen the timing of 
the dose is important to keep the concentration of RIF at an effective level. 
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Figure 5.17 Average time to clear infection following non-adherence to a prescribed dosing 
regimen.  (A) Each dose is taken with probability p.  When infection is not cleared within 1000 
days of treatment, the time to clearance is set to 1000 days.  (B) Each dose is taken at the wrong 
time.  The noise in the dosing times is distributed according to a Gaussian distribution with 
variance #2, where # is the standard deviation.  The error bars show the standard error in the 
times, which is equal to #/#N.  N is the number of runs performed in each case.  Here N=100. 
 
5.4 Conclusion 
 
A mathematical model of drug treatment during tuberculosis infection has been 
developed that allows us to predict the outcome, or success, of anti-TB chemotherapy.  
The outcome of tuberculosis therapy depends on a number of factors, including 
pharmacokinetic and pharmacodynamic parameters, the prescribed treatment regimen, 
patient compliance and the bacterial load at the start of treatment. 
 
Different pharmacokinetic and pharmacodynamic parameters in the model were varied 
to determine their contribution to the outcome of treatment.  The bactericidal activity of 
the drug and the kinetics of the drug in the body play a key role in determining the 
outcome of treatment.  Decreasing the efficacy or potency of the drug can affect the 
effectiveness of the treatment.  Simulation results show that efficient killing of both 
extracellular and intracellular bacteria is required to clear infection, and that increasing 
the rate of killing of intracellular bacteria has a greater bactericidal effect than 
increasing the rate of killing of extracellular bacteria.  It has been proposed that a 
protected intracellular bacterial compartment could contribute to the loss of EBA of 
anti-TB drugs that is observed clinically (Goutelle et al., 2011). 
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Parameters that govern the concentration of the drug at the site of action (the ELF and 
AC compartments) can also influence the outcome of treatment.  The drug must be able 
to reach and maintain effective concentrations in the body to clear infection, and this 
depends on the elimination rate constant, the absorption constant and the rates of 
transfer between the different compartments, as well as the dose and dosing interval.  
The short-term dynamics of the drug in the body, i.e. whether the drug is able to 
accumulate in the ELF and AC compartments, affect the efficiency of treatment. 
 
Previous studies suggest that the current RIF dosing regimen is suboptimal and that 
patients may benefit from a regimen that incorporates a higher dose of RIF (Goutelle et 
al., 2011; Gumbo et al., 2007a; Jayaram et al., 2003).  Simulation results show that 
increasing the dose of RIF from the current standard 600mg dose (for example to 
900mg or 1200mg) would reduce the length of treatment.  However, this model may 
overestimate the bactericidal effect of RIF at high doses (Goutelle et al., 2011).  The 
model assumes linear pharmacokinetics of RIF, while nonlinear pharmacokinetics in 
plasma have been reported.  Pharmacokinetic parameters were estimated from data 
obtained from patients receiving a 600mg dose of RIF per day, and these rates may not 
apply at higher doses. 
 
Increasing the dosing frequency from once per day could also shorten the length of 
treatment, even if the total daily dose remains constant at 600mg/day.  A 300mg dose 
taken twice per day is more effective than a 600mg dose taken once per day.  This 
dosing regimen is also more robust to missed doses, but it is less robust to noise in the 
dosing time, so may only be appropriate for patients who display good adherence.  
However, these results are dependent on pharmacodynamic and individual 
pharmacokinetic rates.  In addition, increasing the dosing frequency will increase the 
cost of treatment and might lead to an increase in non-compliance, negating any 
beneficial effects. 
 
In this model it is assumed that all extracellular and intracellular bacteria are equally 
susceptible to the drug.  However, during infection subpopulations of bacteria that are 
resistant or refractory to the action of the drug may be present.  This may be due to 
acquired drug resistance or drug tolerance. 
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It is assumed that in the absence of drug resistance primary TB can be treated with a 
single drug.  However, during primary TB the number of tubercle bacilli in the lung is 
high and it is likely that naturally resistant mutants are present in the bacterial 
population before treatment starts.  Anti-TB therapy requires multi-drug treatment 
administered over a long period of time.  Active disease should never be treated with a 
single drug (Frieden et al., 2003).  Drug resistant strains of M. tuberculosis have 
become increasingly prevalent, posing a significant problem for TB control (World 
Health Organization, 2012b).  The number of patients diagnosed with MDR-TB has 
increased during the last five years (World Health Organization, 2011a).  Future studies 
could explore the emergence of resistant strains and the use of combination therapy to 
overcome drug resistance and treat infection. 
 
Drug treatment must be given at an appropriate dosage and for an appropriate period of 
time to be effective.  Non-adherence to a prescribed treatment regimen can contribute to 
the spread of tuberculosis and the emergence of drug resistance.  Inappropriate 
treatment, e.g. from incorrect use of anti-TB drugs or use of poor quality medicines, is 
the primary cause of MDR-TB (World Health Organization, 2012b). 
 
In this model it is assumed that all extracellular and intracellular bacteria are killed at 
the same rate.  However, the bacterial population may contain slow-growing or non-
replicating bacilli that are not killed by RIF as efficiently as actively growing bacteria, 
as well as RIF tolerant cells that persist in the host after treatment has been completed 
(Zhang et al., 2012).  Bacilli that persist in the host can contribute to tuberculosis 
relapse.  This model can be modified to include populations of bacteria with different 
replication rates, or a population of RIF tolerant persister cells.  This will allow us to 
study the effect of these populations on the outcome of treatment.  Slow-growing and 
non-replicating bacilli may be significant in the treatment of latent tuberculosis, which 
involves a nine-month regimen of isoniazid.  The model can also be used to investigate 
how the treatment regimen needs to be modified to overcome RIF tolerant persister 
cells. 
 
This work considers the use of RIF to treat infection, but the model can be modified to 
consider treatment with different anti-TB drugs, or a combination of drugs.  The model 
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can be used to further investigate treatment strategies that may improve the success of 
anti-TB chemotherapy, and to find optimal treatment regimens for clearing infection.  
Intermittent dosing can be modelled, including different dosing intervals in the initial 
and continuation phases of treatment.  However, this model does not take into account 
the post-antibiotic effect of the drug (the continued suppression of bacterial growth 
following exposure to an antimicrobial agent (Chan et al., 2001)), which may be 
important when designing optimal dosing regimens (Chang et al., 2011). 
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6.1 Introduction 
 
Latent infection can be thought of as a state of equilibrium between bacteria and host.  
This may be a static equilibrium in which bacterial growth is slow or absent, or a 
dynamic equilibrium in which continuous bacterial growth is balanced by the rate of 
killing by the host immune system (Munoz-Elias et al., 2005).  It has been hypothesized 
that slow-growing or non-replicating bacilli play a significant role in the pathogenesis 
of tuberculosis infection and contribute to the establishment of a latent state (Zhang, 
2004).  The objective in this chapter is to investigate conditions under which latency is 
achieved and the effect of persistent bacteria in determining the outcome of infection. 
 
In this chapter a different modelling approach is taken compared with previous chapters.  
Simple models are constructed that ignore all the details and complexities of the 
immune system.  The aim is that by using these simple models some of the basic 
mechanisms of latency and mycobacterial persistence can be unravelled.  A series of 
predator-prey type models are developed to describe the dynamics of tuberculosis 
infection in the lung.  These models capture both innate (non-specific) and adaptive 
(specific) immune responses.  The adaptive immune response is modelled explicitly, 
while the innate immune response is represented by a constant killing term. 
 
The first model presented consists of two state variables: a population of bacteria and a 
population of M. tuberculosis specific immune cells.  Two different functions are used 
to model killing by these cells: a mass action term that is dependent on the product of 
the densities of the two populations and a saturating function.  These models are then 
modified to incorporate extracellular and intracellular bacterial populations.  Finally, an 
intracellular population of non-replicating or slow-growing bacteria is added to the 
model. 
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As noted by Handel et al., 2009, the models describing the dynamics of the immune 
response are simple and heuristic, meant to capture certain aspects of the complex 
immune response to M. tuberculosis.  We are interested in the qualitative properties of 
the models and parameter values are chosen simply to show the different possible 
outcomes.  The models can be rescaled to achieve a desired result. 
 
In these models it is assumed that the existence of a bounded solution and a (stable) 
positive fixed point represents latent infection, a situation where bacterial growth is 
controlled by the immune system, but not eliminated.  Active disease is characterized by 
unbounded solutions.  Only non-negative fixed points are of physiological relevance. 
 
6.2 Non-persistence Models 
 
6.2.1 Model 6.1 
 
Consider a single population of bacteria, and a population of adaptive immune cells 
represented by M. tuberculosis specific T cells.  The bacterial population consists of 
both the extracellular and intracellular bacterial populations described in the model in 
Chapter 4, and the T cell population includes Th1 cells and effector CD8+ T cells.  Let 
B(t)  be the population density of bacteria at time t  and T (t)  be the population density 
of T cells at time t , t ! 0 .  It is assumed that in the absence of an immune response, 
bacteria grow exponentially in the host at rate ! .  This bacterial population is subject to 
killing by both innate and adaptive immune responses.  Bacteria are killed by the innate 
immune system (e.g. by resting macrophages, neutrophils and other phagocytic cells) at 
a constant rate p3 .  This term encompasses the innate immune killing mechanisms 
described in the model developed in Chapter 4 (the killing of extracellular bacteria by 
resting macrophages and the uptake of extracellular bacteria by immature dendritic 
cells).  We can think of this as the killing of bacteria by a fixed population of innate 
immune cells that does not change during the course of infection.  The impact of 
adaptive immunity on bacteria is modelled by a mass action term that depends on the 
product of the bacterial and T cell population densities, p4BT .  This term represents the 
killing of the bacterial population due to the action of T cells, including the activation of 
macrophages and cytotoxic activity.  It incorporates all the adaptive immune killing 
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mechanisms described in Chapter 4 (the killing of extracellular bacteria by activated 
macrophages, Fas-FasL induced apoptosis of chronically infected macrophages, 
TNF-!  induced apoptosis of chronically infected macrophages and cytotoxic killing of 
chronically infected macrophages).  The growth of the T cell population is induced by 
bacteria at rate p1 , and these cells decay at rate p2 .  This model is described by the 
following system of ODEs 
 
 
dB
dt =!B " p3B " p4BT
dT
dt = p1B " p2T
  (6.1) 
 
This system is nonlinear and cannot be solved analytically for B(t)  and T (t) .  
However, we can gain insights into the system by investigating the long-term or steady 
state behaviour.  The analysis of persistent infections focuses on within-host equilibria 
so transient dynamics can often be ignored (Alizon and van Baalen, 2008).  Fixed points 
B*,T *( ) , also known as critical points, equilibrium points or steady state values, for 
which dBdt = 0  and 
dT
dt = 0  are of special importance. 
 
The equilibrium values of system (6.1) are found by solving the equations 
 
 !B " p3B " p4BT = 0   (6.2) 
 p1B ! p2T = 0   (6.3) 
 
This system has at most two non-negative fixed points: one at the origin E1 = 0,0( ) , 
which corresponds to an uninfected steady state, and one at E2 =
p2
p1
! " p3
p4
,! " p3p4
#
$%
&
'(
, 
corresponding to an endemically infected steady state when ! > p3 , i.e. when the 
growth rate of bacteria is greater than the rate of killing by the innate immune system. 
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A nonlinear system can be considered to be linear in the neighbourhood of a fixed point.  
Linearization about the fixed points allows us to determine the type and stability of the 
steady states. 
 
If we define new variables x1 = B ! B*  and x2 = T !T *  then the linear system that 
approximates the nonlinear system (6.1) near a fixed point is 
 
  !x = Ax   (6.4) 
 
where x = x1x2
!
"#
$
%&
, A =
!F1
!B
!F1
!T
!F2
!B
!F2
!T
"
#
$
$
$
$
%
&
'
'
'
'
B* ,T *( )
 is the Jacobian matrix evaluated at the  fixed 
point B*,T *( ) , and  F1 B,T( ) =!B " p3B " p4BT , F2 B,T( ) = p1B ! p2T ,. 
 
For system (6.1) 
 
 A = ! " p3 " p4T " p4Bp1 " p2
#
$
%%
&
'
((
B* ,T *( )
  (6.5) 
 
Thus the linear system that approximates the nonlinear system (6.1) near a fixed point is 
 
 ddt
x1
x2
!
"#
$
%&
=
' ( p3 ( p4T * ( p4B*
p1 ( p2
!
"
#
#
$
%
&
&
x1
x2
!
"#
$
%&
  (6.6) 
 
To analyse the stability of the fixed points we need to calculate the eigenvalues of the 
matrix A .  For E1 = 0,0( )  (the uninfected steady state) we have 
 
 A = ! " p3 0p1 " p2
#
$
%%
&
'
((
  (6.7) 
 
 170 
The eigenvalues of this matrix are obtained by solving the characteristic equation 
det A ! "I( ) = 0 .  For matrix A  given by (6.7) the characteristic equation is 
! " p3 " #( ) " p2 " #( ) = 0 , and the eigenvalues are !1 =" # p3  and !2 = " p2 . 
 
The fixed point E1  is asymptotically stable if the eigenvalues of the matrix A  have 
negative real part, i.e. Re!i < 0  for i = 1,2 .  If ! > p3  then we have !2 < 0 < !1 , so the 
origin is a saddle point and is unstable.  If ! < p3  then !1,2 < 0  and the origin is a stable 
node. 
 
The matrix A  evaluated at the fixed point E2 =
p2
p1
! " p3
p4
,! " p3p4
#
$%
&
'(
 is 
 
 A =
0 ! p2p1
" ! p3( )
p1 ! p2
#
$
%
%
%
&
'
(
(
(
  (6.8) 
 
The eigenvalues of this matrix, !1,2 , are given by solutions of the characteristic equation 
 ! 2 + p2! + p2 " # p3( ) = 0   (6.9) 
 
Thus !1,2 =
" p2 ± p22 " 4 p2 # " p3( )
2 . 
 
If p2 > 0  and ! > p3  then Re!1,2 < 0 , and the fixed point E2  is asymptotically stable.  
If ! > p3  and p22 ! 4 p2 " ! p3( ) > 0 , i.e. p2 > 4 ! " p3( ) , the characteristic equation 
(6.9) has two real negative roots and the fixed point is a stable node.  If ! > p3  and 
p2 < 4 ! " p3( ) , the roots of equation (6.9) are a complex conjugate pair with negative 
real part and the fixed point is a stable spiral.  If ! < p3  then we have !2 < 0 < !1 , and 
this fixed point is an unstable saddle point.  Figure .)( shows the vector field of system 
(6.1) in  R+
2  for these three separate cases.  The nullclines of this system, lines or curves 
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in the phase space (the BT  plane) for which dBdt = 0  or 
dT
dt = 0 , are also shown.  Points 
where the nullclines intersect are equilibrium points. 
 
We note that a transcritical bifurcation occurs at ! = p3 , where the non-zero fixed point 
passes through zero and changes sign, and the two fixed points exchange stability.  For 
! < p3  the fixed point E1  is stable and the fixed point E2  is negative and unstable, 
while for ! > p3  E1  is unstable and E2  is positive and stable. 
 
  
Figure 6.1 Vector fields and nullclines of system (6.1) when (A) the positive fixed point is a stable 
node, (B) the positive fixed point is a stable spiral and (C) no positive fixed point exists.  The B nullclines 
are the magenta and green lines.  The T nullcline is the blue line.  Equilibrium points are represented by 
solid black circles. 
 
Suppose that infection occurs with B 0( ) = B0  bacteria.  If ! > p3  then for any initial 
condition not on the T  axis, i.e. for B0 > 0  and T 0( ) = T0 ! 0 , all solutions 
B t( ),T t( )( )  converge to E2  as t!" .  If this condition is satisfied a state of 
equilibrium is achieved between the bacteria and host and the bacterial population will 
establish a persistent or chronic infection.  If ! < p3  the origin is the only non-negative 
fixed point, and this point will attract all solutions B(t),T t( )( )  starting in the non-
negative quadrant  R+
2 = B,T( )!!2 | B " 0,T " 0{ } .  Time courses for different initial 
inoculums of bacteria in a naïve host that has no previous exposure to mycobacterial 
antigens (so T0 = 0 ) for the case where ! > p3  are shown in Figure .)*. 
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Figure 6.2 Time courses for different initial inoculums of bacteria for (A) the bacterial population and 
(B) the T cell population when an infected steady state exists.  The equilibrium values of the bacterial and 
T cell populations are denoted by B* and T*. 
 
Stability of the uninfected steady state implies that the innate immune response is strong 
enough to clear infections of arbitrary initial size, while instability of E1  implies that 
the infection will never be cleared.  In this case the bacterial population is able to escape 
elimination by the innate immune system, but the infection can be controlled by 
adaptive immunity.  This may correspond to a latent infection, although the actual 
bacterial burden is likely to be important in determining the outcome of infection. 
 
6.2.2 Model 6.2 
 
The T cell killing function in Model 6.1 is now adapted to consider a saturating effect of 
T cell killing at high T cell loads.  In this model the rate of killing of bacteria due to T 
cell activity increases at a decreasing rate towards a maximum value.  Then equations 
(6.1) become 
 
 
dB
dt =!B " p3B " p4B
T
T + s
dT
dt = p1B " p2T
  (6.10) 
 
 173 
where p4  is the maximum rate of killing of B  by T cells and s  is the value of T  when 
the killing rate is half its maximum value.  All other parameters are as described in 
Section 6.2.1. 
 
This system has two fixed points: the uninfected steady state E1 = 0,0( )  and 
E2 = !
p2
p1
s " ! p3( )
" ! p3 ! p4
,! s " ! p3( )
" ! p3 ! p4
#
$%
&
'(
, which corresponds to an endemically infected 
steady state when p3 <! < p3 + p4 . 
 
Linearizing equations (6.10) about the fixed point B*,T *( )  as was done in Section 6.2.1 
we obtain the matrix A  
 
 A =
! " p3 " p4
T *
T * + s " p4B
* s
T * + s( )2
p1 " p2
#
$
%
%
%%
&
'
(
(
((
  (6.11) 
 
At the fixed point E1 = 0,0( )  
 
 A = ! " p3 0p1 " p2
#
$
%%
&
'
((
  (6.12) 
 
which has eigenvalues !1 =" # p3  and !2 = " p2 .  If ! > p3  we have !2 < 0 < !1 , so the 
origin is a saddle point and is unstable.  If ! < p3  then !1,2 < 0 , and the origin is a 
stable node. 
 
The matrix A  evaluated at the fixed point E2 = !
p2
p1
s " ! p3( )
" ! p3 ! p4
,! s " ! p3( )
" ! p3 ! p4
#
$%
&
'(
 is 
 
 A = 0
p2
p1
! " p3( ) ! " p3 " p4( )
p4
p1 " p2
#
$
%
%
%
&
'
(
(
(
  (6.13) 
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The eigenvalues of this matrix, !1,2 , are given by solutions of the characteristic equation 
 ! 2 + p2! " p2
# " p3( ) # " p3 " p4( )
p4
= 0   (6.14) 
 
So !1,2 =
" p2 ± p22 " 4#
2 , where ! = " p2
# " p3( ) # " p3 " p4( )
p4
. 
 
If p2 > 0  and p3 <! < p3 + p4  (so ! > 0 ), then Re!1,2 < 0  and the fixed point E2  is 
asymptotically stable.  If p3 <! < p3 + p4  and p22 ! 4" > 0 , this fixed point is a stable 
node.  If p3 <! < p3 + p4  and p22 ! 4" < 0  then E2  is a stable spiral.  If ! < p3  or 
! > p3 + p4  (so ! < 0 ) !2 < 0 < !1  and this fixed point is an unstable saddle point. 
 
This implies that for ! < p3  the origin attracts all solutions B(t),T t( )( )  starting in the 
non-negative quadrant  R+
2 , i.e. for initial conditions B 0( ) = B0 ! 0  and T 0( ) = T0 ! 0 .  
For p3 <! < p3 + p4  E2  is asymptotically stable and attracts all solutions with initial 
conditions not on the T  axis. 
 
Suppose that infection occurs with B0 > 0  bacteria.  If p3 <! < p3 + p4  all positive 
solutions B t( ),T t( )( )  with initial conditions not on the T  axis converge to E2  as 
t!" , and the bacterial population will establish a persistent or chronic infection.  If 
! < p3  then for all solutions starting in the non-negative quadrant  R+
2  B t( ),T t( )( )! 0  
as t!" , implying that the immune system is able to clear infections of arbitrary initial 
size.  If ! > p3 + p4  this system has no positive fixed points and the uninfected steady 
state is unstable.  So, for any B 0( ) = B0 > 0  the bacterial population will grow 
exponentially and B,T !"  as t!" .  The vector field for system (6.10) in this case 
is shown in Figure .)+. 
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Figure 6.3 Vector field and nullclines of system (6.10) when the uninfected steady state is unstable and 
no positive fixed point exists.  Only one of the B nullclines lies in the region  R +
2  (the magenta line).  The 
T nullcline is the blue line.  Equilibrium points are represented by solid black circles. 
 
These results imply that if the strength of innate immunity is sufficiently high the 
infection will be cleared.  If bacteria are able to escape killing by the innate immune 
response but not the combination of innate and adaptive immunity the bacterial 
population will establish a persistent or chronic infection, potentially corresponding to a 
latent state.  If bacteria are able to escape killing by both innate and adaptive immune 
responses the infection cannot be controlled and the bacterial population grows 
unbounded.  This corresponds to active disease. 
 
6.2.3 Model 6.3 
 
Now consider two populations of bacteria: a population of extracellular bacteria, BE , 
and a population of intracellular bacteria, BI , which consists of the population of 
bacteria that reside within chronically infected macrophages (similar to the extracellular 
and intracellular bacterial populations described in the model in Chapter 4).  The 
population of M. tuberculosis specific T cells is denoted by T , and includes Th1 cells 
and effector CD8+ T cells. 
 
In the absence of an immune response extracellular bacteria grow exponentially at rate 
!E  and intracellular bacteria grow exponentially at rate ! I .  It is assumed that 
extracellular bacteria can be killed by both innate and adaptive immune responses 
(macrophages activated by IFN-! -producing T cells), but intracellular bacteria can 
only be killed by the adaptive immune system.  Intracellular bacteria are killed when 
their host macrophage is killed by CTL activity or undergoes apoptosis.  It is also 
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assumed that intracellular bacteria only become extracellular when their host cell is 
killed.  k3  is the rate of killing of BE  by the innate immune system.  This term 
encapsulates the innate immune mechanisms described in Chapter 4 that are responsible 
for eliminating extracellular bacteria (the killing of extracellular bacteria by resting 
macrophages and the uptake of extracellular bacteria by immature dendritic cells).  A 
mass action term is used to model the rate of killing of extracellular and intracellular 
bacteria due to T cell activity.  k4  is the rate of killing of the extracellular bacterial 
population by T cells.  It includes the killing of extracellular bacteria by activated 
macrophages, as described in Chapter 4.  k6  is the rate of killing of the intracellular 
bacterial population by T cells.  It incorporates the adaptive immune mechanisms 
described in Chapter 4 that are responsible for the killing of intracellular bacteria (Fas-
FasL induced apoptosis of chronically infected macrophages, TNF- !  induced 
apoptosis of chronically infected macrophages and cytotoxic killing of chronically 
infected macrophages).  A proportion f1 , 0 < f1 <1 , of these bacteria are not killed by T 
cells and become extracellular.  Extracellular bacteria become intracellular at a constant 
rate k5 .  This term is similar to the term describing the chronic infection of 
macrophages in the model in Chapter 4.  The growth of the T cell population is induced 
by extracellular bacteria at rate p1 , and these cells decay at rate p2 .  The following set 
of equations is used to model this system 
 
 
dBE
dt =!EBE " k3BE " k4BET " k5BE + f1k6BIT
dBI
dt =! I BI + k5BE " k6BIT
dT
dt = k1BE " k2T
  (6.15) 
 
The equilibrium values of this system, BE* ,BI*,T *( ) , are given by solutions of the 
equations dBEdt = 0 , 
dBI
dt = 0  and 
dT
dt = 0 , that is 
 
 !EBE " k3BE " k4BET " k5BE + f1k6BIT = 0   (6.16) 
 ! I BI + k5BE " k6BIT = 0   (6.17) 
 k1BE ! k2T = 0   (6.18) 
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Equation (6.18) gives BE* =
k2
k1
T * , and substituting this into equation (6.17) we get 
BI* = k5
k2
k1
T *
k6T * !" I( )
.  Therefore the values of T *  are given by the roots of the 
equation 
 
 k2k1
T *
k6T * !" I
!k4k6T *2 + "E ! k3 ! k5( )k6 + k4" I + k5 f1k6#$ %&T * !" I "E ! k3 ! k5( )#$ %& = 0   
  (6.19) 
 
T * = 0  is a solution of this equation so the uninfected steady state E1 = 0,0,0( )  is one 
of the fixed points of system (6.15).  For k4 > 0 , k6 > 0  the other solutions of equation 
(6.19) are found by solving the quadratic equation 
 
 k4k6T *2 ! "E ! k3 ! k5( )k6 + k4" I + k5 f1k6#$ %&T * +" I "E ! k3 ! k5( ) = 0   (6.20) 
 
Let ! = " #E " k3 " k5( )k6 + k4# I + k5 f1k6$% &' .  Then the solutions of this equation are 
 
 T1,2* =
!" ± " 2 ! 4k4k6# I #E ! k3 ! k5( )
2k4k6
  
 
If !E > k3 + k5  (so ! < 0 ) and ! 2 " 4k4k6# I #E " k3 " k5( ) > 0  then equation (6.20) has 
two positive real roots.  For !E > k3 + k5  ! 2 " 4k4k6# I #E " k3 " k5( )  is greater than 
zero if k4 , ! I , k5 , f1  and k6  are positive.  If !E < k3 + k5  then equation (6.20) has one 
positive root and one negative root.  Finally, if !E = k3 + k5  equation (6.20) has only 
one non-zero solution, !"k4k6
, which is positive if k4! I + k5 f1k6 > 0 . 
 
 178 
BE*  is proportional to T * , so if T *  is positive then BE*  is also positive.  For T * > 0 , 
BI* = k5
k2
k1
T *
k6T * !" I( )
 is positive if k6T * !" I > 0 . 
 
Let T1* =
!" + " 2 ! 4k4k6# I #E ! k3 ! k5( )
2k4k6
.  k6T1* !" I > 0  if k4! I k5 f1k6 > 0 .  Since 
the parameters cannot be negative this condition is only satisfied if k4 , ! I , k5 , f1  and 
k6  are non-zero. 
 
Now let T2* =
!" ! " 2 ! 4k4k6# I #E ! k3 ! k5( )
2k4k6
.  If T2* > 0  then k6T2* !" I < 0  so BI*  
will be negative.  Therefore if the parameters k4 , ! I , k5 , f1  and k6  are positive, and in 
addition k1  is positive, system (6.15) will always have one positive fixed point 
corresponding to an endemically infected steady state. 
 
We note that if either k4  or k6  are equal to zero, i.e. if either extracellular bacteria or 
intracellular bacteria are not killed by adaptive immunity, then system (6.15) has only 
two distinct fixed points, one of which is the uninfected steady state 0,0,0( ) .  If k4 = 0 , 
i.e. extracellular bacteria are not killed by the adaptive immune response, there is an 
endemically infected steady state if !E < k3 + 1" f1( )k5 .  If k6 = 0 , i.e. intracellular 
bacteria are not killed by the adaptive immune response, the origin is the only non-
negative fixed point. 
 
In order to determine the stability of the fixed points we compute the Jacobian matrix of 
system (6.15) at an equilibrium point BE* ,BI*,T *( ) .  This matrix A  is obtained by 
finding the partial derivatives of the functions 
 
F1 BE ,BI ,T( ) =!EBE " k3BE " k4BET " k5BE + f1k6BIT
F2 BE ,BI ,T( ) =! I BI + k5BE " k6BIT
F3 BE ,BI ,T( ) = k1BE " k2T
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Then 
 
 
A =
!F1
!BE
!F1
!BI
!F1
!T
!F2
!BE
!F2
!BI
!F2
!T
!F3
!BE
!F3
!BI
!F3
!T
"
#
$
$
$
$
$
$
$$
%
&
'
'
'
'
'
'
''
BE* ,BI* ,T *( )
=
(E ) k3 ) k4T * ) k5 f1k6T * )k4BE* + f1k6BI*
k5 ( I ) k6T * )k6BI*
k1 0 )k2
"
#
$
$
$
%
&
'
'
'
  (6.21) 
 
The matrix A  evaluated at the fixed point 0,0,0( )  is 
 
 A =
!E " k3 " k5 0 0
k5 ! I 0
k1 0 "k2
#
$
%
%
%
&
'
(
(
(
  (6.22) 
 
The eigenvalues of this matrix, given by solutions of the characteristic equation 
det A ! "I( ) = 0 , are !1 ="E # k3 # k5 , !2 =" I  and !3 = "k2 , so the uninfected steady 
state is always unstable for ! I > 0 .  This result suggests that the existence of an 
intracellular bacterial population that is shielded from the innate immune system 
prevents the host from being able to clear infection and benefits the bacteria.  If some 
background level of immunity that does not depend on the presence of bacteria and is 
able to kill both bacterial populations was added to the model, for example a constant 
source of T cells or memory T cells, the uninfected steady state can be stable. 
 
The matrix A  evaluated at the infected steady state E2 = BE ,BI ,T( )  is 
 
 A =
!E " k3 " k4T " k5 f1k6T "k4BE + f1k6BI
k5 ! I " k6T "k6BI
k1 0 "k2
#
$
%
%
%
&
'
(
(
(
  (6.23) 
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which has eigenvalues given by solutions of the characteristic equation 
 
 ! 3 + A! 2 + B! +C = 0   (6.24) 
 
where 
 
 
A = k2 ! "E ! k3 ! k5( ) + k4T + k6T !" I( )
B = k2 k6T !" I( )! k2 "E ! k3 ! k5 ! k4T( )! "E ! k3 ! k5 ! k4T( ) k6T !" I( )
!k5 f1k6T ! k1 !k4BE + f1k6BI( )
C = !k2 "E ! k3 ! k5 ! k4T( ) k6T !" I( )! k5k2 f1k6T + k1k4BE k6T !" I( )
+k1" I f1k6BI
 (6.25) 
 
This fixed point is stable if the three roots of equation (6.24) have negative real part.  By 
the Routh-Hurwitz criterion the necessary and sufficient conditions for this to hold are 
A > 0 , C > 0  and AB !C > 0  (Murray, 2002).  If this fixed point is stable then all 
solutions BE t( ),BI t( ),T t( )( )  with initial conditions not on the T  axis (i.e. BE 0( ) > 0  
or BI 0( ) > 0  and T 0( ) ! 0 ) converge to E2  as t!"  (Figure .),). 
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Figure 6.4 Dynamics for a stable fixed point.  (A) Time courses for extracellular bacterial population 
for different initial inoculums of bacteria when system (6.15) has a stable positive fixed point.  (B) 
Trajectories in the three dimensional BEBIT space for different initial conditions.  The equilibrium value is 
marked with an asterisk. 
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The model may exhibit oscillatory behaviour (Figure .)-) for certain parameter regimes 
due to the existence of Hopf bifurcations.  A cubic equation can have either three real 
roots or one real root and a complex conjugate pair of roots.  For a three dimensional 
system a Hopf bifurcation occurs when a complex conjugate pair of eigenvalues 
!1,2 = µ ± i"  cross the imaginary axis.  When this happens the sign of Re!1,2 = µ  
changes, resulting in a change in the stability of the fixed point.  When a system 
undergoes a Hopf bifurcation a limit cycle periodic solution exists about the equilibrium 
point.  A limit cycle is an isolated closed trajectory.  Neighbouring trajectories either 
spiral in towards a limit cycle or spiral away from it.  A limit cycle is said to be stable if 
neighbouring trajectories approach it from both sides (Murray, 2002).  If the real 
eigenvalue is negative the Hopf bifurcation is supercritical, resulting in a stable limit 
cycle.  The characteristic equation (6.24) has one negative real root and a pair of purely 
imaginary roots ±i!  if A > 0 , C > 0  and AB !C = 0  (El Kahoui and Weber, 2000). 
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Figure 6.5 Dynamics for a periodic solution.  (A) Time course for bacterial populations when system 
(6.15) has an unstable positive fixed point.  (B) Trajectories in the three dimensional BEBIT space for 
different initial conditions.  The equilibrium value is marked with an asterisk.  Solutions approach a 
stable limit cycle. 
 
This model contains ten different parameters that can affect the stability of the positive 
fixed point, so a detailed bifurcation analysis is not feasible.  However, we can gain 
insights into the system by investigating the stability of this equilibrium point for a large 
range of parameters.  5000 different parameter sets were randomly generated.  Values 
for ki , i = 1,..,6 , !E  and ! I  were chosen over the range 10-4 – 104 and values for f1  
were chosen over the range 10-4 – 1.  All parameters were chosen uniformly in the 
logarithmic space. 
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In this parameter space the positive fixed point may be stable or unstable.  This fixed 
point was found to be stable for approximately 70% of the parameter values considered.  
Of these stable fixed points approximately 80% had one negative real eigenvalue and a 
complex conjugate pair of eigenvalues with negative real part and the other 20% had 
three negative real eigenvalues.  All the unstable fixed points had a complex conjugate 
pair of eigenvalues with positive real part and one negative real eigenvalue, so when 
this fixed point is unstable we get oscillatory behaviour.  These results suggest that this 
fixed point is stable for a wide range of parameters, and that periodic solutions are 
common due to the existence of supercritical Hopf bifurcations (Figure .).).  So for the 
range of parameters considered all solutions with initial conditions not on the T  axis 
either converge to E2  as t!"  or they approach a stable limit cycle about E2 .  All of 
these solutions are bounded, so we can consider this to be a latent infection. 
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Figure 6.6 Bifurcation diagram for system (6.15).  A supercritical Hopf bifurcation occurs as the 
extracellular bacterial growth rate ("E) is varied ("E=0.535).  The black line denotes the stable equilibrium 
continuation curve and the red line denotes the unstable equilibrium continuation curve. The maxima and 
minima of the stable periodic solutions are denoted by the blue and green points, respectively. 
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6.2.4 Model 6.4 
 
In this model the T cell killing function from Model 6.3 is adapted to include a 
saturating effect for T cell killing of BE  and BI  at high levels of T .  The following set 
of equations is used to model this system 
 
 
dBE
dt =!EBE " k3BE " k4BE
T
T + c " k5BE + f1k6BI
T
T + c
dBI
dt =! I BI + k5BE " k6BI
T
T + c
dT
dt = k1BE " k2T
  (6.26) 
 
k4  is the maximum rate of killing of BE  by T cells, k6  is the maximum rate of killing 
of BI  by T cells and c  is the value of T  when the killing rates are at half their 
maximum value.  All other parameters are as described in Section 6.2.3. 
 
At equilibrium BE* =
k2
k1
T *  and BI* =
k5
k2
k1
T * T * + c( )
k6 !" I( )T * !" Ic#$ %&
.  T *  is given by solutions of 
the equation 
 
 k2k1
1
T * + c
T *
k6 !" I( )T * !" Ic
#
$%
&
'(
pT *2 + qT * + r( ) = 0   (6.27) 
 
where 
p = !E " k3 " k5 " k4( ) k6 "! I( ) + k5 f1k6
q = c !E " k3 " k5( ) k6 " 2! I( ) + k4! I + k5 f1k6#$ %&
r = "! Ic2 !E " k3 " k5( )
 
 
This equation has three solutions: T * = 0 , and the roots of the quadratic equation 
 
 pT *2 + qT * + r = 0   (6.28) 
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So this system has three fixed points, including the uninfected steady state 0,0,0( ) .  
The roots of equation (6.28) are T1,2* =
!q ± q2 ! 4 pr
2p . 
 
If a saturating function is used to model T cell killing, there may not be a positive 
equilibrium point.  This was also observed for the model with two variables in Section 
6.2.2.  The equation for BI*  indicates that if ! I " k6  there will be no positive fixed 
points. 
 
In this model the matrix A  is given by 
 
 A =
!E " k3 " k4
T *
T * + c " k5 f1k6
T *
T * + c "k4BE
* c
T * + c( )2
+ f1k6BI*
c
T * + c( )2
k5 ! I " k6
T *
T * + c "k6BI
* c
T * + c( )2
k1 0 "k2
#
$
%
%
%
%
%
%
%
&
'
(
(
(
(
(
(
(
   
  (6.29) 
 
At the fixed point 0,0,0( )  we have 
 
 A =
!E " k3 " k5 0 0
k5 ! I 0
k1 0 "k2
#
$
%
%
%
&
'
(
(
(
  (6.30) 
 
This matrix has eigenvalues !1 ="E # k3 # k5 , !2 =" I  and !3 = "k2 , so again the 
origin is an unstable fixed point for ! I > 0 .  This implies that if system (6.26) has no 
positive fixed points, then all solutions BE t( ),BI t( ),T t( )( )  with initial conditions not 
on the T  axis will grow unbounded. 
 
Using the same approach described in Section 6.2.3 it was observed that this system has 
one positive fixed point for approximately 40% of the parameter sets considered.  
Approximately 80% of these positive fixed points were stable and 80% of these stable 
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fixed points had one negative real eigenvalue and a complex conjugate pair of 
eigenvalues with negative real part.  All the unstable positive fixed points had a 
complex conjugate pair of eigenvalues with positive real part and one negative real 
eigenvalue.  So for the range of parameters considered all solutions with initial 
conditions not on the T  axis either converge to the positive fixed point as t!"  or 
approach a stable limit cycle.  Values for ki , i = 1,..,6 , !E  and ! I  were chosen 
randomly over the range 10-4 – 104, f1  was chosen over the range 10-4 – 1 and c  was 
chosen over the range 1 – 108.  These bounded solutions correspond to latent 
tuberculosis.  For the remaining 60% of parameter sets no positive fixed point exists so 
the solutions will grow unbounded.  This corresponds to active disease. 
 
Active disease is a common outcome of infection when the T cell killing function is 
bounded.  For example, if intracellular bacteria are able to escape killing by the immune 
system, i.e. ! I " k6 , infection cannot be controlled and we get primary TB 
( BE ,BI ,T !"  as t!" ). 
 
6.3 Persistence Model 
 
6.3.1 Model 6.5 
 
Model 6.4 is modified to include an intracellular persistent bacterial population that is 
slow-growing or non-replicating and is less susceptible to killing by the immune 
system.  This population is denoted by PI .  It is assumed that intracellular bacteria 
switch to a persistent phenotype in response to stresses exerted on the population by T 
cell activity (Wayne and Sohaskey, 2001).  The following set of equations is used to 
model this system 
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dBE
dt =!EBE " k3BE " k4BE
T
T + c " k5BE + f1k6BI
T
T + c
dBI
dt =! I BI + k5BE " k6BI
T
T + c "# 1BIT + # 2PI
dT
dt = k1BE " k2T
dPI
dt =!PIPI " g1k6PI
T
T + c + # 1BIT "# 2PI
  (6.31) 
 
where  !PI !! I  is the growth rate of the PI  population, ! 1  is the rate of switching from 
normal bacteria to persistent bacteria and ! 2  is the rate of switching from PI  to BI .  PI  
are less susceptible to killing by the immune system and are killed by T cells at rate 
g1k6  with 0 < g1 <1.  The remaining parameters are as described earlier.  Time courses 
for the bacterial and T cell populations are shown in Figure .)/. 
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Figure 6.7 Dynamics of bacterial and T cell populations for system (6.31). 
 
This system has five fixed points, one of which is the uninfected steady state 0,0,0,0( ) .  
The number of positive fixed points is difficult to determine analytically, but the 
methods described in Section 6.2.3 can be used to gain a better understanding of this 
system. 
 
In order to investigate the effect of a persistent population on the outcome of infection 
this model is compared to the model that does not include persistent bacteria (Model 
6.4).  The same values are used for the parameters that are common to both models.  
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Values for ! 1  and ! 2  were randomly chosen over the range 10
-4 – 104 and g1  was 
chosen over the range 10-4 – 1.  The growth rate of the persistent population, !PI , was 
set to zero. 
 
It was observed that when a non-replicating population exists a positive fixed point 
occurs for a larger set of parameters.  This model has one positive fixed point for 
approximately 75% of the parameter sets considered.  Approximately 95% of these 
positive fixed points were stable and 50% of these stable fixed points had two negative 
real eigenvalues and a complex conjugate pair of eigenvalues with negative real part.  
All the unstable positive fixed points had a complex conjugate pair of eigenvalues with 
positive real part and two negative real eigenvalues.  Therefore all solutions with initial 
conditions not on the T  axis either converge to the positive fixed point as t!"  or 
approach a limit cycle solution for the range of parameters considered.  These bounded 
solutions represent latent tuberculosis.  No positive fixed point exists for 25% of 
parameter sets.  In these cases solutions grow unbounded and we get active disease. 
 
These results combined with those in Section 6.2.4 suggest that the presence of a non-
growing bacterial population makes latency a more common outcome of M. 
tuberculosis infection.  Oscillatory behaviour is also less common in this model, 
indicating that the presence of a non-growing population makes the persistent infection 
a more stable state. 
 
6.4 Conclusion 
 
In this chapter a series of predator-prey type models were developed to investigate the 
dynamics of latent infection.  The existence of either a positive fixed point that is stable, 
or a stable limit cycle when this fixed point is unstable, represents a situation where 
bacterial growth is controlled by the immune system but cannot be eliminated.  This 
may correspond to latent infection if the bacterial load is not too high or too low.  If a 
positive fixed point does not exist and the uninfected steady state is unstable, then the 
bacterial population grows unbounded.  This represents active disease.  Clearance 
corresponds to a stable fixed point at the origin. 
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These models predict a differential role for the innate and adaptive immune responses in 
determining the outcome of infection.  In the models containing one bacterial 
population that is susceptible to both innate and adaptive immune responses (Models 
6.1 and 6.2) infection can only be cleared when the strength of innate immunity is 
sufficiently high.  If the bacterial population is able to escape killing by the innate 
immune system infection can be controlled when the adaptive immune response is 
sufficiently strong.  If the T cell killing rate is unbounded the adaptive immune response 
will always be strong enough to control infection (Model 6.1).  This corresponds to 
latent tuberculosis.  When a saturating function is used to model killing by the adaptive 
immune system (so the killing rate is bounded) infection cannot always be controlled 
(Model 6.2).  Uncontrolled bacterial growth corresponds to active disease.  These 
results are consistent with those observed in the model described in Chapter 4 when a 
minimum limit was set for the presence of bacteria.  In these models the bacterial 
population includes both the extracellular and intracellular bacterial populations 
described in the model in Chapter 4, and Th1 cells and effector T cells (adaptive 
immune cells) are represented by a single variable. 
 
The outcome of infection also depends on the location and phenotypic status of the 
bacteria.  The existence of an intracellular bacterial population that is shielded from the 
innate immune response protects the bacteria from elimination.  In these models the 
only possible outcomes are an endemically infected steady state or active disease.  
Infection can be controlled when the strength of adaptive immunity is sufficiently high.  
If the T cell killing rate is unbounded the infection can always be controlled (Model 
6.3).  This corresponds to latent tuberculosis.  If this killing rate is bounded bacterial 
growth may not be contained and we get active disease (Model 6.4).  For example, if 
intracellular bacteria are able to escape killing by the immune system, the bacterial 
populations will grow unbounded to give active disease.  When a persistent population 
was added to Model 6.4, it was observed that a (stable) positive fixed point exists for a 
larger range of parameters, making latency a more robust state. 
 
The model in Chapter 4 is able to support the three disease states (with a threshold set 
for the minimum number of bacteria), and the outcome of infection depends on the 
choice of parameter values.  Different simple models support different numbers of 
disease states, (one, two or three), depending on the form of the immune system killing 
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function and the inclusion of an intracellular bacterial population that is protected from 
the innate immune response.  For the model in Chapter 4, the outcome of infection also 
depends on the state of the system at the time of exposure (the initial conditions), 
suggesting that for some parameter regimes multiple stable steady states exist.  This was 
not observed in the models presented in this chapter, but bistability may be introduced 
by adding further complexity to the models. 
 
The models presented in this chapter are simple and conceptual in nature, and are only 
meant to capture certain key aspects of host-pathogen interactions.  The advantage of 
using some of these simple models is that they allow a more analytical investigation, 
but we see that a full mathematical analysis quickly becomes difficult as the models 
become more complex and more parameters are introduced.  However, the inclusion of 
additional biological processes may improve the models or allow better comparison 
with data.  One possible direction for future improvement is to model the immune 
response in more detail.  For example, the innate immune response could be modelled 
explicitly, as well as the interactions between innate and adaptive immune cells and 
cytokine production.  The development of effector T cells could also be modelled or 
different functions could be used to model T cell activation and proliferation.  It is clear 
that the form of the killing functions is important in determining the outcome of 
infection, so different forms could also be investigated.  A detailed model of the 
immune response to M. tuberculosis infection was developed in Chapter 4 and in other 
work (Marino and Kirschner, 2004; Marino et al., 2010; Sud et al., 2006; Wigginton 
and Kirschner, 2001).  These types of models may be more realistic physiologically, but 
we can often gain some biological insight through the use of simpler models. 
 
In the persistence model (Model 6.5) it is assumed that switching from an actively 
growing state to a persistent state is a bacterial stress response to the host immune 
system.  However, during infection there may be different populations of bacteria in a 
state of non-replicating persistence, and spontaneous switching between the two 
bacterial populations may also occur; for example, the formation of persister cells 
(Balaban et al., 2004; Keren et al., 2011).  This type of switching could be added to the 
model, or used instead of a stress response so the models can be compared.  It is also 
assumed that persistent bacteria are only present inside chronically infected 
macrophages, so this model could be extended to include an extracellular persistent 
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population.  Extracellular bacteria may represent an important reservoir of persistent 
organisms (Karakousis et al., 2008; Karakousis et al., 2004). 
 
Slow-growing and non-replicating bacteria are less susceptible to killing by antibiotics 
than bacteria that are actively replicating (Zhang, 2004).  This model can be modified to 
investigate the effect of a persistent population on drug treatment, and to look at how 
the treatment regimen needs to be modified in order to eradicate this population.  
Similar work was done by Cogan, 2006, who investigated the use of intermittent drug 
dosing for targeting persister cells. 
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The outcome of tuberculosis infection depends on complex host-pathogen interactions 
that occur across numerous scales.  A full understanding of the disease requires an 
interdisciplinary approach that combines quantitative techniques with traditional 
experimental approaches.  Mathematical models provide a powerful tool for studying 
complex biological systems, offering insights into the underlying mechanisms that 
govern their behaviour. 
 
This research focuses on the progression of disease within a single host.  In this thesis 
mathematical models were developed to describe the within-host dynamics of M. 
tuberculosis infection and tuberculosis therapy.  Ordinary differential equations were 
used to describe the temporal dynamics of the pathogen M. tuberculosis and various 
components of the immune system.  The particular focus has been the development of a 
mechanistic understanding of the system by investigating the parameter dependence of 
the underlying models. 
 
A detailed mathematical model of human tuberculosis infection in the lung and nearest 
draining lymph node was developed that builds on models published in the literature 
(Marino and Kirschner, 2004; Sud et al., 2006).  The model was used to identify 
components of the system that lead to different disease trajectories.  Numerical 
simulation results predict a differential role for innate and adaptive immune responses 
in determining infection outcome.  Clearance depends on the strength of innate 
immunity, while latency is controlled by the adaptive immune system.  This suggests 
that utilizing immunotherapy to stimulate the innate immune response may prove 
effective in fighting tuberculosis infection.  However, enhancement of the immune 
response may lead to harmful inflammatory responses, so any increase in microbial 
killing must be weighed against potential host damage.  The use of immunotherapeutic 
approaches to fight microbial infections is an area that requires further research.  In 
addition, the model predicts that the growth rate of intracellular bacteria has a more 
significant effect on bacterial load than the growth rate of the extracellular population.  
The model was also used to investigate the dependence of the system on initial 
conditions, and it was observed that the outcome of infection depends not only on 
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parameter values, but also on the state of the system at the time of exposure.  This 
suggests that for some parameter regimes multiple stable steady states exist. 
 
The disease model was then extended to incorporate treatment with a single drug.  
Pharmacokinetic and pharmacodynamic models were added to the model to simulate the 
antibacterial effect of rifampicin (Goutelle et al., 2011), one of the most powerful 
antimycobacterial drugs.  This model was used to identify factors that affect the 
outcome of drug treatment.  The influence of different pharmacokinetic and 
pharmacodynamic parameters was explored and different dosing regimens were tested.  
Simulation results suggest that the current standard 600mg rifampicin dose may be 
suboptimal and that the length of treatment could be reduced by increasing the daily 
dose or by splitting the standard dose into two 300mg doses for patients with good 
compliance.  However, this result will depend on the pharmacodynamic and 
pharmacokinetic rates.  Further experimental and clinical studies are required to confirm 
these hypotheses and to find the optimal dosing regimen for rifampicin.  The toxic 
effects of higher daily doses also need to be investigated. 
 
The assumptions made in this model represent a considerable simplification of the 
dynamics of human disease and anti-tuberculosis chemotherapy, and these limitations 
should be considered when interpreting the results.  A number of components of host 
immunity that may play a role in the protective immune response to tuberculosis, such 
as neutrophils, !"  T cells and B cells, are not included in the disease model, and the 
model does not incorporate the development of immunological memory. 
 
It is assumed that the extracellular and intracellular bacterial populations during M. 
tuberculosis infection are homogeneous, replicating at a constant rate and equally 
susceptible to the action of the drug.  However, it is thought that subpopulations of 
bacteria in different metabolic and replicative states co-exist in infected tissue.  These 
populations may include bacilli that are less susceptible to killing by the host immune 
system and bacilli that are refractory to the action of antimycobacterial drugs (which 
can contribute to treatment relapse).  The physiological state of the bacteria may play a 
significant role in determining the outcome of infection and anti-tuberculosis 
chemotherapy.  Non-replicating and slow-growing bacteria could be added to the full 
model to gain further insights into mycobacterial persistence. 
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Another limitation of the treatment model is the omission of drug resistance.  The 
model includes only one antimycobacterial drug, although primary tuberculosis requires 
treatment with a combination of drugs due to the emergence of resistant strains (Frieden 
et al., 2003).  MDR-TB poses a major problem for tuberculosis control (World Health 
Organization, 2012b).  The inclusion of resistance and multi-drug therapy would be a 
priority in future modelling work. 
 
Simple predator-prey type models of tuberculosis infection were constructed to gain a 
better understanding of the mechanisms behind mycobacterial persistence.  The first 
models presented included one immune system variable, representing adaptive 
immunity, and one bacterial population that is susceptible to both innate and adaptive 
immune responses.  Analysis of these models confirmed earlier observations that the 
innate and adaptive immune systems have differential roles in determining the outcome 
of infection.  Clearance is achieved when the innate immune response is strong.  If 
innate immune cells are unable to eliminate bacteria, infection can still be controlled if 
the adaptive immune system is strong enough.  These models were then modified to 
incorporate extracellular and intracellular bacterial populations, with only extracellular 
bacteria killed by the innate immune system.  Steady state analysis highlighted the role 
of a protected intracellular compartment in allowing bacteria to establish a persistent 
infection and avoid elimination by the host.  A population of non-replicating or slow-
growing bacteria was then added to the model.  Simulation results showed that a 
persistent intracellular population makes latent infection a more robust and stable state 
that is less dependent on the strength of the adaptive immune response. 
 
These models are simple and heuristic, and ignore the details and complexities of the 
immune response to M. tuberculosis infection.  The inclusion of additional biological 
processes would provide a more realistic description of the host immune response to 
tuberculosis and allow better comparison with experimental data.  An extracellular 
persistent population could also be included in the persistence model, as this population 
may represent an important reservoir of persistent organisms (Karakousis et al., 2008; 
Karakousis et al., 2004).  In addition, this model could be modified to incorporate drug 
treatment, allowing us to investigate the effect of persistent populations on anti-
tuberculosis chemotherapy. 
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There are a number of interesting and important issues in tuberculosis research that 
could benefit from mathematical modelling, and given appropriate biological 
knowledge and experimental data, these models are readily modified to incorporate 
different interactions and populations.  One potentially fruitful area for future modelling 
work is the development of immunological memory.  The full disease model can be 
modified to include the development of memory T cells in the lung and lymph node, 
allowing us to predict the effects of vaccination and suggest potential targets for new 
vaccines.  The efficacy of BCG in the prevention of TB is variable, and there is a 
pressing need for new and improved vaccines (Young and Dye, 2006).  This model 
would also allow us to predict the outcome of re-challenge with a new infection.  
Central memory and effector memory T cells can be incorporated into the model.  Non-
polarized T cells in the lymph node and lung differentiate into central memory cells, and 
effector T cells in the lung differentiate into effector memory cells (Lanzavecchia and 
Sallusto, 2000).  Cytokines that play a role in the development and maintenance of 
memory T cells could also be included in the model.  The addition of immunological 
memory requires the generation of experimental data for the different processes 
involved in memory formation so the model can be validated and calibrated against 
data. 
 
A proper investigation into the effectiveness of different treatment strategies requires a 
more realistic description of events in patients with primary tuberculosis.  The drug 
treatment model could be extended to include the emergence of resistance and the use 
of combination therapy to overcome resistance and treat infection.  The model would 
include populations of bacteria that are resistant to each of the drugs and 
pharmacokinetic and pharmacodynamic models for each antimycobacterial drug.  This 
requires pharmacokinetic and pharmacodynamic data for the different antimycobacterial 
drugs and information on the combined action of drugs (Goutelle et al., 2011).  The 
extended model could then be used to explore different treatment strategies that may 
improve the success of anti-tuberculosis chemotherapy and reduce the length of 
treatment. 
 
The development of novel treatments or vaccines for different infectious diseases 
requires a mechanistic insight into the dynamics of host-pathogen interactions.  This can 
 195 
only be achieved by combining mathematical modelling with traditional clinical 
research.  This work provides some insight into the mechanisms that govern the 
outcome of infection and contributes to our understanding of tuberculosis in particular, 
and the interactions between host immune systems and pathogens in general. 
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Table 4 Parameter values. 
Name Description Value Units Reference 
 
Macrophages     
srM  MR recruitment rate 1000 (cells/cm3)/day (Sud et al., 2006) 
! 4A  
Rate of MR recruitment induced 
by MA and MI 
0.005 1/day (Sud et al., 2006) 
w2  Weight, contribution of MI to cell recruitment 0.15  (Sud et al., 2006) 
sr4B  Maximum rate of TNF-"-dependent recruitment of MR 2x10
4 (cells/cm3)/day (Sud et al., 2006) 
f11  Ratio adjustment, TNF-"/IL-10 on MR recruitment 1  (Sud et al., 2006) 
s11  Half-saturation constant, TNF-" on MR recruitment 165 pg/mL (Sud et al., 2006) 
k4  Maximum rate of MA deactivation induced by IL-10 0.08 1/day (Sud et al., 2006) 
c8  Half-saturation constant, IL-10 on MA deactivation 1 pg/mL (Sud et al., 2006) 
k2  Maximum rate of MR infection induced by BE 0.4 1/day (Sud et al., 2006) 
c9  Half-saturation constant, BE on MR infection 2x10
6 bacteria/cm3 (Sud et al., 2006) 
k3  Maximum rate of MR activation 0.01 1/day (Sud et al., 2006) 
f1  Ratio adjustment, IFN-!/IL-4 on MR activation 100  (Sud et al., 2006) 
s1  Half-saturation constant, IFN-! on MR activation 70 pg/mL (Sud et al., 2006) 
!  Scaling factor of TNF-" for MR activation 100 bacteria/pg (Sud et al., 2006) 
s!  Half-saturation constant, BT and TNF-" on MR activation 1x10
5 bacteria/cm3 (Sud et al., 2006) 
µMR  MR death rate 0.0033 1/day (Sud et al., 2006) 
k17  Maximum rate of MI death due to BI 0.02 1/day (Sud et al., 2006) 
k14A  Maximum rate of Fas-FasL induced apoptosis of MI 0.03 1/day (Sud et al., 2006) 
w3  Weight, contribution of Th1 to Fas-FasL induced apoptosis of MI 0.4  (Sud et al., 2006) 
c4  Half-saturation constant, (TC+w3T1)/MI on apoptosis of MI 40  (Sud et al., 2006) 
k14B  Maximum rate of TNF-" induced apoptosis of MI 0.1 1/day (Sud et al., 2006) 
f9  
Ratio adjustment, TNF-"/IL-10 
on TNF-" induced apoptosis of 
MI 
50  (Sud et al., 2006) 
s9  Half-saturation constant, TNF-" on apoptosis of MI 165 pg/mL (Sud et al., 2006) 
k52  Maximum rate of cytotoxic killing of MI 0.07 1/day (Sud et al., 2006) 
cT1  Half-saturation constant, effect of Th1 on TC cytotoxicity 10 cells/cm
3 (Sud et al., 2006) 
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Name Description Value Units Reference 
w1  Weight, contribution of Th1 to cytotoxic activity 0.5  (Sud et al., 2006) 
c52  
Half-saturation constant, 
(TC{T1/( T1+cT1)}+w1T1)/MI on 
cytotoxic killing of MI 
50  (Sud et al., 2006) 
µMI  MI death rate 0.0011 1/day (Sud et al., 2006) 
µMA  MA death rate 0.07 1/day (Sud et al., 2006) 
 
Cytokines     
! 30  Rate of TNF-" production by MI 0.003 (pg/cells)/day (Sud et al., 2006) 
! 31  
Maximum rate of TNF-" 
production by MA 
0.004 (pg/cells)/day (Sud et al., 2006) 
!2  
Scaling factor of BT for TNF-" 
production by MA 
0.001 pg/bacteria (Sud et al., 2006) 
f10  
Ratio adjustment, IFN-!/IL-4 on 
TNF-" production by MA 
100  (Sud et al., 2006) 
f7  
Ratio adjustment, IFN-! /IL-10 on 
TNF-" production by MA 
1  (Sud et al., 2006) 
s10  
Half-saturation constant, IFN-! 
and BT on TNF-" production by 
MA 
80 pg/mL (Sud et al., 2006) 
! 32  Rate of TNF-" production by Th1 8.16x10-4 (pg/cells)/day (Sud et al., 2006) 
! 33  Rate of TNF-" production by TC 5x10-5 (pg/cells)/day (Sud et al., 2006) 
µF!  TNF-" decay rate 1.112 1/day (Sud et al., 2006) 
sg  
Maximum rate of IFN-! 
production by other sources (NK 
cells, !$ T cells) 
100 (pg/mL)/day (Sud et al., 2006) 
c10  
Half-saturation constant, bacteria 
on IFN-! production by other 
sources 
1000 bacteria/cm3 (Sud et al., 2006) 
s7  Half-saturation constant, IL-12 on IFN-! production by other sources 40 pg/mL (Sud et al., 2006) 
!5A  
Maximum rate of IFN-! 
production by Th1 0.4 (pg/cells)/day (Sud et al., 2006) 
c5A  Half-saturation constant, MA on IFN-! production by Th1 7000 cells/cm
3 (Sud et al., 2006) 
!5B  
Maximum rate of IFN-! 
production by TC 
0.4 (pg/cells)/day (Sud et al., 2006) 
c5B  Half-saturation constant, MA on IFN-! production by TC 7000 cells/cm
3 (Sud et al., 2006) 
!5C  Rate of IFN-! production by MI 3x10-4 (pg/cells)/day (Sud et al., 2006) 
! 7A  
Maximum rate of IFN-! 
production by Th0 0.03 (pg/cells)/day (Sud et al., 2006) 
f4A  Ratio adjustment, IL-12/IL-10 on IFN-! production by Th0 2  (Sud et al., 2006) 
s4A  Half-saturation constant, IL-12 on IFN-! production by Th0 50 pg/mL (Sud et al., 2006) 
! 7B  
Maximum rate of IFN-! 
production by T80 
0.03 (pg/cells)/day (Sud et al., 2006) 
f4B  Ratio adjustment, IL-12/IL-10 on IFN-! production by T80 2  (Sud et al., 2006) 
s4B  Half-saturation constant, IL-12 on IFN-! production by T80 50 pg/mL (Sud et al., 2006) 
µI!  IFN-! decay rate 2.16 1/day (Sud et al., 2006) 
s12  
IL-12 production by immature 
DCs 0.015 (pg/cells)/day (Sud et al., 2006) 
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Name Description Value Units Reference 
c230  
Half-saturation constant, BT on 
IL-12 production by immature 
DCs 
1000 bacteria/cm3 (Sud et al., 2006) 
!23  
Maximum rate of IL-12 
production by MR 
2x10-4 (pg/cells)/day (Sud et al., 2006) 
c23  Half-saturation constant, BT on IL-12 production by MR 5000 bacteria/cm
3 (Sud et al., 2006) 
!8  
Maximum rate of IL-12 
production by MA 
8x10-5 (pg/cells)/day (Sud et al., 2006) 
s  Describes IL-10 down-regulation of IL-12 production by MA 10 pg/mL (Sud et al., 2006) 
µI12  IL-12 decay rate 1.188 1/day (Sud et al., 2006) 
!7  
Maximum rate of IL-10 
production by MI 
0.1 (pg/cells)/day (Sud et al., 2006) 
s6  Describes IL-10 self-inhibition in MI 60 pg/mL (Sud et al., 2006) 
f6  Ratio adjustment, IL-10/IFN-! on IL-10 production by MI 0.025  (Sud et al., 2006) 
!16  
Rate of production of IL-10 by 
Th1 0.02 (pg/cells)/day (Sud et al., 2006) 
!17  
Rate of production of IL-10 by 
Th2 0.06 (pg/cells)/day (Sud et al., 2006) 
!18  Rate of production of IL-10 by TC 0.02 (pg/cells)/day (Sud et al., 2006) 
µI10  IL-10 decay rate 3.7 1/day (Sud et al., 2006) 
!11  Rate of production of IL-4 by Th0 5x10-4 (pg/cells)/day (Sud et al., 2006) 
!12  Rate of production of IL-4 by Th2 0.001 (pg/cells)/day (Sud et al., 2006) 
µI 4  IL-4 decay rate 2.77 1/day (Sud et al., 2006) 
 
T cells in the 
lung 
    
! A  
Maximum contribution of 
macrophages to Th0 migration 
into the lung 
0.5   
!6A  
Half-saturation constant, MA and 
MI on Th0 migration from the 
blood 
1.5x104 cells/cm3 (Marino and Kirschner, 2004) 
!2A  
Maximum rate of Th0 
proliferation 0.4 1/day 
(Marino and 
Kirschner, 2004) 
c15A  Half-saturation constant, MA and MI on Th0 proliferation 1x10
5 cells/cm3 (Marino and Kirschner, 2004) 
f8A  Ratio adjustment, TNF-"/IL-10 on Th0 recruitment 1  (Sud et al., 2006) 
s8A  Half-saturation constant, TNF-" on Th0 recruitment 1 pg/mL  
k6A  Maximum rate of Th0 differentiation to Th1 5x10
-3 (mL/pg)/day (Sud et al., 2006) 
f3A  Ratio adjustment, IFN-!/IL-4 on Th1 differentiation 200  (Sud et al., 2006) 
f5A  Ratio adjustment, IFN-!/IL-10 on Th1 differentiation 1  (Sud et al., 2006) 
s3A  Half-saturation constant, IFN-! on Th1 differentiation 70 pg/mL (Sud et al., 2006) 
k7  Maximum rate of Th0 differentiation to Th2 0.05 1/day 
(Marino and 
Kirschner, 2004) 
f2  Ratio adjustment, IL-4/IFN-! on Th2 differentiation 0.12  
(Marino and 
Kirschner, 2004) 
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Name Description Value Units Reference 
s2  Half-sat, IL-4 on Th2 differentiation 2 pg/mL 
(Marino and 
Kirschner, 2004) 
! B  
Maximum contribution of 
macrophages to T80 migration into 
the lung 
0.5   
! 6B  
Half-saturation constant, MA and 
MI on T80 migration from the 
blood 
1.5x104 cells/cm3  
! 2B  Maximum rate of T80 proliferation 0.4 1/day  
c15B  Half-saturation constant, MA and MI on T80 proliferation 1x10
5 cells/cm3  
f8B  Ratio adjustment, TNF-"/IL-10 on T80 recruitment 1   
s8B  Half-saturation constant, TNF-" on T80 recruitment 1 pg/mL  
k6B  Maximum rate of T80 differentiation to TC 5x10
-3 (mL/pg)/day  
f3B  Ratio adjustment, IFN-!/IL-4 on TC differentiation 200   
f5B  Ratio adjustment, IFN-!/IL-10 on TC differentiation 1   
s3B  Half-saturation constant, IFN-! on TC differentiation 70 pg/mL  
µT 40  Th0 death rate 0.33 1/day (Sud et al., 2006) 
µT !  
Maximum rate of IFN-!-induced 
apoptosis of Th1 1.22x10
-4 (cm3/cells)/day (Sud et al., 2006) 
c  
Half-saturation constant, IFN-! on 
apoptosis of Th1 1100 pg/mL (Sud et al., 2006) 
µT1  Th1 death rate 0.33 1/day (Sud et al., 2006) 
µT 2  Th2 death rate 0.33 1/day (Sud et al., 2006) 
µT 80  T80 death rate 0.33 1/day (Sud et al., 2006) 
µTc!  Maximum rate of IFN-!-induced apoptosis of TC cells 1x10
-4 (cm3/cells)/day (Sud et al., 2006) 
cc  Half-saturation constant, IFN-! on apoptosis of TC cells 550 pg/mL (Sud et al., 2006) 
µTC  TC death rate 0.33 1/day (Sud et al., 2006) 
 
Bacteria     
!20  BE growth rate 0.05 1/day (Sud et al., 2006) 
Nmax  Carrying capacity for BE 1x109 bacteria/cm3 
(Goutelle et al., 
2011) 
µI  
Rate of BI turnover to BE due to 
MI death 
0.004 1/day (Sud et al., 2006) 
k15  Maximum rate of BE killing by MA 1.25x10
-7 (cm3/cells)/day (Sud et al., 2006) 
k18  Maximum rate of BE killing by MR 5x10
-9 (cm3/cells)/day (Sud et al., 2006) 
N  Carrying capacity of infected macrophages 20 bacteria/cell (Sud et al., 2006) 
N fracc  
Average proportion of BI released 
following Fas-FasL-induced 
apoptosis of MI 
0.1  (Sud et al., 2006) 
N fraca  
Average proportion of BI released 
following TNF-"-induced 
apoptosis of MI 
0.5  (Sud et al., 2006) 
!19  BI growth rate 0.2 1/day (Sud et al., 2006) 
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Name Description Value Units Reference 
w  
Weight, contribution of BI to 
antigen stimulation 0.14  
(Marino and 
Kirschner, 2004) 
 
T cells in the 
DLN 
    
sN 4  Rate of naïve CD4+ T cell recruitment 1020 (cells/cm
3)/day (Marino and Kirschner, 2004) 
!2A  
Rate of naïve CD4+ T cell 
recruitment by mature DCs 0.1 1/day 
(Marino and 
Kirschner, 2004) 
!1A  
Recirculation rate of naïve CD4+ 
T cells through the DLN 0.1 1/day 
(Marino and 
Kirschner, 2004) 
µN 4  Naïve CD4+ T cell death rate 0.002 1/day (Marino and Kirschner, 2004) 
sN8  Rate of naïve CD8+ T cell recruitment 1020 (cells/cm
3)/day  
! 2B  
Rate of naïve CD8+ T cell 
recruitment by mature DCs 0.1 1/day  
!1B  
Recirculation rate of naïve CD8+ 
T cells through the DLN 0.1 1/day  
µN8  Naïve CD8+ T cell death rate 0.002 1/day  
! 4A  
Rate of naïve CD4+ T cell 
activation by mature DCs 1x10
-4 (cm3/cells)/day (Marino and Kirschner, 2004) 
!5A  Net proliferation rate of Th0 in the DLN 0.9 1/day 
(Marino and 
Kirschner, 2004) 
!A  Threshold in Th0 proliferation 3x106 cells/cm3  
!A  
Proportion of Th0 migrating into 
the blood 0.9 1/day 
(Marino and 
Kirschner, 2004) 
! 4B  
Rate of naïve CD8+ T cell 
activation by mature DCs 1x10
-4 (cm3/cells)/day  
! 5B  
Net proliferation rate of T80 cells 
in the DLN 0.9 1/day  
!B  Threshold in T80 cell proliferation 3x106 cells/cm3  
!B  
Proportion of T80 cells migrating 
into the blood 0.9 1/day  
 
Dendritic cells     
!  Scaling factor 1  (Marino and Kirschner, 2004) 
!10  
Maximum rate of immature DC 
migration from the lung to the 
DLN 
0.02 1/day (Marino and Kirschner, 2004) 
!11  
Half-saturation constant, BE on 
immature DC migration from the 
lung 
1x104 bacteria/cm3 (Marino and Kirschner, 2004) 
µMDC  Mature DC death rate 0.02 1/day 
(Marino and 
Kirschner, 2004) 
sIDC  Immature DC recruitment rate 500 (cells/cm3)/day (Marino and Kirschner, 2004) 
!8  
Maximum rate of immature DC 
recruitment by BE 
0.01 1/day (Marino and Kirschner, 2004) 
!9  
Half-saturation constant, BE on 
immature DC recruitment 1.5x10
5 bacteria/cm3 (Marino and Kirschner, 2004) 
µIDC  Immature DC death rate 0.01 1/day 
(Marino and 
Kirschner, 2004) 
!12  
Rate of bacterial uptake by 
immature DCs 1x10
-7 (cm3/cells)/day (Marino and Kirschner, 2004) 
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